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TURUN YLIOPISTO 
Lääketieteellinen tiedekunta 
Tutkimuslaboratorio MediCity, Lääketieteellinen Mikrobiologia ja 
Immunologia, Turku (2019) 
MINNA TERVAHARTIALA: Virtsarakon syövän immunologia 
Väitöskirja, 170 s. 
Molekyylilääketieteen tohtoriohjelma (TuDMM)  
05/2019 
Tiivistelmä 
Virtsarakon syöpä on sairaus, jonka ennuste vaihtelee laajalti taudin vaikeusasteen 
mukaan. Paikallisilla, rakon lihakseen ulottumattomilla tautimuodoilla on hyvä 
ennuste, mutta ne myös uusiutuvat herkästi ja saattavat edetä vaikeammaksi 
taudiksi. Lihakseen ulottuvalla taudilla on huonompi ennuste ja kuolleisuus on 
korkea. Suuren uusiutumisriskin vuoksi virtsarakon syöpä on yksi kalleimmista 
syöpäsairauksista hoitaa. 
Väitöskirjan tavoitteena oli tutkia immunologisia tekijöitä virtsarakon syövässä. 
Makrofageja tunnistavien molekyylien, CD68, MAC387 ja CLEVER-1, ennus-
teellista merkitystä virtsarakon syövässä tutkittiin immunohistologisin keinoin. 
Molekyylejä tutkittiin virtsarakon syövän taudin kulkua ennustavina sekä neoad-
juvantin sytostaattihoidon vastetta ennustavina tekijöinä. Lisäksi CD73-molekyyliä 
tutkittiin virtsarakon syövän eri solutyypeissä.  
Tutkimustulokset osoittivat, että kasvainmakrofagit liittyvät huonoon ennustee-
seen virtsarakon syövässä. MAC387- ja CLEVER-1-molekyylit ennustavat neo-
adjuvantin kemoterapian vastetta leikkauspotilailla. Myös CD73-molekyyli en-
nustaa kuolleisuutta virtsarakon syöpään, mutta CD73:n esiintyminen ja merkitys 
eri solutyypeissä virtsarakonsyöpäkasvaimissa vaihtelee kuitenkin suuresti. 
Yhteenvetona voidaan todeta, että CD68, MAC387 ja CLEVER-1 toimivat en-
nusteellisina tekijöinä virtsarakon syövässä. Makrofageja voidaan mahdollisesti 
käyttää ennustamaan virtsarakon syövän taudinkulkua ja tunnistamaan potilaat, 
joiden uusiutumisriski on kohonnut. MAC387 ja CLEVER-1 ovat myös mahdol-
lisia neoadjuvantin sytostaattihoidon vasteen ennustetekijöitä. Myös CD73-
molekyyli toimii ennusteellisena tekijänä virtsarakon syövässä, mutta tämän mo-
lekyylin merkitys vaihtelee eri solutyypeissä. Tutkimus herättää uusia kysymyksiä 
immunologisista tekijöistä virtsarakon syövässä ja lisää tutkimuksia tarvitaan 
tulosten vahvistamiseksi. 
Avainsanat: Virtsarakon syöpä, makrofagit, ennusteelliset tekijät, immunologia 
4
31187368_Vaitoskirja_Minna_Tervahartiala_Laaketiet_tdk_sisus_B5_1308.indd   4 13.8.2019   10.47
2 
UNIVERSITY OF TURKU 
Faculty of Medicine, MediCity Research Laboratory, Department of Medical 
Microbiology and Immunology (2019) 
MINNA TERVAHARTIALA: Immunology of bladder cancer  
Doctoral Dissertation, 170 pp. 
Turku Doctoral Programme of Molecular Medicine (TuDMM) 
05/2019 
Abstract 
Bladder cancer (BC) is a highly prevalent disease with wide variety in outcome. 
Non-muscle invasive tumors have good prognosis but are prone to recur and, 
furthermore, have a major risk of progression. Muscle-invasive disease has 
significantly poorer survival with high mortality. Due to the high recurrence rate of 
the disease, BC is one of the most expensive cancers to treat. 
The aim of the present study was to investigate the roles of the immunological 
biomarkers in BC. Macrophage markers CD68, MAC387, and CLEVER-1 were 
evaluated as prognostic factors in BC. Muscle-invasive bladder cancer patients 
receive neoadjuvant chemotherapy before definitive surgery and the predictive role 
of the biomarkers in neoadjuvant treated patients was also investigated. In 
addition, the prognostic role of CD73 in different cellular components of bladder 
tumors was studied.  
The results of the study show, that tumor-associated macrophages associate 
with poor outcome in BC. In contrast, CLEVER-1 positive vessels show protective 
role in BC. MAC387 and CLEVER-1 are predictive biomarkers in neoadjuvant 
treated patients. CD73 has also a prognostic role in BC. However, the expression of 
CD73 varies greatly between different cellular components. 
As conclusion, CD68, MAC387, CLEVER-1, and CD73 have prognostic and 
predictive role in BC. Macrophage markers are potential prognostic biomarkers in 
BC. MAC387 and CLEVER-1 could separate the patients who would benefit from 
the neoadjuvant chemotherapy from patients who might suffer from delayed 
operation and toxicity without the benefit from the treatment. CD73 has a 
prognostic role in BC, but it is important to investigate the expression in different 
cells and not to draw conclusions based on the expression status only on one cell 
type in the tumor. New questions about immunological factors in BC arise from the 
study and new studies are needed to validate the results. 
Keywords: Bladder cancer, macrophages, prognostic biomarker, predictive bi-
omarker, immunology  
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Introduction 
 
Cancer is a heterogenous group of diseases with different prognosis and treatment 
alternatives depending on the type of cancer. Even among same cancer type, 
survival can vary widely and the aggressiveness of the treatment modalities needs 
to be chosen individually according to the risks of the disease. However, it is not 
simple to predict patient’s prognosis and the risk for recurrence and progression of 
the disease. Biological markers are needed to guide the decision-making among the 
treatment alternatives. It is important to be able to identify accurately patients with 
worse prognosis and higher risk for recurrence, progression, and death. Prognostic 
biomarkers are designed to aid in this. In addition, biomarkers are needed to 
identify which patients will benefit from specific treatments and to which patients 
the treatment causes possibly only toxic side effects and delay for the more 
effective treatment. Predictive biomarkers are used to separate responders from 
non-responders to treatment to limit the side effects and optimize the treatment. 
Bladder cancer (BC) is a disease requiring new biomarkers to the clinical work. 
Biomarkers are needed to identify the patients with more aggressive disease and to 
guide the clinicians to select effective treatment alternatives to each patient. Local 
disease is readily treatable and the mortality is low. However, BC is prone to recur 
and progress to more aggressive and potentially fatal invasive disease. The 
continuous follow-up causes major social costs and individual inconveniences or 
decreased quality of life. After metastatic spread of the disease treatment alterna-
tives are limited and the mortality is high. 
In addition to the need for prognostic biomarkers, there is a lack of predictive 
biomarkers to select the right treatment options to each BC patient. Neoadjuvant 
chemotherapy prior to the surgery is effective to up to half of the patients. The 
prediction, who will benefit from the treatment (responders) and who will suffer 
from the toxicity of the chemo agents and delay of the surgery (non-reponders), is 
challenging. New immunotherapies have brought light to the treatment of ad-
vanced BC. However, there are no tools to predict the most suitable patients to 
these treatment options, either.  
9
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Immunological processes are known to have a major effect to development of 
cancer. Immunological cells are a crucial part of the tumor microenvironment. 
Immune cells and mediators have been studied widely as prognostic and predic-
tive biomarkers in different cancer types, but more knowledge is needed to specify 
their possible role as biomarkers in BC.  
10
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Review of literature 
1 Cancer 
 
Cancer is a heterogeneous group of diseases with abnormal cell growth and poten-
tial to invade and metastasize. Over one hundred types of cancer affect humans and 
the symptoms vary according to the origin of the tumor.1 In 2015, the incidence of 
all new cancers was 18.6 million.2 In Finland, there were 33 000 new cancer 
patients in 2015 (610 per 100 000) and 270 000 patients were living with diagnosed 
cancer.3 
Cancers are caused by several factors acting simultaneously. The risk of cancer 
increases with age, but the most important lifestyle exposures are tobacco smoking, 
dietary factors, alcohol consumption, and obesity.3, 4 Fundamentally, cancer is a 
disease of tissue growth dysregulation, where the tumor develops from cells 
escaping the normal cell control and acquiring several capabilities required to form 
a malignant tumor. “The hallmarks of cancer” by Douglas Hanahan and Robert A. 
Weinberg constitute an organizing principle for rationalizing the complexities of 
malignant disease.5 The development of tumor depends upon changes between the 
cancer cells and their normal neighboring cells. The hallmarks include (I) self-
sufficiency in growth signals; (II) insensitivity to inhibitory signals; (III) resistance 
of the programmed cell death or apoptosis; (IV) the indefinite capability to 
replicate; (V) stimulation of angiogenesis to supply nutrients to tumors; and (VI) 
the capability to invade and spread to distant sites. In 2011, the hallmarks were 
updated with two new emerging hallmarks, deregulated metabolic pathways and 
evading the immune system. In addition, genome instability and inflammation were 
added to the list as enabling characteristics, since their acquisition leads to the 
development of the cancer hallmarks. Thereby, inflammation has a dual role in 
cancer development: on one hand, it can be tumor promoting assisting the cancer 
development by e.g. supplying growth factors and proangiogenic factors and 
supporting invasion and metastasis, but on the other hand, inflammatory cells also 
fight against cancer cells and malignant cells need to require a capability to evade 
the immune destruction to develop an invading and metastasizing tumor.  
11
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In 2015, cancer killed 8.8 million people worldwide and 12 200 in Finland..3, 6 
Traditionally, cancer is treated with surgery, chemotherapy, and radiation therapy. 
However, new therapies and diagnostic tools are studied constantly. Due to the 
massive cancer research, the knowledge about preventing cancer is increasing, 
diagnoses are made in early phase of the disease, and the overall cancer mortality is 
decreasing.  
12
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2 Bladder cancer 
2.1 Epidemiology and etiology 
BC is globally the ninth most common cancer with estimated 430 00 new diag-
nosed cases worldwide in 2012 (the age-adjusted incidence rate of 5.3/100 000). It 
is the 13th most common cause of cancer death and the most common malignancy 
involving the urinary system.7, 8 Three-quarters of all cases are in men, and 
majority of the BC cases are occurring in the western countries.9 The median age at 
the diagnosis is 69 years in men and 73 in female. Ninety percent of the people 
with BC are older than 55.10 In Finland, BC is the fourth most common cancer in 
male (incidence 34/100 000) and 15th in female (incidence 11/100 000), with 1200 
new diagnoses in 2012. The 5-year surveillance of BC in Finland is 74%.3 
Tobacco smoking is the most important risk factor for BC and explains partly 
the differences in incidences between geographical regions and gender.11, 12 
Occupational exposure to different chemicals in painting, rubber and aluminium 
industries is considered as the second most important risk factor for BC.11 The 
most common parasitic infection after malaria, Schistosoma haematobium, a 
parasitic worm in the urinary tract, causes BC in its endemic regions in Northern 
and sub-Saharan Africa.13 Although BC is not an inherited disease, the risk for BC 
is almost two-fold higher in first-degree relatives.14 Inherited genetic factors, such 
as N-acetyltransferase 2 (NAT2) variants and gluthathione S-transferase-µ1 
(GSTM1)-null genotypes, have been considered to increase the risk for BC via 
sensitizing to extrinsic carcinogens, such as tobacco smoke.11 
2.2 Diagnosis of bladder cancer 
The most common symptom of BC is gross painless haematuria (in 80-85% of the 
BC patients). The incidence of urological cancer in patients with macroscopic 
hematuria varies between 19 and 24%. (20) Unexplained urinary frequency, ur-
gency, and irritative voiding symptoms are also possible signs of a urinary tumor. 
(21) Fatigue, weight loss, renal failure, respiratory symptoms, and a suprapubic 
palpable mass are signs of an advanced or metastatic disease.15  
When a diagnosis of BC is suspected, the initial assessment consists of urine cy-
tology, cystoscopy, and radiological investigation of the upper urinary tracts. 
Cystoscopy with pathological investigation of the specimens gives most often the 
diagnosis of the disease. Carcinoma in situ (CIS), often macroscopically invisible 
tumor, may be diagnosed with combination of cystoscopy and cytology.16 
However, positive urinary cytology may originate from anywhere in the urinary 
3
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tract, while negative cytology does not exclude tumor (specificity of 86-94%, 
sensitivity 35-48%).17, 18 
Transurethral resection of bladder tumor (TUR-BT) is performed to establish 
the diagnosis and the stage of the disease. The resection includes muscularis 
propria to evaluate the stage of the tumor. Photodynamic diagnosis (PDD, 
fluorescence/blue-light cystoscopy) is a useful tool to target the surgery.19, 20  
During the cystoscopy, the mobility of the bladder and pelvic organs are assessed 
with a rectal/vaginal bimanual examina-tion. A second TUR-BT 2 to 6 weeks after 
the initial procedure might be required to reduce the risk of understaging in high-
risk NMIBC. Guidelines recommend re-TUR after incomplete initial resection, for 
high-risk tumors (recurrent, multi-focal, over 3 cm, high grade tumor), and for any 
T1 tumors especially if the initial resection does not include detrusor muscle (the 
staging and grading of BC is reviewed in the next Chapter).21-22 Repeated TUR-BT 
for high-grade T1 tumors results in upstaging and thus, a change in the 
management, in 24-49% of patients.24  
Imaging (computed tomography, CT, or magnetic resonance imaging, MRI) 
may be used for assessment of local invasion and to detect extravesical T3b or 
higher staged tumors. In case of invasive disease, a metastatic assessment is 
performed, including abdominal/pelvic and chest CT, liver function tests, and 
serum creatinine and electrolytes.25 Lung and liver metastases are common 
metastatic sites, but bone and brain metastases are rare at the time of diagnosis of 
invasive BC and the investigations are indicated only based on the symptoms.26 
2.3 Classification of bladder cancer 
BC is a heterogeneous disease and can be classified in several ways to help clini-
cians to select right treatment modalities and predict the patient survival. At the 
time of diagnosis, pathologists assess the histology of the BC from TUR-BT 
specimens. Pathologists also grade the tumor sample to describe the aggressive-
ness of the disease. The stage of the disease describes the anatomical extent of the 
disease with possible invasion and metastases, and thus, guide the use of the 
treatment alternatives. In addition, studies have recognized distinct molecular 
subtypes of BCs, which vary according to their survival profiles. 
2.3.1 Histology 
Urothelium, the epithelial cells lining the bladder wall, is a transitional epithelium 
consisting of basal cells, intermediate cells and umbrella cells.27 In normal and 
healthy urothelium, the basal cells attach to the basement membrane and constitute 
14
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the urothelial stem cells. Umbrella cells, which make up the upper layer of the 
urothelium, form a protective barrier for toxic components in the urine.  
Morphologically, BC tumors can be divided into papillary (predominant type), 
solid, and mixed types.28 The most of the BCs (90-95%) are pure urothelial 
carcinomas (transitional cell carcinomas).29 However, BC is a heterogeneous 
disease consisting also urothelial carcinoma with divergent differentiation or non-
urothelial carcinoma. Urothelial carcinoma may consist partially with squamous 
and/or glandular differentiated histology. Additional variant histologies include 
tumors with micropapillary or microcystic histology, small cell carcinoma, 
sarcomatoid carcinoma, and lymphoepithelioma.30 Furthermore, BC can have 
plasmocytoid, giant cell, signet ring, diffuse or undifferentiated histology or they 
can have a nested variant histology. Squamous cell differentiation is the most 
commonly found non-urothelial histological type occurring in 20% of the urothe-
lial carcinomas.31, 32 Different histological types have their own distinct biological 
behaviors and may have different responses to different treatment modalities. In 
general, it is considered that variant histology subtype increases the risk of more 
advanced disease and metastasis and, thus, poorer prognosis, but the results from 
multivariate analyses are controversial.32-35  
2.3.2 Cancer stage 
BC is classified according to Tumor, Node, Metastasis (TNM) classification sys-
tem to describe the anatomical extent of the disease (Table 1).36 Invasion to the 
muscularis propria is the strongest predictor of tumor recurrence and progression.37 
The division of the tumors to non-muscle invasive (NMIBC) and muscle-invasive 
(MIBC) is widely used. Pathological staging (pT-category) by TUR-BT is the gold 
standard, but can be limited by the quality of the specimens and cautery and 
distortion artifacts, whereas clinical staging (cT-category) involving bimanual 
examination, cystoscopy, and cross-sectional radiographic assessment is 
unfortunately often inaccurate (over or understaging may occur as high as 40% of 
the cases).38-40 
At the time of diagnosis, approximately 85% of patients have a non-muscle 
invasive, local disease, while 15% have already a muscle-invasive disease with re-
gional lymph node or distant metastases. NMIBC can be divided into papillary and 
flat tumors.41, 42 Papillary tumors include Ta (70% of the NMIBC tumors) and T1 
tumors (20% of the NMIBCs). Flat tumors are Carcinoma in situ tumors (Tis), 
which consist 5-10% of the NMIBCs. 50 to 70% of the non-invasive tumors will 
recur and 10 to 20% progress to MIBC.25, 28, 43 However, the progression is mainly 
limited to high-grade disease and carcinoma in situ. To detect which patients will 
5
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progress to invasive disease remains a challenge, and thus, BC patients require 
repetitive investigations and long follow-up. 
Advanced BC may extend locally into the surrounding tissues, such as the pros-
tate, uterus, sacral vertebra, and further to the retroperitoneal soft tissues.44 BC can 
metastasize via blood vessels or lymphatics. Distant lymph nodes and lungs are the 
most common sites of metastases, but liver, bones, skin, and brain metastases 
occur, too. BC patients with metastatic disease have a poor survival, only three to 
six months, despite the treatment.45  
Table 1. TNM classification adapted from UICC 2009.36 
T - Primary tumor 
 TX Primary tumor cannot be assessed 
 T0 No evidence of primary tumor 
NMIBC (non-muscle invasive bladder cancer) 
 Ta Non-invasive papillary carcinoma, confined to the mucosa 
 Tis Carcinoma in situ (flat tumor confined to the mucosa). 
 T1 Tumor invaded to the subepithelial connective tissue/lamina propria 
MIBC (muscle invasive bladder cancer) 
 T2 Tumor invaded to the muscle 
  T2a Tumor invaded to the superficial muscle (inner half) 
  T2b Tumor invaded to the deep muscle (outer half) 
 T3 Tumor invaded to the perivesical tissue 
  T3a Tumor invaded to the perivesical tissue microscopically 
  T3b Tumor invaded to the perivesical tissue macroscopically  
 T4 Tumor invades extravesical organs 
  T4a Tumor invaded to the prostate, uterus or vagina 
  T4b Tumor invaded to the pelvic wall or abdominal wall 
N – Lymph nodes 
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Metastasis in a single lymph node in the true pelvis  
N2 Metastasis in multiple lymph nodes in the true pelvis  
N3 Metastasis in common iliac lymph node(s) 
M – Distant metastasis 
 MX Distant metastasis cannot be assessed 
 M0 No distant metastasis 
 M1 Distant metastasis 
2.3.3 Tumor grade 
Tumor grading correlates to the aggressiveness of the tumor, predicts the progno-
sis of the disease, and helps on the selection of the treatment. BC tumors are graded 
histologically according to the classification of the World Health Organization 
16
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(WHO, 1973) to describe the appearance of tumor cells and cellular anaplasia.46 In 
2004 WHO and the International Society of Urological Pathology (ISUP) 
published revisions to the 1973 grading system to allow more standardized 
pathologic description.47 The grading systems are described in detail in Table 2 and 
the representative examples of the histological BC samples of different grades are 
shown in Figure 1.  
In the 1973 classification, Grade 1 tumors have a significantly better prognosis 
than Grade 2 or 3 tumors.37 They have an orderly arrangement and minimal 
architectural abnormalities and mitotic figures are rare or absent (Figure 1). Grade 
3 tumors, on the other hand, demonstrate extreme nuclear abnormalities, disordered 
architecture and frequent mitotic activity. Grade 2 is an intermediate group of 
tumors and it is considered more of a diagnosis of exclusion. 
The 2004 classification system is considered superior to the 1973 system, 
although they are recommended to be used simultaneously.37, 48 The two grading 
systems correlate well only at the ends of the grading spectrum; approximately 
40% of the Grade 2 tumors are classified as high-grade in the 2004 system.28 
Papillary urothelial neoplasms of low malignant potential (PUNLMP) have a low 
probability of progression, but they are not pure benign tumors either with recur-
rence rates up to 60% a and progression rate up to 8%.49 As majority of the MIBC 
tumors are high-grade tumors, the 2004 system is particularly important with non-
invasive tumors, in which about 50% of the tumors are low-grade.28, 37  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. BC grading systems, adapted from EAU guidelines on non–muscle-invasive 
urothelial carcinoma of the bladder.48 
1973 WHO grading system 
 Urothelial papilloma 
 Grade 1 Well differentiated 
 Grade 2 Moderately differentiated 
 Grade 3 Poorly differentiated 
2004 WHO and ISUP grading system 
 Urothelial papilloma 
 PUNMLP Papillary urothelial neoplasm of low malignant potential 
 Low grade Low-grade papillary urothelial carcinoma 
 High grade High-grade papillary urothelial carcinoma 
7
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2.3.4 Carcinoma in situ 
Carcinoma in situ (CIS) is a flat, non-invasive, often multifocal, and by definition, 
high-grade bladder tumor. It can be easily missed at cystoscopy, although it is 
nearly always detected with urine cytology.16, 42 Five to ten percent of all patients 
with NMIBC have CIS.42 CIS is classified into three different clinical types: (I) 
primary (isolated CIS and no previous or concurrent papillary tumors), (II) 
secondary (detected during follow-up of previous non-CIS tumor), and (III) 
concomitant (in the presence of any other urothelial tumor). CIS tumors should be 
excluded from Ta and T1 tumors because these tumors have a different natural 
behavior pattern than papillary tumors. CIS is highly malignant and has a much 
higher risk of progression than Ta or T1 tumors: approximately 54% of the CIS 
tumors progress to MIBC in contrast to 10-20% of other NMIBCs.37, 42, 50, 51 CIS is 
also a strong predictor for ureter involvement, and thus, increases the risk for 
recurrence in the upper urinary tract after RC.52 However, its aggressiveness varies 
greatly and it is considered unpredictable tumor type. 
 
 
 
Figure 1. Representative BC tumors with different grading according to the 2004 and 1973 
grading systems: Low grade/WHO Grade 1, high grade/WHO Grade 2, and high 
grade/WHO Grade 3. Scale bar 200µm in the upper row and 50µm in the lower row. 
Graph. courtesy of Dr. Pekka Taimen, Department of Pathology, Turku University Hospital. 
18
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2.3.5 Molecular subtypes of bladder cancer 
Studies have shown, that different cancers can be grouped into molecular sub-
types, which have common gene expression patterns and biological characteris-
tics, such as survival outcomes and therapy responses. Large-scale mRNA ex-
pression profiling and DNA sequencing studies have demonstrated, that as many 
other cancers, BC can be divided into subtypes according to tumors gene 
expression. In particular, NMIBCs and MIBCs have been shown distinct 
underlying molecular biology: NMIBCs are characterized by activating FGFR3 
(fibroblast growth factor receptor-3) mutations, whereas MIBCs are characterized 
by frequent p53 mutations.53-57 For MIBCs, dichotomization to luminal tumors 
(urothelial differentiation) and basal squamous tumors (basal cell or squamous 
differentiation) is broadly used. According to different studies, MIBCs can be 
divided at least into five molecular subgroups: (I) luminal papillary/uroA, (II) 
luminal infiltrated/p53-like, (III) luminal/genomically unstable, (IV) basal 
squamous, and (V) neuroendocrine subtype.58-64 In addition, a recent meta-cohort 
analysis from 2411 BC samples identified six molecular subtypes of BC (MC1-6), 
which overlap with subtypes from previous reports: MC1/neural-like, 
MC2/luminal, MC3/papillary-like, MC4/HER2-like, MC5/squamous-cell 
carcinoma-like, and MC6/mesenchymal-like subtypes.65 However, further studies 
are still needed, and additional subtypes may emerge. There is also evidence, that 
BC is often molecularly heterogenous and different molecular subtypes can emerge 
in one tumor.66 The subtypes display prognostic significance and associate with 
different benefit from systemic therapies. Basal squamous and neuroendocrine 
tumors express high levels of epithelial-to-mesenchymal transition (EMT) 
biomarkers and are aggressive, more prone to invade and metastasize than luminal 
subtypes.59, 63, 64 However, basal squamous tumors tend to respond most to 
neoadjuvant chemotherapy, which improves the prognosis.67, 68 Luminal 
papillary/uroA tumors are low-stage tumors with the longest disease-specific 
survival (DSS) and overall survival (OS).59, 69 However, the response to 
neoadjuvant chemotherapy varies and they have the lowest response rate to new 
checkpoint inhibitors.63, 68, 70 On the other hand, the luminal/genomically unstable 
and the luminal infiltrated/p53-like tumors appear to be chemoresistant but 
particularly sensitive to immune checkpoint blockade therapies.63, 68, 70, 71 Molecular 
subtyping could aid clinicians to select right treatment modalities to each patient in 
the future, but it is still long way to get the subtype classifications in the clinical 
practice. 
 
 
9
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2.4 Treatment of bladder cancer 
Bladder tumors were mentioned the first time in literature by Lacuna in year 1551. 
During the 16th and 17th centuries the first surgeries targeting bladder tumors were 
performed.72 Primary TUR-BT procedures (bladder tumor electro-resection) were 
done in 1910 by Edwin Beer, and TUR-BT, as such, was introduced in the 1930s.73 
Since then, TUR-BT has become the primary avenue for diagnosis and removing 
the tumor tissue. Today there is a variety of BC treatment guidelines published by 
organizations such as European Association of Urology (EAU), American 
Urological Association (AUA), National Comprehensive Cancer Network 
(NCCN), and National Institute for recommended treatments in order to facilitate 
the decision making of the clinicians.21 TUR-BT remains as the gold standard in 
the treatment of NMIBC whereas muscle-invasive tumors are treated with 
cystectomy with or without systemic therapies. Immunological treatment 
alternatives have taken a leap recently in patients with advanced disease. The 
treatment modalities for BC are summarized in Table 3. 
 
Table 3. Summary of bladder cancer treatment. 
NMIBC 
Low-risk patients (solitary, small, low-grade Ta): 
      TUR-BT + single immediate chemotherapeutic instillation (mitomycin) 
High-risk patients (multiple, recurrent, large, T1 and/or G3, high-grade and/or CIS): 
     TUR-BT + adjuvant BCG 
     RC (considered for high-grade, multiple or at difficult sites to resect T1 tumors  high grade + CIS) 
MIBC 
     Neoadjuvant chemotherapy + RC 
     (RC + adjuvant chemotherapy) 
     (TUR-BT + radiation therapy, chemotherapy) 
METASTATIC BLADDER CANCER 
     1. line chemotherapy (cisplatin-based: gemcitabine/cisplatin or MVAC1) 
         - If ineligible: gemcitabine/carboplatin or CPI (pembrolizumab, atezolizumab) 
     2. line chemotherapy (non-platinum-based) or CPI (pembrolizumab, nivolumab, atezolizumab, 
         avelumab, duvalumab) 
 
1 MVAC; methotrexate, vinblastine, adriamycin, cisplatin 
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2.4.1 NMIBC 
NMIBC is the most prevalent type of bladder cancer. A complete trans-urethral 
resection of bladder tumor (TUR-BT) is recommended for all NMIBC patients for 
the initial diagnosis and treatment. Management protocols are based on the patients 
risk of recurrence and progression.23, 74 NMIBC is divided into low, intermediate, 
and high-risk groups. The 5-year recurrence rate varies from 50 to 70% and the 
progression rate varies from 10 to 30% in TUR-BT treated NMIBC tumors. High 
stage and grade, large tumor size, multifocality, high number of previous 
recurrences, and the presence of concomitant in situ associate with recurrence and 
progression. Other negative prognostic factors are the presence of lymphovascular 
invasion (LVI), histological variants, and greater depth of invasion.28 
For low risk patients (solitary, small, primary low-grade Ta tumor) a single im-
mediate chemotherapeutic instillation (most commonly mitomycin) is recom-
mended after the resection of the tumor to reduce the recurrence.75-77 Intravesical 
chemotherapy destroys tumor cells floating in the irrigation fluid and urine after 
TUR-BT and it has an ablative effect on residual tumor cells at the site of the 
resection and on small overlooked tumors.74, 78 High-risk patients do not benefit 
from the immediate instillation of chemotherapy.79 Patients with high-risk disease 
(multiple, recurrent, large, T1 and/or G3 and/or CIS) are suggested to have further 
adjuvant therapies with intravesical drugs after complete TUR-BT. Bacillus 
Calmette-Guérin (BCG) instillations are considered to be the most effective 
treatment alternative to prevent the risk of tumor recurrence and progression.23, 28, 
80-82 Despite BCG has been used for treatment of BC for over 40 years, the exact 
mechanism of the antitumor effect of the treatment is still unknown (see Chapter 
3.7 Immunity in bladder cancer for more about the mechanism of the BCG 
treatment). The optimal schedule of the BCG regimen has been broadly discussed, 
but it is still not fully known, either. However, at least one year of maintenance 
BCG is required, and three-year maintenance is considered even more effective to 
prevent recurrence. The procedure is generally well tolerated, but can be associated 
with complications including irritative voiding symptoms, such as frequency, 
urgency, and dysuria. BCG instillations can also potentially cause bladder fibrosis 
and contracture. Major complications related to BCG treatment can appear after 
systemic absorption of the drug. Complications include fever, arthritis, 
granulomatous prostatitis, BCG sepsis, disseminated tuberculosis, and death. Thus, 
contraindications, such as immunosuppression, should be respected.25, 48 For 
patients with recurring tumors after BCG, RC should be considered.48, 83 
Patients, who experience disease progression from NMIBC to MIBC, have 
worse prognosis than those with primary muscle-invasive disease.84 Thus, radical 
cystectomy (RC) should be considered for high-grade, multiple T1 tumors; T1 
tumors located at difficult site to resect; residual T1 tumors; or high-grade tumors 
21
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with CIS, especially for patients with longer life expectancy.23, 85 Despite being 
superficial tumors, high-grade NMIBCs are aggressive. High-grade T1 BC has 
50% progression rate and 30% mortality in 15 year follow-up time.86 The staging 
accuracy for T1 tumors by TUR-BT is low, and 27-51% of the patients are 
upstaged to MIBC at RC.40 
BC is prone to recur and it is potentially lethal without aggressive treatment in 
about one third of the patients. The high recurrence rate makes the follow-up an 
important component of an effective management. Due to the high recurrence rate, 
a substantial risk of progression, and intensive treatment and follow-up protocols, 
BC is one of the most expensive cancers to manage.87 The recommended schedule 
for follow-up varies among BC guidelines and the follow-up protocol should 
reflect the patients degree of risk.23 The first cystoscopy after primary TUR-BT at 
three months is an important prognostic indicator for recurrence and progression.88 
According to the EAU guidelines, low-risk patients should undergo cystoscopy 
yearly for 5 years.89 After this, the risk of recurrence is low and discontinuation of 
cystoscopies can be considered. High-risk patients should undergo cystoscopy 
every 3 month for a period of 2 years and every 6 months after that until 5 years, 
and then annually. In addition, upper urinary tract imaging should be performed 
every 12-24 month.25 Because recurrence after 10 years of tumor-free interval is 
possible for intermediate or high-risk patients, life-long follow-up is recommended. 
2.4.2 MIBC 
Approximately every fifth BC patient has already at the time of diagnosis an in-
vasive disease with poor prognosis. The standard treatment for localized muscu-
laris propria invasive BC is radical cystectomy. The operation includes en bloc 
removal of the anterior pelvic organs; the bladder, prostate, seminal vesicle, and 
distal ureters in men and bladder, uterus, ovaries, anterior vaginal wall, and distal 
ureters in females.90 An extended bilateral pelvic lymphadenectomy is rec-
ommended.91 Traditionally, RC is the treatment of choice for tumors with T2-4a, 
N0-Nx, M0. RC can be considered with patients having a single lymph node 
metastasis in the true pelvis, but curative results are unlikely in N2-3 cases. Other 
indications include high-risk and recurrent non-invasive tumors, BCG-resistant Tis 
and T1G3 tumors. Salvage cystectomy is recommended after failure of 
conservative treatments. Cystectomy is also used as a palliative intervention 
including for fistula formation, pain, or recurrent macrohaemoturia.30 In well 
selected patients, who are not candidates or refuse definite cystectomy, bladder 
preservation with TUR-BT followed by radiation therapy with concurrent 
chemotherapy remains a viable option.92 
22
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During the cystectomy, urinary diversion is done with a segment of bowel in a 
non-continent or a continent way.93 Non-continent ileal conduit according to 
Bricker is the simplest urinary diversion draining into an external collecting-bag 
attached to the abdominal wall (urostomy). The ileal conduit is often selected in 
elderly patients with comorbidities and higher operative risk, whereas the conti-
nent diversion is often selected in young, healthy patients.25 The continent 
reconstructive procedures involve the creation of an internal reservoir with an 
antireflux mechanism, which is either brought to the abdominal wall (continent 
cutaneous or heterotopic neobladder) or sutured to the urethra (orthotopic ne-
obladder).44 This allows the patient either to self-catheterize or to void in the 
normal position. From an anatomical standpoint, currently used alternatives after 
cystectomy are (I) abdominal diversion (such as ureterocutaneostomy and ileal or 
colonic conduit), (II) urethral diversion (various forms of gastrointestinal pouches 
to the urethra as a continent, orthotopic urinary diversion), and (III) rectosigmoid 
diversions (such as uretero-ileo-rectostomy).30 RC results changes in quality of life 
by sexual dysfunction and reduction in urinary control. Prostate sparing cystectomy 
is possible for selected patients. The risks of this operation include prostate cancer, 
carcinoma in situ of the prostatic urethra, cancer in the prostatic duct/glands, or 
invasion to the prostate.94 
The peri-operative mortality associated with RC is 1.2-3.2% at 30 days and 2.3-
8.0% at 90 days after the operation.30 Early complications within three months after 
surgery occur in 58% of patients, most of being diversion related.95 The five-year 
recurrence-free survival after RC is approximately 58-68%. However, the five-year 
recurrence-free survival in node-positive patients is only 34-43%.30 
Because the five-year survival after RC is suboptimal, neoadjuvant 
chemotherapy (NAC, most commonly cisplatin combination chemotherapy) has 
been used to improve the results of the surgery.28, 44, 96-100 Distant metastases after 
RC are more common than local disease, which indicates that micrometastases may 
be present at the time of the operation. This microscopic dissemination is the target 
of NAC.101 NAC responders might reveal a favourable pathological status in RC 
(pT0, pN0, and negative surgical margins), but in contrast, patients resistant to 
chemotherapy might compromise the outcome with delayed RC.102 The 
downstaging of the tumor increases with NAC, which increases the survival 
benefits of the treatment.102 NAC treatment has 5-8% five-year OS benefit 
compared to surgery only treated patients.101 The downstaging is a potential 
surrogate marker for chemosensitivity and survival in BC patients.102 The challenge 
is the treatment of non-responders and overtreatment of patients without 
micrometastatic disease. Only approximately 40% of the patients experience a 
complete response to NAC and have no residual tumor in RC.103 A delay in RC 
might associate with decreased survival and the patients are exposed to 
3
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unnecessary toxicity.104 Persistent invasive BC after NAC is considered 
chemoresistant.103 Basal/squamous type tumors have been reported as best potential 
candidates for NAC, but however, to date, there are no validated biomarkers or 
tools to indicate which patients will most likely benefit from NAC.68 
As opposed to neoadjuvant chemotherapy, adjuvant chemotherapy enables im-
proved patient selection to patients with positive nodes or high pathological stage 
(Table 4). The role of the adjuvant chemotherapy is, however, not clear in the 
management of BC as the results from randomized trials are limited by poor ac-
crual and conflicting results.105-107 The disadvantage of the treatment is the delay in 
the systemic therapy against metastases and poor tolerance in postoperative period, 
but it does not cause delay in RC and the patient selection is more careful with 
precise pathological staging compared to NAC treated patients.25, 101  
Table 4. Pros and cons of the neoadjuvant and adjuvant chemotherapy, adapted from Raghavan et 
al. 2002.44 
 Neoadjuvant chemotherapy Adjuvant chemotherapy 
Pros Possibility to assess the response. Early systemic impact. 
Early treatment of occult metastases. Data from other cancers imply survival benefit. 
Survival benefit in some randomized trials. Trend in favor of survival from some studies. 
 Improved patient selection. 
Cons  Early and increased toxicity. Enhanced toxicity. 
Potential delay of effective therapy. No proof that the benefit is from chemotherapy. 
Poor patient selection. 
May not be needed if clinical 
understaging. 
No proven significant survival benefit. 
Inability to asses response (potential for 
continues ineffective therapy) 
  
2.4.3 Metastatic bladder cancer 
Metastatic BC is an incurable disease and the survival is poor: only 15% of these 
patients are alive at 5 years.108 The initial spread of the disease is typically to the 
pelvic lymph nodes, but metastases occur via lymphatic and haematogenous 
channels in other organs, most frequently the lungs and bones.109 Systemic 
chemotherapy has been the choice of treatment in metastatic disease.25 Cispla-tin-
based chemotherapy has a 60-70% overall response rate and it leads to median 
survival of around one year.110-, 111 However, up to 30-50% of the patients with 
metastatic BC are ineligible to the cisplatin treatment and until recently, 
carboplatin-based regimens have been the only treatment option for these 
patients.112 Furthermore, the treatment options after failure of the first line 
chemotherapy have been poor: second-line chemotherapies, including paclitaxel, 
pemetrexed, docetaxel, and vinflunine, have shown modest efficacy with an overall 
response rate of 12% and a median OS of 5-7 months.30, 113 For decades, there has 
been a lack of any improvements in the treatment of BC. However, recent 
24
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advancements in studies of novel immunotherapy agents have led to rapid changes 
in the treatment of advanced/metastatic BC and immunotherapy is now recognized 
as the fourth treatment alternative in BC. 
Immune checkpoint inhibitors (here referred as CPIs) selectively target 
pathways whose main target is to remove inhibitory signals or “brakes” on T cells 
allowing them to work as an effective antitumoral immune response (see Chapter 
3.5 Cancer immunotherapy for the detailed mechanism).114 The Programmed death 
1/programmed death-ligand 1 (PD-1/PD-L1) and the cytotoxic T-lymphocyte-
associated protein 4 (CTLA-4) pathways play important roles in the T-lymphocyte-
mediated response and are important drug targets.115 It has been speculated, that 
PD-1/PD-L1 blockade drugs will redefine the standard of care for BC. Five PD-
1/PD-L1 blockade drugs have been approved by the United States Food and Drug 
Administration (FDA) in the treatment of BC after the first approval in May 2016: 
PD-1 inhibitors pembrolizumab and nivolumab (Keytruda and Opdivo as brand 
names, respectively), and PD-L1 inhibitors atezolizumab, avelumab, and 
duvalumab (Tecentriq, Bavencio, and Imfinzi, respectively).116, 117 Pembrolizumab, 
nivolumab, and atezolizumab have also been approved in Europe.111 
Pembrolizumab is a highly selective, humanized monoclonal IgG4 antibody against 
PD-1 blocking both PD-L1 and PD-L2. It is the only checkpoint inhibitor that has 
shown significantly better survival than standard chemotherapy.115, 118-120 Median 
survival for pembrolizumab treated patients in a randomized phase III trial was 
10.3 months whereas chemotherapy treated patients had 7.4 months median 
survival. In addition, immunotherapy was better tolerated than chemotherapy.121 
However, the four other CPIs have also been approved for treatment of refractory 
metastatic BC in patients who have disease progression during the platinum-
containing chemotherapy. In addition, pembrolizumab and atezolizumab have been 
approved as the first-line treatment for cisplatin-ineligible metastatic BC patients. 
Although new CPIs have shown major improvements for treatment of metastatic 
BC, there are no tools for predicting which patients will benefit from the treatment. 
No clear correlation between the PD-L1 positivity on tumor cells and the response 
rate for the PD-1/PD-L1 inhibitors has been observed.117 Tumor-mutation burden 
and neoantigen load, as well as gene signatures, such as interferon γ (IFNγ) and 
basal molecular subtype, have shown to be potential predictive biomarkers to the 
CPIs, but further studies are needed to find a reliable biomarker to improve the 
patient selection.117 Immunotherapy will continue to shape the treatment 
alternatives for BC patients. There are ongoing trials to investigate the PD-1/PD-L1 
inhibitors further in the treatment of BC, e.g. in the treatment of NMIBC and as a 
neoadjuvant or adjuvant therapy for MIBC alone or combined with CTLA-4 
antibodies or chemotherapy.122 
5
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Despite the development with the CPIs, new rational targeted therapeutic 
options to improve outcomes of BC are needed. Most patients will eventually 
develop resistance to chemotherapy and/or CPIs. Studies have revealed several 
promising agents that are being developed and studied in advanced BC.123 Vascular 
endothelial growth factor (VEGF) has been shown to associate with more 
aggressive BC. Anti-VEGF receptor antibody combined with docetaxel 
chemotherapy has shown improvements in progression-free survival compared 
with docetaxel alone in patients progressed during/after platinum therapy.124 Other 
potential therapy targets under investigation are fibroblast growth factor receptor-3 
(FGFR3) family proteins, human epidermal growth factor receptors (EGFR and 
HER), and phosphoinositide 3 kinase (PI3K)/protein kinase B (AKT)/the mam-
malian target of rapamycin (mTOR) pathway proteins.123 
2.5 Biomarkers in bladder cancer 
There are several scenarios in which biomarkers would have a role in the 
diagnostics and treatment of BC in clinical practice: (I) in the screening of the 
high-risk population, (II) in the risk stratifying patients with asymptomatic 
hematuria, (III) in the surveillance setting to guide the treatment alternatives and 
follow-up, and (IV) in the prediction of the possible benefit of a specific treatment. 
A prognostic biomarker predicts the natural history of the disease independent of a 
particular treatment whereas predictive biomarkers are used to discriminate and 
determine differences in treatment-specific responses. An ideal biomarker would 
be accurate, reproducible, easy to use, and it should be validated in multiple 
datasets. The incidence of BC in population with increased risk of the disease is 
considered to be too low for screening program with a socioeconomic benefit.125 
On the other hand, patients with asymptomatic gross hematuria have a significant 
risk of BC, approximately 10%, and thus, need urologic investigations to make or 
rule out the diagnosis. In this group, urinary biomarkers for BC could limit the 
need for invasive and expensive procedures and urologic workup. In addition, 
patients diagnosed with BC need accurate information about their disease and the 
prognosis to select the right treatment modalities.126 Long follow-up periods after 
treatments make BC one of the costliest cancers and patients with very low risk of 
recurrence suffer from invasive and continual follow-ups.127 It remains a challenge 
to predict which patients will progress from non-invasive to invasive disease, to 
select administration of intravesical therapy (immediate postoperative instillation 
vs. adjuvant chemotherapy) or early RC vs. intravesical BCG for high-grade T1 
patients, or predict the benefit of the neoadjuvant chemotherapy or immunotherapy. 
In addition, the investigations of marker molecules and genes provide new 
information of possible new therapeutic approaches. 
26
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Despite several biomarkers being reported to be clinically promising, there are 
currently no prognostic BC biomarkers in routine clinical practice.128 The aim of 
the biomarker studies is to show that adding a molecular marker to existing 
parameters (with most important clinical and pathologic factors) improves the 
prognostic or predictive capacity of the current clinical tools. Many promising 
biomarkers have not been validated, or lack prospective clinical trials to confirm 
the role of the marker. Also, the reproducibility of biomarker assessment is often 
understudied. 
Urinary biomarkers represent an attractive choice as prognostic biomarkers with 
their non-invasive approach. Despite the FDA has approved some urinary bi-
omarkers (such as fluorescence in situ hybridization (FISH) assay UroVysion, a 
combination of urine cytology and immunohistochemical staining uCyt+ assay, and 
protein based bladder tumor antigen (BTA) and nuclear matrix protein 22 
(NMP22) assays) the suboptimal accuracy has limited the clinical use of the bi-
omarkers.21, 129, 130 The challenges with these biomarkers are the low sensi-tivity 
(18-43% of the BCs would be missed, approximately 10% in combination with 
cytologic evaluation) and specificity (false positive results in 12-26% of the 
patients), and the accuracy is poor especially for low-stage and low-grade 
tumors.21, 131  
In several studies, FGFR3 mutation has been shown to protect against progres-
sion in NMIBC, while overexpression of the tumor suppressor p53 and the 
proliferation marker Ki67 are examples of unfavorable molecular pathway in BC.64 
The p53 gene mutation is the most common genetic defect in human cancers. A 
large number of studies define Ki67 as an independent prognostic marker in BC. 
Although these markers are widely studied in BC and other cancers, the final 
prognostic role of these molecules in BC is still debated, and the studies are in-
sufficient to assess the outcome of BC with these markers into standard practice.128, 
132 Several studies have shown that overexpression of EGFR is an independent 
prognostic factor in patients with advanced BC. The overexpression of HER-2 
protein has been shown to correlate with increased tumor grade, cancer-specific 
survival, and metastatic disease and it has been also an independent prognostic 
factor is some studies. However, the investigations about EGFR and HER-2 are 
still heterogeneous and insufficient to prove the prognostic role of these markers.132 
VEGF is also an interesting potential prognostic marker with the possibility of 
urine measurements, but the prognostic studies of VEGF in BC are still 
insufficient.132 Survivin, an antiapoptotic biomarker, has been shown to associate 
with recurrence, DSS, and OS in a meta-analysis of 14 studies, but it lacks 
prospective large series to confirm the results.133  
Next-generation sequencing and gene expression profiling have led to 
identification of different molecular subtypes of BC (see Chapter 2.3.5 Molecular 
7
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subtypes of bladder cancer). The distinct subtypes show different clinical 
phenotypes and response rates to different treatment strategies. Tumors with basal 
subtypes are aggressive and often invasive, but also mostly sensitive to NAC while 
luminal tumors have best prognoses, but the responses to chemotherapy and CPIs 
vary.68, 70 However, the consensus of the subtypes has not been reached and they 
need further validations before getting into the clinical practice.  
New therapy modalities, such as NAC and CPIs, have revolutionized the treat-
ment of BC. There is an urgent need for predictive biomarkers to help guide the 
therapy options for each patient. Chemotherapy agents, such as platinum-
containing compounds, kill cancer cells via DNA damage. Cancer cells that have 
deficient DNA damage repair mechanisms are unable to fix the damage caused by 
the chemotherapy and thus, are more susceptible being destroyed by these drugs. 
Excision repair cross complementing 1 and 2 (ERCC1/2) are key enzymes in the 
nucleoside excision repair (NER) of DNA damage. ERCC1 have been considered 
as an attractive biomarker to evaluate the cisplatin sensitivity.134 Other DNA 
damage response genes, such as ataxia telangiectasia mutated gene (ATM), 
retinoblastoma gene (RB1), and Fanconi anemia complementation group C gene 
(FANCC), have also investigated as predictive markers for neoadjuvant cisplatin-
based chemotherapy.135 However, further prospective evaluations are needed to 
validate the predictive role of DNA damage response gene alterations in BC. In 
addition to the systemic chemotherapy, the PD-L1/PD-1 blockade drugs have been 
approved in the treatment of metastatic BC. PD-L1 is a T-cell regulatory molecule 
that is found frequently overexpressed in tumors and associates with higher grade, 
increased pathological stage, and poorer survival in BC.136, 137 However, there are 
no biomarkers to select the patients who would benefit most of these therapies 
either and the studies about the CPI biomarkers are ongoing (see Chapter 2.4 
Treatment of bladder cancer). 
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3 Tumor immunity 
The idea of cancer-related inflammation goes back to the 19th century, when Ru-
dolph Virchow, a German pathologist, provided a potential link between inflam-
mation and cancer.138 In 2000, Hanahan and Weinberg introduced six hall-marks of 
cancer that included sustaining proliferative signaling, evading growth suppressors, 
resisting cell death, enabling replicative immortality, inducing angiogenesis, and 
activating invasion and metastasis.5 A decade later, tumor-promoting inflammation 
and the capability to avoid immune destruction were added to the list among with 
the deregulation of cellular energetics and genome instability and mutation as 
enabling and emerging hallmarks (Figure 2).139 This proves the evident relationship 
between cancer and inflammation and describes the dual role of immune cells in 
cancer: on one hand the elimination of tumor cells and on the other, support for the 
tumor development. In 2018, the success in the field of cancer immunotherapy has 
been recognized, when Nobel Prize was awarded to James P. Allison and Tasuku 
Honjo for their discovery of cancer therapy by inhibition of immunosuppression. 
Tumors consist not only of a collection of homogenous cancer cells, but con-
struct a tumor microenvironment during tumorigenesis. This microenvironment 
includes individual specialized cell types, which contribute to the biology in the 
tumors and participate in the regulatory signaling of cancer cells. Tumor paren-
chyma and stroma contain distinct cell types, such as cancer cells and cancer stem 
cells, cancer-associated fibroblasts, vascular/lymphatic endothelial cells, and 
pericytes, which all collectively enable tumor growth and progression. In addition 
to these cells, immune cells are a crucial part of the tumor microenvironment.139 
Immune cells can act in conflicting ways being tumor-antagonizing or tumor-
promoting, and can be found in various proportions in the most of the neoplastic 
lesions.139 Leukocyte infiltration in tumors contains innate immune cells (including 
macrophages, neutrophils, dendritic cells, and natural killer cells) and adaptive 
immune cells (T and B lymphocytes). Inflammatory cells crosstalk with each other 
by direct contact or cytokine and chemokine production, and act in autocrine and 
paracrine manners to control tumorigenesis.140 Immune cells release tumor 
promoting signaling molecules, such as tumor growth factor EGF, proangiogenic 
factors (such as VEGF), chemokines and cytokines, and proangiogenic and/or 
proinvasive matrix-degrading enzymes (e.g. matrix metalloproteinase-9, MMP-9). 
Via these effectors, inflammatory cells stimulate cell proliferation, induce and help 
sustain angiogenesis, facilitate tissue invasion, and are involved in the metastatic 
seeding of cancer cells. In addition, immune cells can release mutagenic chemicals, 
which can accelerate the genetic evolution of nearby cancer cells toward advanced 
malignancy.139, 141 
 
9
31187368_Vaitoskirja_Minna_Tervahartiala_Laaketiet_tdk_sisus_B5_1308.indd   29 13.8.2019   10.47
Minna Tervahartiala 
 27 
Figure 2. The relationship of inflammation and cancer can be divided into two individual 
pathways: extrinsic and intrisic. Both pathways lead to activation of transcription factors, such 
as NF-κB, STAT3 and HIF, which regulate the activation of inflammatory cells and mediators. 
Resulted cancer-related inflammation is one of the hallmarks of cancer.139, 141 
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3.1 Extrinsic and intrinsic pathway 
In some cancers, inflammation is present before malignant change occurs (e.g. 
chronic inflammation in inflammatory bowel disease and inflammation due to 
tobacco smoking or obesity; viral/bacterial antigens, such as Helicobacter pylori, 
hepatitis B/C viruses, or Schistosoma; and cryptogenic inflammations of uncertain 
origin, such as prostatitis and pancreatitis), while in others, carcinogenesis induces 
an inflammatory microenvironment which promotes the development of tumors.140-
144 These two origins of inflammation can be viewed as two pathways connecting 
cancer and inflammation: (I) an extrinsic pathway driven by inflammatory 
conditions and increased risk of cancer and (II) an intrinsic pathway driven by 
genomic alterations causing inflammation and neoplasia (Figure 2).142 The 
microenvironment-driven extrinsic and the oncogene-driven intrinsic pathways 
converge and activate transcription factors, e.g. nuclear factor-κB (NF-κB), signal 
transducer and activator of transcription 3 (STAT3), and hypoxia-inducible factor 
(HIF), which orchestrate the activation of inflammatory cells and mediators, and 
generate a cancer-related inflammatory microenvironment.141, 142 However, 
inflammatory cells and their mediators are present in the microenvironment of 
most of the cancers despite the origin of the tumorigenesis. 
In the intrinsic pathway, different genetic alterations, such as activation of onco-
genes or inactivation of tumor suppressors, can trigger the inflammatory cascade.142 
The most frequently mutated oncogenes in human cancer are RAS family 
oncogenes, which can induce the production of inflammatory mediators, such as 
CXCL8 to promote angiogenesis and tumor progression.145 Another oncogene, 
MYC, promotes cell proliferation, instructs remodeling of the extracellular 
microenvironment with inflammatory cells and mediators, and recruits mast cells 
via CC chemokines to sustain angiogenesis and tumor growth.146 Like oncogenes, 
tumor suppressors have also capability to regulate the production of inflammatory 
mediators: Von Hippel Lindau/hypoxia-inducible factor (VHL/HIF) participates 
for example in the production of chemokine receptor CXCR4 and proinflammatory 
cytokine TNF-α.147 Mutation of tumor suppressor phosphatase and tensin 
homologue (PTEN) in non-small cell lung cancer activates the upregulation of 
HIF-1 and CXCR4, which promotes metastasis. Ablation of alpha catenin induces 
for example NF-κB activation, cell proliferation, and wound healing.148  
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3.2 The players of the cancer-related inflammation 
3.2.1 Tumor-infiltrated leukocytes 
 
Tumor-promoting inflammation and antitumor immunity coexist in different points 
of the tumorigenesis.140 Tumor microenvironment constitutes of several non-
immune and immune cells, which impact on tumor growth. Tumor-infiltrated 
leukocytes (TILs) are a major component of the tumor microenvironment (Table 
5): 10% of all cell types infiltrating the tumor consists of T cells.139 T cells 
maturate in the thymus. Naïve T cells bearing antigen-specific T cell receptors 
(TCR) are introduced to antigens by dendritic cells (DCs) in the secondary 
lymphoid organs.149 
Table 5. Roles of different inflammatory cells in the tumor microenvironment. Table adjusted from 
Grivennikov et al, 2010.140 
Cell type Antitumor immunity Tumor-promoting inflammation 
Macrophages, 
DCs, MDSCs 
Antigen presentation, cytokine 
production (IL-12, type I IFN) 
Immunosuppression, production of 
cytokines/chemokines/proteases/growth 
factors/angiogenic factors  
Mast cells --- Cytokine production 
B cells Production of tumor-specific 
antibodies 
Cytokine and antibody production, mast 
cell activation, immunosuppression 
CD8+ CTLs Direct lysis of cancer cells, cytotoxic      
cytokine production (perforin, 
granulysin, granzymes) 
--- 
Th1 cells Help to CTLs in tumor rejection, 
proinflammatory cytokine production 
(IFNγ, TNFα, IL-2, IL-12)  
--- 
Th2 cells --- Suppression of antitumor immunity, 
education of macrophages, cytokine 
production (IL-4, -5, -6, -10, -13), B cell 
activation 
Th17 cells Activation of CTLs Production of proinflammatory cytokine 
(IL-17, -21, -22), promotion of 
angiogenesis, inhibition of CTL 
differentiation 
Treg cells --- Suppression of effector T cell functions, 
production of cytokines (TGFβ, IL-35, IL-
10), upregulation of CTLA-4 and PD-1 
NK cells Direct cytotoxicity towards cancer 
cells, cytotoxic cytokine production 
--- 
Neutrophils Direct cytotoxicity, regulation of CTL   
responses 
Cytokine/protease/ROS production 
32
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CD8+ cytotoxic T cells  (CTLs) and natural killer cells (NK cells) are critical 
mediators of the anti-tumor response by producing IFNγ and directly killing cancer 
cells (see Figure 3).150 In addition, NK cells produce several cytokines and 
chemokines and thus, regulate immune responses and promote the recruitment of 
DCs into tumors.151 CTLs recognize tumor-specific neoantigens introduced by 
APCs and release cytotoxic granules containing perforin, granulysin, and 
granzymes leading to cancer cell death.152 CTL infiltration in the tumor tissue is 
associated with more favourable prognosis in several cancers, e.g. in bladder, 
prostatic, breast, and colorectal cancers.153 
While CD8+ CTLs have a well-defined role in preventing cancer development, 
CD4+ T lymphocytes have more paradoxal functions. CD4+ T cells are a hetero-
geneous group of cells that develop various functional lineages depending on the 
cytokine signals during the activation by antigens.154 Predominant CD4+ cell 
subset can even vary depending on the stage of the disease.155 Classically, CD4+ T 
cells include Th1 and Th2 subgroups (T helper cells) fostered by interleukins 12 
and 4 (IL-12 and IL-4), respectively. Th1 restrain cancer development: they 
regulate CD8+ CTL responses by secreting IFNγ, tumor necrosis factor α (TNFα), 
IL-2, and IL-12, and can directly kill tumor cells with IFNγ, TNFα and cytolytic 
granules. In contrast to Th1 cells, Th2 cells associate with cancer progression by 
expressing high levels of IL-4, IL-5, IL-6, IL-10, and IL-13. They are not directly 
cytotoxic; they rather modify adaptive immunity by releasing cytokines to activate 
other immune cell types.156 Th2 cells induce T cell anergy, inhibit T cell mediated 
cytotoxicity and foster humoral immune response. The total outcome of Th2 cells 
to cancer prognosis is controversial: Th2 cells are considered as protumoral in 
general, but they have been shown to promote anti-tumor activities for example in 
colorectal cancer, as well.157 
In addition to Th1 and Th2 cells, CD4+ cells include Th17 subset that is 
differentiated by IL-6 and transforming growth factor β (TGFβ), and secrete IL-17, 
IL-21, and IL-22. The role of Th17 cells in cancer development is probably context 
dependent. Another subgroup of CD4+ cells is T regulatory cells (Tregs, 
CD4+FoxP3+) that correlate with poor prognosis in several cancers, such as in 
pancreatic, lung, renal, and breast cancer.150 They control tumor development by 
suppressing CD8+ CTLs, NKs, and DCs, increase local levels of immunosup-
pressive cytokines (e.g. TGFβ, IL-35, and IL-10), and have direct cytolytic effects 
through production of perforin and granzyme.158 However, it has been suggested, 
that there are multiple tissue-specific Treg subpopulations with various bioeffector 
activities.159-161  
Neutrophils are the dominant leukocyte subgroup in the peripheral blood. They 
have a major role in the first line defense against pathogens. With their short life 
span and fully differentiated phenotype, neutrophils have been considered as neg-
3
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ligible in tumors. However, it has recently been noticed, that tumor-associated 
neutrophils (TANs) can be polarized towards distinct phenotypes in response to 
tumor-derived signals and have both anti- and pro-tumoral functions, as well.162 
Neutrophils are involved in carcinogenesis through the release of nitric oxide 
derivatives and reactive oxygen species (ROS). Neutrophil-derived cytokines and 
proteins from the granules of neutrophils may also play a dual role in tumor 
progression.163  
In addition to other leukocytes, macrophages are a significant part of the tumor 
microenvironment. Tumor-associated macrophages are covered later in Chapter 3.5 
Macrophages. 
 
3.2.2 Immune mediatoris in cancer-related inflammation 
Most of the inflammatory cells in the tumor microenvironment have both pro- and 
antitumorigenic functions. However, the cytokine and chemokine profile of the 
microenvironment may be more crucial than its specific immune cell content 
(Table 6). The key orchestrators in cancer-related inflammation include tran-
scription factors (e.g. NF-κB and STAT3), cytokines (e.g. IL-1β, IL-6, IL-23, and 
TNF-α), and chemokines. Some of the most essential orchestrators are introduced 
briefly as follows. 
Table 6. Tumor microenvironment includes cytokines and chemokines that act as mediators in the 
cancer-related inflammation. 
Cytokine Function 
Interferon γ (IFNγ) Proinflammatory/Th1 
Interleukins 1, 6 (IL-1, -6) Proinflammatory, prometastatic 
Interleukins 4, 5, 10 (IL-4, -5, -10) Immune regulatory/Th2 
Macrophage colony-stimulating factor (M-CSF) Growth factor 
Migration inhibitory factor (MIF) Proinflammatory 
Transforming growth factor β (TGFβ) Growth factor, immunosuppressive 
Tumor necrosis factor (TNF) Proinflammatory 
Vascular endothelial growth factor (VEGF) Angiogenic, vascular permeability 
Chemokine Attract 
Eotaxin/CCL11 Eosinophils 
B cell attracting chemokine-1 (BCA-1)/CXCL13 B cells 
Growth-regulated oncogene-α (gro-α)/CXCL1 Neutrophils 
Interleukin 8 (IL-8)/CXCL8 Neutrophils 
Macrophage derived chemokine (MDC)/CCL22 Th2 cells 
Monocyte chemotactic protein-1 (MCP-1)/CCL2 Polarizes immunity to the Th2 direction 
Thymus and activation regulated chemokine 
(TARC)/CCL17 
Th2 cells 
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NF-κB (Nuclear factor kappa light chain enhancer of activated B cells) 
NF-κB is a key player in inflammation. It is crucial for both cancer cells and in-
flammatory cells.141, 142, 144 NF-κB is the coordinator of the innate immunity and has 
been shown to function as an important tumor promoter. As a transcription factor, 
NF-κB controls cell survival by regulating programmed cell death, proliferation, 
and growth arrest. It has a dual role in tumor promotion: it prevents the death of 
malignant cells and stimulates the production of proinflammatory cytokines. 
Despite the predominantly protumoral role of NF-κB, in some cases and especially 
in early cancers, NF-κB may be tumor suppressive.147 NF-κB activates the 
expression of genes encoding cytokines, adhesion molecules, prostaglandin-
synthesis pathway enzymes (such as cyclooxygenase 2, COX2), inducible nitric 
oxide synthase (iNOS), and angiogenic factors. It also induces the expression of 
anti-apoptotic genes (such as BCL2), and thus, promotes the cancer cell survival. 
NF-κB pathway is tightly controlled by activators and inhibitors, such as in 
intestinal mucosa expressed Toll-interleukin receptor-8 (TIR8) and single 
immunoglobulin interleukin 1 receptor-related protein (SIGIRR).142 Deficiency in 
TIR8 encoding gene is associated with increased risk of intestinal inflammation 
and carcinoma, as well as with B cell proliferation and autoimmunity. TNF-α 
produced by neighboring inflammatory cells controls also the NF-κB activation 
state and localization in the cell. However, NF-κB activation in malignant cells 
occurs often as a result of genetic mutation rather than in response to signals from 
surrounding cells.164, 165 NF-κB has also been shown to be involved in macrophage 
polarization to M2 macrophages (see Chapter 3.5 Macrophages).142  
STAT3 (Signal transducer and activator of transcription 3) 
Transcription factor STAT3 is a point of convergence in several oncogenic sig-
naling pathways, and is involved in oncogenesis and in the inhibition of apoptosis. 
STAT3 is activated both in tumor and immune cells. Its activation has been shown 
to increase the capacity of cancer cells to evade the immune system by inhibiting 
the maturation of DCs and suppressing the immune response. STAT3 has a dual 
role in cancer-related inflammation: it promotes protumoral inflammatory 
pathways, including NF-κB and IL-6/glycoprotein 130 (gp130)/Janus kinase (JAK) 
pathways, and opposes STAT1 and NF-κB-mediated Th1 anti-tumor immune 
responses.141, 142  
TNF-α (Tumor necrosis factor-α) 
TNF-α has a role in the persistence of inflammation and tumor growth and pro-
gression.138 It is a major mediator of inflammation, with actions directed to-wards 
both tissue destruction and recovery. TNF induces death of diseased cells and 
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stimulates fibroblast growth. It can destroy blood vessels but also induce an-
giogenic factors. As its name says, tumor necrosis factor-α causes hemorrhagic 
necrosis and can stimulate antitumor immunity in high doses. However, cancer cell 
produced TNF-α acts usually as a tumor promoter.147 In addition to cancer cells, 
macrophages and CD4+ cells secrete TNF-α and trigger inflammation. The 
production of pro-inflammatory TNF-α is associated with increased release of 
chemokines, IL-6, and MIF-1. Via CXCR4 TNF-α participates in cancer cell 
spread and tumor cell survival.142 It also stimulates angiogenesis due to in-duction 
of CXCL12 and VEGF. 
IL-1 (Interleukin-1) 
Another soluble mediator of cancer-related inflammation is cytokine IL-1. Patients 
with increased expression of IL-1 have generally bad prognosis: it promotes tumor 
growth and metastasis by inducing several pro-metastatic genes. IL-1 can stimulate 
the expression of endothelial adhesion molecules, such as intercellular adhesion 
molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1). In 
addition, IL-1 is a potent proangiogenic cytokine and mediates VEGF release. On 
the other hand, small amounts of IL-1α can be poured out from necrotizing cells 
and serve as a danger signal for anti-tumoral immune responses.142  
IL-6 (Interleukin-6) 
IL-6 is an inflammatory cytokine promoting tumor growth and antiapoptotic re-
sponses. It is one of the effector signals of activated NF-κB and activator of on-
cogenic STAT3. IL-6 protects cells from apoptosis and promotes proliferation.142 
TGFβ (Transforming growth factor β) 
TGFβ is one of the regulators in the inflammatory reaction in the tumor microen-
vironment. Specific deletion of tgfbr2 increases tumor progression and metastasis 
in several cancers, such as breast, pancreatic, intestinal, and head and neck can-
cers. It is assumed that TGFβ effects are regulated through NF-κB. TGFβ regu-
lates the production of chemokine/chemokine receptors (e.g. CXCL12) important 
to inflammatory cell recruitment. TGFβ secretion by cancer cells leads to inhibi-
tion of DC activation and direct inhibition of T cell and NK cell function, as 
well.166 
Chemokines 
Chemokines are a major subgroup of cytokines playing a central role in the re-
cruitment of leukocytes to the site of inflammation. Most tumors produce chem-
okines α (CXC group) and β (CC group). Typically CXC chemokines (such as    
36
31187368_Vaitoskirja_Minna_Tervahartiala_Laaketiet_tdk_sisus_B5_1308.indd   36 13.8.2019   10.47
Review of literature 
 34 
IL-8) are active on neutrophils and lymphocytes, whereas CC chemokines (such as 
eotaxin, macrophage derived chemokine, MDC, or thymus and activation reg-
ulated chemokine, TARC) act on several leukocyte subsets including monocytes, 
eosinophils, DCs, and NK cells (but not on neutrophils). Leukocytes and cancer 
cells express chemokine receptors (CCR and CXCR) and thus, tumor cells can use 
chemokine gradients to spread around the body.138 
 
3.3 Cancer immunosurveillance and immunoediting 
The immune system can prevent tumors in three ways: (I) immune cells can sup-
press viral infections and thus, protect the host from virus-induced tumors, (II) 
inflammation can prevent the establishment of a protumoral microenvironment, 
and (III) immune cells can specifically identify and eliminate malignant cells 
through tumor-specific antigens by a process called immunosurveillance.167 The 
immune system can operate as a barrier to tumor formation and progression which 
cancer cells need to beat in order to develop a tumor.139 Follow-up studies of 
immunosuppressed transplant patients and patients with primary immuno-
deficiencies have shown that immunosuppressed patients have a significantly 
higher risk for cancer development.168 
The innate and adaptive immune systems can protect from the tumor develop-
ment through immunosurveillance. High numbers of lymphocytes (especially T 
cells) have been reported to associate with good prognosis in various types of can-
cer (e.g. in melanoma, breast, ovarian, head and neck, esophagus, bladder and colo-
rectal cancer).143, 167, 169 The mechanisms of inflammation fighting against cancer 
include presenting cancer antigens to T-cells via antigen-presenting cells (APCs), 
priming and activating T cells in lymph nodes, T cell trafficking and infiltration 
into tumor tissue, recognition of cancer cells by T cells, antigen-specific systemic 
effector and memory T cell development, and humoral immunity.170 As the 
immune system can act as an extrinsic tumor suppressor, it can paradoxically also 
promote cancer initiation, promotion, and progression. Immunosurveillance and 
tumor-promoting inflammation can coexist even in the same tumor and thus, the 
prognostic value of these components needs wide-ranged research.140,  167 
Cancer immunosurveillance represents only one part of a more complex and dy-
namic process, cancer immunoediting. The term “immunoediting” contains not 
only immune system protecting the host against cancer but also sculpting the tu-
mor immunogenicity.167, 168, 171 At the early stages of tumorigenesis, cancer cells 
express proinflammatory “danger” signals that initiate the cancer immunoediting. 
Cells from innate immunity (such as NK cells activated by cytokines released by 
tumor cells and macrophages and stromal cells surrounding the tumor cells) and 
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adaptive immunity (mainly tumor antigen specific T lymphocytes) protect the host 
from tumor formation and eliminate the developing tumor (immunosurveillance or 
elimination, the first phase of immunoediting).171-173 The strongest evidence for the 
elimination phase in humans is the phenomenon of spontaneously regressing 
melanoma lesions accompanied by T cells.174, 175 Lymphocytes recognize 
transformed cells and promote IFNγ production. IFNγ initiates a cascade of innate 
immune response that includes the induction of chemokines, antiproliferative 
action on the developing tumor, the activation of cytocidal effect in macrophages, 
and NK cells infiltrating the tumor.168, 171, 175 Chemokines, such as CXCL10, 
CXCL9, and CXCL11, block the neovascularization in the tumor and recruit NK 
cells, DCs, macrophages, and other immune cells. If the sporadic cancer cells 
survive from this process, they may be maintained chronically or sculpted by 
immune editors to produce new populations of tumor variants with decreased 
immunogenity. This is called equilibrium, the second phase of immunoediting.171, 
172 In the equilibrium phase, the immune system, especially adaptive immunity, and 
cancer cells hold a dynamic balance.167 The correlation between the quality and 
quantity of intratumoral immune response and patient survival has been revealed in 
colon and lung cancer.176, 177 Moreover, the type and density of infiltrating 
lymphocytes were more powerful prognostic factors than pathological tumor 
staging. The enhanced survival is associated particularly with subsets of T cells, 
such as CTLs and Tregs. The term dormancy describes a latent tumor that may 
eventually, after years or even decades, recur as a local lesion or form distant 
metastases.178-180 Evidence of an immune derived equilibrium phase has been seen 
in the unintentional transplantation of cancer cells from organ donor to 
immunosuppressed recipient. In these cases the donors had no signs of cancer at 
the time of organ donation but the recipients undergoing immunosuppression for 
organ engraftment later developed cancers of donor origin.181 These variants of 
tumor cells have evaded the immune system and become macroscopic tumors 
(escape, the last phase of immunoediting).171 The macroscopic tumor growth is 
enabled by changes occurring in the tumor cell population (immunoediting), or in 
the host immune system resulting from cancer-induced immunosuppression or 
immune system breakdown due to the natural aging process.167 The escape phase 
represents the failure of the immune system to eliminate or control the transformed 
cells allowing tumors to develop in an immunologically unrestricted manner. 
According to the Darwinian selection, the most fit tumor variants survive and form 
overt cancer in an immunocompetent host. 
Tumor antigens (specific mutant cell antigens consisting of products of mutant 
genes, abnormal metabolic modifications released by cancer cell death) are the 
cores of the intrinsic antitumor system. They can be absorbed by DCs and deliv-
ered to lymph nodes to introduce the antigen to the lymphocytes (Figure 3). In-
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duced B cells differentiate into plasmacytes and produce specific antitumor anti-
bodies, which can direct NK cells to kill tumor cells (antibody-dependent cell 
cytotoxicity, the ADCC effect) and guide macrophages to phagocytose tumor cells 
(antibody-dependent cell phagocytosis, the ADCP effect). The killing of the cancer 
cells releases additional tumor-associated antigens to increase the immune 
response. DCs can also induce the production of CD8+ CTLs to selectively kill 
tumor cells after delivered to T cells via TCR. IFN cytokine family can enhance the 
antitumor responses in several ways: IFNγ increases major histocompatibility 
complex I (MHC I) expression on tumor cells, making them better targets to CD8+ 
CTLs.167 It also plays an important signaling role in host immune and stromal cells. 
NK cells (having cytoplasm filled with active particles, such as perforin, granzyme 
and IFNγ, that can be released to destroy cells) and macrophages are natural 
immune cells that do not need direct antigen stimulation to have a powerful killing 
effect on cancer cells. In contrast, T cells need to be activated by tumor antigens. 
However, T cell antigen receptor by itself is insufficient to generate T cell 
responses. Thus, for proper activation T cells have a combination of TCR signals: 
costimulatory signals (such as B7/CD28, CD137/CD137L, CD40/CD40L), 
inhibitory receptor signals (such as CTLA4, PD-1/PD-L1), and environmental 
factor signals.140,  182, 183 
The antitumoral immune response can be triggered also with certain bacterial 
infections. There is evidence of regression and increased survival after bacterial 
infections. This approach is utilized in bladder cancer treated with Mycobacterium 
bovis BCG. The infection triggers favorable inflammatory response through Toll-
like receptors (TLRs), which promotes the M1 phenotype macrophage dif-
ferentiation and effective adaptive immune response in tumor. However, the 
mechanism how to trigger the immune response to antitumoral type is still not clear 
and it is an important field of study to find the optimal stimuli to change the tumor-
promoting microenvironment to a tumor-inhibiting one.141 
To survive from antitumor responses, cancer cells need to escape from NK cells 
and macrophages by encapsulation/camouflage or formation of natural barrier by 
tumor stroma.182 Several pathways in the tumor microenvironment suppress the 
effective adaptive immune responses.184 For example, the differentiation of DCs is 
inhibited by different signals, such as IL-10. In addition, protumorigenic Tregs 
suppress both adaptive and innate immune cells, and tumor-associated 
macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs) are potent 
suppressors of antitumor immunity.141 Tumor cells can express ligands to suppress 
T cells (such as PD-L1) and inhibit the activity of effector immune cells by 
recruiting Tregs and MDSCs. CTL proliferation and activation is suppressed 
through various mechanisms by tumor cells.166 In cancer patients, the cycle of 
cancer immunity does not function optimally: the tumor antigen may not be de-
9
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tected, DCs and T cells can treat the tumor antigens as self rather than foreign, 
Treg responses may be created rather than effector responses, T cells may not 
properly home to tumors, or the effector cells might be suppressed by the factors 
from tumor microenvironment.185 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
3.4 Cancer-related inflammation and metastasis 
From a clinical point of view, metastasis is the most critical part of the tumor-
igenesis, because most of the cancer mortality occurs due to tumor formation at 
distant sites of the body. Inflammatory components have an essential role in the 
process of metastasis.141 Chemokines and cytokines coordinate autocrine and 
paracrine interactions between cancer cells and infiltrating leukocytes, which 
Figure 3. Tumor antigens are released for example from dying tumor cells and presented to naive T 
cells in the lymph nodes by DCs. T cells are a heterogeneous group of cells that are activated in the 
draining lymph nodes through antigen presentation. Tregs suppress the function of effector T cells. 
T cells need several signals for proper function. PD-1/PD-L1 represents an example of an inhibitory 
signal, which reduces the antitumoral effect of T cells. 
40
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promote cell migration, invasion and survival. They also affect the growth of the 
tumor and the ability to colonize the metastatic niche. Cancer is a systemic disease 
and primary tumors produce molecules that influence metastatic outcome at distant 
sites. However, metastasis as a process is very inefficient in human tumors: only 
few successful cells make finally metastasis despite the fact that many thousands of 
cancer cells circulating in the blood stream daily.186 Tumor cells use the same 
molecular tools (adhesion molecules, cytokines, chemokines, and chemokine 
receptors) and pathways as leukocytes when spreading to distal sites during 
inflammation.138, 144 Cancer cells start to express chemokine receptors when 
transformed to invasive and metastatic cells. Chemokine receptors and their ligands 
direct the movement of the cancer cells and promote metastasis by maintenance of 
tissue homeostasis and survival at sites distant from the primary tumor.141 For 
example, CXCR4 and its ligand CXCL12 are important for cell movement. 
CXCR4 is the most frequently up-regulated chemokine receptor in tumor cells, and 
the amount of expression correlates with the extent of metastasis in colorectal, 
breast, liver, and oesophageal cancer. Expressions of different chemokine recep-
tors in tumor cells are implicated in organ-specific metastases: e.g. CCR7 corre-
lates with lymph node metastasis and CCR9 correlates with small intestine me-
tastasis in melanoma. Chemokine-receptor expression is upregulated by cytokines 
such as TNF-α, IL-1β, and IL-6. The invasive capacity of cancer cells increases 
simultaneously with the chemokine-receptor expression. 
The process of metastasis can be divided into four stages: (I) epithelial-
mesenchymal transition (EMT), (II) intravasation into vascular and lymphatic 
vessels, (III) trafficking throughout the circulation, and (IV) extravasation from the 
vessels and proliferation at the metastatic niche. In the first stage, cancer cells 
acquire fibroblastoid characteristics. This increases the mobility of cancer cells and 
allows them to invade epithelial lining/basal membrane to reach the vessels. The 
key event in the EMT is the loss of E-cadherin expression. TGFβ, produced by 
cancer cells, myeloid cells, and T lymphocytes, regulates the EMT and, thus, 
metastasis. Increased TGFβ expression in tumors is often associated with poor 
prognosis. Inflammation promotes the second step, intravasation of the cancer 
cells, by production of mediators that increase vascular permeability. Intravasation 
of cancer cells is regulated by prostaglandins, cytokines, and MMPs. Only 
approximately 0.01% of the cancer cells entering the circulation will survive to 
give rise to micrometastases. A variety of cytokines, such as TNF-α, IL-6, and 
epiregulin, can promote the survival of circulating metastatic seeds. However, 
single metastatic cells in the circulation, away from the immunosuppressive tumor 
microenvironment, can be targeted by immunosurveillance. At the last stage of 
metastasis, metastatic seeds arrest on the endothelium and extravasatate into the 
tissue with the help from e.g. integrins. Several proinflammatory cytokines 
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elevated in the circulation upregulate the expression of adhesion molecules on the 
endothelium in the target organ and increase the probability of metastatic cell 
attachment. In the tissue, single metastatic progenitors interact with inflammatory 
and stromal cells and start to proliferate resulting a metastatic tumor.140  
 
3.5 Macrophages 
Macrophages act in innate immunity with multiple functions. Myelomonocytic 
cells act as the first line defense against pathogens. They activate adaptive re-
sponses and are among the first cells to arrive to the wounding or infection site 
after neutrophils.187 They produce chemokines and cytokines to recruit other 
inflammatory cells and promote tissue repair by growth factors, angiogenic fac-
tors, and proteases. In addition, macrophages produce reactive oxygen and nitro-
gen radicals to kill pathogens and function as APCs to T cells.188 Macrophages 
originate from bone marrow precursors common hematopoietic stem cells (HSC). 
In response to M-CSF, they divide and differentiate into monocytes through 
monoblast and pro-monocyte stages and exit to the circulation from the bone 
marrow. In response to inflammation, these monocytes integrate into tissues and 
activate as tissue-specific macrophages, such as osteoclasts in bone, microglial 
cells in the central nervous system, and Kupffer cells in liver.189-191 
Plasticity and diversity are the known hallmarks of the multifunctional mono-
cyte-macrophage lineage.192 They undergo reprogramming of their functional 
properties in response to signals from microbes, damaged tissues, and lympho-
cytes. Macrophages constitute a part of the innate immunity, but they have also a 
built-in adaptive component: they are reshaping their subsequent responses to 
microbial encounters.187 In physiological conditions, the main function of 
macrophages is to clear the interstitial environment from extraneous cellular ma-
terial by phagocytosis. They remove cellular debris e.g. from necrosis, clear the 
apoptotic cells, and recycle e.g. iron and hemoglobin by phagocytosis of erythro-
cytes.190 Macrophages are the primary sensors of danger in the host. They detect 
endogenous danger signals present in the debris of necrotic cells. Macrophages are 
critical components of the wound healing process. In addition, macrophages play a 
role in development and morphogenesis of many tissues.188  
3.5.1 Macrophage polarization 
Two distinct types of polarized activation of macrophages are recognized: the 
classically activated M1 macrophage phenotype and the alternatively activated M2 
phenotype (Table 7).189, 192 M1 macrophages are activated by microbial components 
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such as lipopolysaccharide (LPS), IFNγ from the Th1 cells, CD8+ T cells or NK 
cells, and TNF from APCs, whereas M2 polarization occurs in response to the 
cytokines IL-4 (from Th2 immune responses or mast cells, basophils, and 
granulocytes during tissue injury) and IL-13 (from Th2 immune responses) or in 
response to stress induced glucocorticoid release.163, 187, 190, 192-194 The activities of 
M1 macrophages have been summarized as “fight” activities while M2 
macrophages are “fixing” type macrophages.195 M1 macrophages produce large 
amounts of proinflammatory cytokines, such as IL-12, IL-23, and TNF, and 
effector molecules, such as reactive oxygen and nitrogen intermediates (ROI and 
RNI, respectively). They are characterized by increased expression of MHCII and 
are efficient in antigen presentation. M1 macrophages have microbicidal and 
tumoricidal activities, and are key mediators of the immunopathology in several 
autoimmune diseases, such as rheumatoid arthritis and inflammatory bowel 
disease.163, 187, 188, 190, 192,  193 
M2 macrophages are a part of Th2 immune response, including humoral 
immunity, and are considered to be involved in intracellular pathogen containment. 
They have a high expression of immunosuppressive cytokine IL-10 and a low 
expression of IL-12. They show phagocytic activities and high expressions of 
scavenging (SR), mannose (MR) and galactose receptors, and are involved in 
wound healing processes. M2 macrophages help with parasite clearance, dampen 
inflammation, promote tissue remodeling and tumor progression, and have immu-
noregulatory functions. In contrast to M1 macrophages, M2 macrophages fail to 
present antigens to T cells, produce minimal amounts of pro-inflammatory cyto-
kines, and are less efficient at killing intracellular pathogens. They suppress T cell 
activation and proliferation by prostaglandin, IL-10, and TGFβ production. In 
addition, M2 macrophages support angiogenesis and lymphangiogenesis by 
releasing proangiogenic growth factors such as IL-8, VEGF, and EGF.187, 190, 192, 193  
M1 and M2 macrophages have distinct chemokine profiles: M1 macrophages 
express chemokines such as CXCL9/monokine induced by IFNγ (MIG) and 
CXCL10/IFNγ-induced protein-10 (IP-10), whereas M2 macrophages express 
CCL17/TARC, CCL22/MDC, and CCL24/Eotaxin-2. Chemokines can also affect 
the polarization of macrophages with CCL2 and CXCL4 driving the polarization 
toward M2-like phenotype.187 
Despite the well-known subdivision of macrophages, the M1/M2 polarization is 
not the whole truth about macrophage diversity and more of an oversimplification 
of the complex biology of mononuclear phagocytes. M1 and M2 phenotypes can be 
considered as two opposite states in a broad macrophage polarization spectrum. 
Especially M2 has been considered as a generic name for a various forms of 
alternatively activated macrophages that have distinct effects according to the 
activating factors.187, 194 M2 macrophages have been suggested to be subdivided 
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into M2a, M2b, and M2c macrophages.193 M2a macrophages are polarized by IL-4 
and IL-13, and promote Th2 immune responses and are involved in allergic 
reactions and parasite killing, whereas M2b cells are activated by immune 
complexes and TLR or IL-1R and promote immune regulation and Th2 responses. 
M2c macrophages are activated by IL-10 and they function also as 
immunoregulators, but as matrix deposition and tissue remodeling cells, too. 
However, this subdivision, too, is probably much simpler than the truth about the 
wide spectrum of M2-like macrophages. Furthermore, a shift in macrophage 
phenotypes during the course of several diseases (such as sepsis, cancer, and 
obesity) has been noticed. Even in the process of wound healing, macrophages 
undergo dynamic changes switching their phenotype form an M1 to an M2 phe-
notype.187,  196 
 
Table 7. Differences in classically activated (M1) and alternatively activated (M2) macrophages. 
 M1 macrophages M2 macrophages 
Activators IFNγ, TNF, LPS IL-4, IL-13, IL-33, IL-10, 
glucocorticoids, vitamin D3  
Cytokine expression IL-12, IL-23, TNF, IL-6, IL-1 IL-10, IL-1RA, MSF  
Chemokine expression CXCL9, CXL10 
à Th1 cells, NK cells 
CCL2, CCL17, CCL18, CCL22, 
CCL2 à Th2 cells, Tregs, 
eosinophils, basophils  
Receptor expression MHC, TLR2/4, CD80, CD86, 
CD16 
SR-A, MR, galactose receptor, 
CD163, CD206, CLEVER-1 
Growth factor and effector 
molecule production 
iNOS, ROI Proangiogenic growth factors (IL-
8, VEGFA, VEGFC, EGF), TGF-β, 
FGF arginase 
Functions Antigen presentation, humoral 
immunity, killing of the 
intracellular pathogens 
Phagocytosis, scavenging, 
parasite clearance, tissue 
remodeling, angiogenesis, allergy, 
wound healing 
Immunity Th1 response, proinflammatory Th2 response, anti-inflammatory 
Tumor function Antitumoral Protumoral 
3.5.2 Tumor-associated macropahges 
Tumor-associated macrophages (TAMs) are an essential component of the cancer-
related inflammation and the tumor microenvironment.141  Stromal and tumor cells 
produce chemokines and growth factors to recruit circulating monocytes and 
differentiate them into macrophages. For example, CCL2/MCP-1, CCL5/regulated 
upon activation normal T cell expressed and secreted (RANTES), CXCL12/stromal 
derived factor-1 (SDF-1), and CXC3L1/fractalkine contribute to macrophage 
recruitment and tumor promotion. In addition, M-CSF/CSF1, VEGF, TGFβ, bFGF, 
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urokinase plasminogen activator (uPa), and antimicrobial peptide β-defensin-3 are 
involved in monocyte recruitment and macrophage differentiation in tumors.141, 192, 
193,  197-199 
In cancer, macrophages can have either beneficial or pathological roles depend-
ing on the tumor microenvironment.200 They can prevent the establishment and 
spread of tumor cells, and simultaneously, support tumor growth and dissem-
ination.201 TAMs generally have an M2-like phenotype.202 Th2 cell-derived IL-4 
and IL-13 have a key role in M2 activation and protumoral roles of macrophages in 
tumors.187 Tumor cells produce IL-10 and CSF1, as well as chemokines CCL17 
and CCL22 to promote M2 polarization in tumor tissue.199 However, variations of 
TAM polarization have been noted depending on the tumor type.187 Furthermore, 
macrophage phenotype can vary according to their location in tumors (sites of 
initial tumor cell invasion, perivascular areas, stromal regions, and 
hypoxic/necrotic areas) in response to local signals.187, 203, 204 As TAMs localized in 
the hypoxic regions in tumors favor angiogenesis, TAMs at the peritumoral area, at 
the tumor-stroma interface, help the cancer cells to invade by producing a variety 
of proteases to breakdown the basement membrane.198, 204, 205 Moreover, TAMs in 
the perivascular areas seem to promote the tumor cell intravasation into the blood 
vessels, and thus promote metastasis.206 In the tumor tissue, macrophages promote 
inflammation, suppress immune regulation, and support angiogenesis.198 In a breast 
cancer model, M2-like macrophages were found in hypoxic regions, while M1-like 
phenotypes were seen in normoxic tissues.207 At the metastatic sites, macrophages 
prepare the tissue for successful colonization of cancer cells.198 
TAMs influence almost all steps of carcinogenesis and tumor progression: they 
contribute to genetic alterations and instability, regulate senescence, promote an-
giogenesis and lymphangiogenesis, suppress adaptive immunity and CTLs, inter-
act and remodel extracellular matrix (ECM), and promote invasion and metastasis. 
They promote tumor growth by producing growth factors, such as EGF, VEGF, 
and bFGF, and suppress immune responses through the release of soluble 
mediators, such as IL-10, indoleamine dioxigenase (IDO) metabolites, and TGF-β, 
as well as through cell-to-cell contact mechanisms (e.g. PD-L1).163, 187, 193, 198 TAMs 
activate Tregs that strongly suppress effector T cells and other inflammatory cells. 
In addition being a target to chemokines, TAMs are also a source of chemo-
attractants, such as CCL2, CCL17, CCL18, and CCL22.193 For example, TAMs 
attract naive T cells to induce T cell anergy. TAMs secrete CXCL8, which 
promotes angiogenesis and reduces CD8+ CTL activity by increasing PD-L1 
expression on macrophages.208 
In the tumor initiation, TAMs are major producers of proinflammatory 
mediators such as IL-6, TNF and IFNγ, reactive oxygen and nitrogen species, 
proteases, and growth factors, such as EGF. After tumor progression, TAMs are 
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recruited continuously into the tumor tissue to have different functions in 
angiogenesis, invasion, intravasation, and immunosuppression. In the invasion 
stage, cancer cells require matrix formation and destruction through macrophage 
produced cathepsin and SPARC (secreted protein, acidic rich in cysteine). 
Macrophages have been described as “the key that unlocks the gate to allow tumor 
cells to escape”: they induce proteolysis to allow the cancer cells to escape through 
the basement membrane and to migrate through the stroma.187, 198 In addition, 
metastasis-associated macrophages (MAMs) send survival and growth signals to 
tumor cells and inhibit the functions of effector T cells.209  MAMs are attracted 
from bone marrow-derived monocytes through CCL2-CCR2 mechanism and 
differentiated through CCR1-CCL3 autocrine signaling.210 They are transcrip-
tionally different from resident macrophages and characterized by the expression of 
CD11b, VEGF receptor 1 (VEGFR1/FLT1), CXCR3, and CCR2.209, 211 MAMs 
support the survival of the metastatic cells interacting physically with them, induce 
EMT by producing TGFβ, and inhibit CTLs.212 Tumor cells and macrophages 
develop a paracrine signaling loop during the initial stages of metastasis, where 
tumor cells produce CSF1 that stimulates macrophages to produce EGF, a 
chemoattractant for the tumor cells expressing EGFR, which in turn activates 
migration of the cancer cells.213 
Angiogenesis is important to tumor survival and development. In addition, angi-
ogenesis associates strongly with the presence of inflammatory cells. TAMs con-
tribute to tumor angiogenesis, and there are evidence of associations between 
macrophage infiltration, tumor vascularity, and disease prognosis.138, 193 
Macrophages preferentially accumulate to poorly vascularized regions of tumors.201 
They cooperate with tumor cells to induce a vascular supply of the area by 
upregulating angiogenic factors and enzymes in response to high levels of adeno-
sine, which is present in the tumor microenvironment during local hypoxia. The 
angiogenic factors diffuse away from the hypoxic region and stimulate endothelial 
cells to migrate, proliferate and differentiate into new vessels.204 Hypoxia induces 
the metabolic adaptation of TAMs through the activation of hypoxia-inducible 
transcription factor-1 and 2 (HIF-1 and 2, respectively).188, 193,  214 HIF-1 and -2 
control the transcription of pro-angiogenic genes VEGF, bFGF, and CXCL8 in 
TAMs.215 TNF, IL-1, and IL-6 stimulate also the production of angiogenic factors. 
In addition, TAMs produce TGF-β1, which is angiogenic itself and induces 
production of VEGF. Some chemokines (e.g. IL-8) are also pro-angiogenic. They 
have direct effects on microvascular endothelial cells and can stimulate 
angiogenesis indirectly via TAMs.138 
The protumoral M2-like phenotype in TAMs is reversible. It has been shown, 
that, for example, IFNγ can reeducate M2 macrophages in vitro.216 Gradual 
switching of TAM polarization from M1 phenotype to M2 phenotype is paralleled 
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by the gradual inhibition of the NF-κB activity and increased STAT3 activity 
during different stages of tumor progression. Early in the carcinogenesis T cell 
driven M1 activated macrophages may contribute to elimination of cancer fol-
lowing with regulatory mechanisms of M2 polarized TAMs that orchestrate tu-
mor-promoting inflammation.199, 201 Transcription factor STAT1 is activated in 
response to M1 polarization signals (e.g. IFNγ and LPS) and is essential for 
immune surveillance against cancer.217 In contrast, STAT3 and STAT6 are 
activated by M2 cytokines (e.g. IL-10, IL-4, and IL-13). Tumor microenvironment 
educates macrophages to become protumoral. NF-κB has been considered as the 
master regulator of TAM transcriptional programs and function.217 It is an essential 
transcription factor guiding the inflammatory response in macrophages, and it has 
an influence on tumor cell proliferation and survival, too. NF-κB activation 
depends on the stage of the tumor growth. NF-κB is activated in macrophages 
during early stages of tumorigenesis but is defective in advanced tumors.203 
Defective NF-κB activation in TAMs associates with M2-like macrophage 
phenotype. On the other hand, full activation of NF-κB in macro-phages inhibits 
M1-like inflammation and promotes tumorigenesis in the early tumors.217 
The research of the prognostic role of macrophages in different cancers has 
shown controversial results. In most of the tumors, a greater amount of TAMs is 
associated with poor prognosis, e.g. in breast, cervix, bladder, gastric, thyroid, 
lung, and hepatocellular cancer.204, 212, 218-221 However, TAMs have been shown to 
associate with better survival e.g. in osteosarcoma, gastric cancer, and in pancreatic 
cancer.222, 223 In colorectal cancer, the prognostic significance is controversial and 
could depend on distinct macrophage phenotypes on a distinct localization within 
the tumor.224, 225 However, differences between studies (antibodies used, 
localization of macrophages, differences in experimental procedures and 
techniques) may lead to these controversial results.  
3.5.3 TAMs as therapeutic targets 
Specific macrophage-targeted therapies are now taking the first steps into the 
clinical arena e.g. in cancer, asthma, and atherosclerosis.226 Therapeutic strategies 
targeting TAMs can be grouped into six mechanisms: (I) blocking the pro-tumoral 
functions of TAMs, (II) promoting the phagocytosis of tumor cells by TAMs, (III) 
using inhibitors to allow CTL activity, (IV) reprogramming TAMs into antitumor 
macrophages to kill tumor cells or activate T cells, (V) inhibiting the tumor 
suppressive microenvironment, and (VI) inhibiting the recruitment of the TAM 
progenitors.212 There are currently several drugs being tested in clinical trials 
targeting TAM recruitment, survival, and reprogramming as monotherapies or in 
combination with chemotherapy or immunotherapy.212 
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TAMs can have direct cytotoxicity toward tumor cells (macrophage-mediated 
tumor cytotoxicity, MTC, or antibody-dependent cellular cytotoxicity, ADCC) or 
indirect cytotoxicity via the secretion of factors that stimulate the anti-tumor 
functions of other cell types. MTC is a slow process taking up to three days. In this 
process, macrophages release toxic factors, such as TNFα, serine proteases and 
RNIs, into cancer cells resulting in cell lysis. ADCC is dependent on tumor-
targeting antibodies. However, the killing mechanism is similar to MTC, although 
faster. Autologous macrophages have been considered using as a form of adoptive 
anti-cancer therapy, but the attempts have proved to be largely ineffective so far. 
There have been no major side effects, but there have been no evidence of an anti-
tumor response, either.197 
Macrophages play an important role in the chemotherapy response and 
resistance and can be selectively recruited to enhance the response rate for example 
by CXCR4 blockade.227, 228 TAMs affect also CPI therapies; TAMs express high 
levels of PD-L1 and PD-L2, as well as PD-1.229 CPIs are presented in detail in next 
Chapter 3.6 Cancer immunotherapy. Manipulation of TAM functions could 
improve the efficacy of immunotherapies. PD-L1 expression by TAMs suppresses 
the T cell response. It has been shown that in the therapy resistant tumors TAMs 
remain inactive and do not exert antigen-presenting activity.230 In addition, 
treatment with PD-L1 antibodies, but not PD-1 antibodies, has been shown to 
reverse the immunosuppressive macrophage phenotype and trigger macrophage-
mediated antitumor-activity.231 PD-L1-expressing macrophages have been found to 
be more abundant in several different tumors than PD-L1-expressing cancer 
cells.232 Moreover, PD-L1 inhibitor treatment has shown to induce antitumor 
activity even in models with non-PD-L1-expressing tumor cells suggesting that 
macrophages may be the key element in the response to PD-L1 inhibitor 
treatment.233 
The hypoxia-HIF-1 pathway has a role in TAM recruitment and activation in tu-
mors, and targeting HIF-1 activity could affect TAM accumulation.193, 215 Inhibitors 
of monocyte attractants include CSF1 receptor inhibitor (studied in acute myeloid 
leukemia and melanoma models), CCL2/CCR2 antibodies (prostate and breast 
cancer), and VEGF inhibitors.226 CSF1 mediates primarily tumor infiltration of 
TAMs and is an important regulator of TAM polarization into an M2 phenotype.234 
Clinical trials have shown promising preliminary results from TAM depletion by 
targeting the CSF1/CSF1R axis especially in tumors overexpressing CSF1, such as 
synovial giant cell tumors.195, 212 However, CSF1 inhibitors affect all macrophages, 
not only M2 typed TAMs, and depleting all macrophages from the body has caused 
some toxicity problems that have limited dose escalation. There have been attempts 
to inhibit the CCL2/CCR2 axis to prevent the recruitment of macrophages, but the 
results from these trials have been disappointing and no effective ways to reduce 
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the TAM recruitment have been discovered.212 In bone metastasis models, 
bisphosphonates have shown anticancer effects by causing apoptosis in 
osteoclasts.235   
The reprogramming of TAMs into tumoricidal macrophages is an attractive 
strategy for novel cancer therapy. This would eliminate the adverse effects of the 
depletion of all macrophages. Polarized phenotypes are reversible in vitro and in 
vivo. Restoration of NF-κB activity in TAMs could restore M1 inflammation and 
intratumoral cytotoxicity.193, 202 IFNγ and CD40 agonist antibodies have been found 
to activate the tumoricidal activity of TAMs and induce high expression of M1 
markers in macrophages.226 CD47 inhibits phagocytosis by macrophages and its 
antibodies targeting CD47 have been studied in the treatment of acute myeloid 
leukemia and in pediatric brain tumors.236, 237 Other molecules studied in switching 
TAMs into tumoricidal macrophages include different TLR ligands, 
proinflammatory cytokines (e.g. CSF2 and IL-12), histone deacetylase inhibitors, 
anti-MARCO antibodies, and phosphoinositide 3-kinase γ (PI3Kγ) inhibitors.212 
However, TLR agonists and cytokines associate with systemic adverse effects.238 
Intratumoral injections and targeted delivery systems have been used to prohibit 
the side effects and selectively target the tumor lesion. PI3Kγ inhibitor studies have 
shown that switching the macrophage phenotype into an M1-like state can turn 
resistant tumors to sensitive to T cell-mediated immune attack.239 Macrophage 
targeted therapies is a growing field of study, but currently, there are no 
macrophage drugs in the clinical practice and further studies are needed to find the 
holy grail of the field, reorienting and reshaping deranged macrophage 
polarization. 
3.6 Cancer immunotherapy 
Classically, cancer treatment consists of surgery, chemotherapy and radiation. 
These are effective treatments, but they have several limitations, too. Surgical 
excision of the tumor is effective only in the early stages of the disease and it fails 
when the cancer becomes metastatic. Chemotherapy is often limited by its severe 
toxicity and numerous side effects. Radiation therapy causes localized tissue 
damage in healthy tissue as well as in the tumor tissue. Immunotherapy will 
revolutionize the standard of care for many types of cancer.240 At present, cancer 
immunotherapies mainly include cytokines, cellular therapies, checkpoint 
blockade, and tumor vaccines.241 Immunotherapeutic agents lack the side effects 
associated with traditional cancer treatment by utilizing components of patient’s 
own immune system to selectively target malignant cells. In 2017, there were 26 
immunotherapies approved in the treatment of 17 types of cancer. To describe the 
future of the field, there were 940 immunotherapy agents in clinical development 
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with another 1064 potential drugs in preclinical phase in 2017, and the numbers are 
constantly growing.240 
Immune checkpoints regulate autoimmunity and decrease tissue damage by 
modulating costimulatory and inhibitory signaling during the immune response. 
Checkpoint inhibitors induce T cell mediated antitumor responses by selectively 
blocking the inhibitory signals of T cell activation. These regulatory mechanisms 
maintain immune responses within desired physiologic range and protect the host 
from autoimmunity in normal physiology.116, 242 CPIs include CTLA-4 and PD-
1/PD-L1 blockades as well as new CPIs that have generated promising results such 
as lymphocyte activation gene-3 (LAG-3), B and T lymphocyte attenuator (BTLA), 
and T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif 
domain-3 (TIM-3). 
Several research groups have been studied CTLA-4 for many years, notably in 
2018 Nobel awarded James P. Allison and his colleagues. It has provided hope for 
late stage melanoma patients with poor prognosis.243, 244 CTLA-4 negatively 
regulates T cell activation and inhibits uncontrolled immune responses. It also 
prevents chronic autoimmune inflammation.170 CTLA-4 is recruited to the plasma 
membrane on T cell activation where it binds to DCs and other APCs via B7 
molecules. (CD80, CD86) This prevents the ligation of the co-stimulatory CD28-
B7 complex needed for full T cell activation, and thus, inhibits further stimulation 
and immune response.116, 183, 185, 243 In cancer, CTLA-4 becomes an inhibitor of 
antitumoral immune responses.245 Anti-CTLA-4 antibodies potentiate the antitumor 
response by blocking CTLA-4 receptors to facilitate T cell activation and unleash 
the immune system to attack cancer.173, 242, 244 Ipilimumab, a monoclonal anti-
CTLA-4 antibody (approved by the FDA in 2011), was the first checkpoint 
inhibitor to demonstrate improved overall survival with previously treated 
metastatic melanoma.246, 247 The problem with ipilimumab is the significant rate of 
on-target toxicities: up to 23% of the patients develop serious adverse events such 
as colitis due to induced inflammation. Also, the stimulation of T cell response 
with ipilimumab may take several months to occur, while tumors may grow and 
progress.242 
In 1992, Tasuko Honjo and co-workers discovered protein called programmed 
cell death-1 (PD-1), which, along with CTLA-4, led to the Nobel price in Medi-
cine 26 years later. Like CTLA-4, PD-1 belongs to the CD28 family and delivers 
negative signals.248 PD-1 is a transmembrane protein expressed upon activation on 
T cells, B cells and NK cells. It activates by binding to PD-L1 and L2 on APCs and 
cancer cells, which inhibits TCR-mediated effector functions, decreases cytokine 
productions and reduces the proliferation of CD8+ T cells. It inhibits directly 
apoptosis, causes peripheral T effector cell exhaustion, and promotes T effector 
cells to convert to Tregs. T cell exhaustion is an important mechanism that limits T 
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cell activity in the chronic antigen stimulation. In normal situation, PD-1 maintains 
peripheral tolerance and T cell responses within a desired physiological range. The 
ligands of PD-1 are expressed widely in non-lymphoid tissues and thus, PD-1 acts 
primarily to dampen T cell activation in the periphery. PD-L1 and PD-L2 (CD274 
and CD273, respectively) expressions are induced in response to inflammatory 
cytokines, such as IFNγ.116, 170, 185, 248 Under physiological conditions, PD-1 on 
activated CD8+ T cells binds to PD-L1 ligands on APCs, deactivating the T cell. 
Many tumor cells express PD-L1 as a survival tactic, while many tumor antigen-
specific T cells express PD-1 receptor.242 PD-1 blockade reinvigorates CD8+ cells 
leading in increased functional activity and frequency and thus, induce tumor 
rejection. There is evidence, that PD-L1 expression on macrophages may lead to 
active eviction of T cells from the tumor microenvironment and regulate T cell 
trafficking and migration.116 CPIs targeting PD-1/PD-L1 have demonstrated 
positive clinical effects on more than 15 cancer types, and after the approval of 
anti-CTLA-4 ipilimumab for the treatment of metastatic melanoma, five PD-1 
blockade drugs have been approved by the FDA in cancer treatment.116, 249 
However, only part of the cancer patients benefit from PD-1 blockade drugs and 
the reason for this disparity is still unknown.  
Immunotherapies are effective treatment modalities, but however, the 
specificity of the treatment is also a limiting factor.250 Therefore, combined 
treatment may be better regulating the immune system to promote antitumor 
effects. Studies have supported the idea of combination of anti-CTLA-4 and anti-
PD-1 to increase response rates. Antibodies to PD-1 have safer toxicity profile than 
ipilimumab. CTLA-4 and PD-1 regulate distinct inhibitory pathways in T cells.173, 
243 They do not overlap and seem to synergize in eliciting an immunogenic 
microenvironment.116, 173, 251, 252 Although they both are CPIs they regulate different 
phases of the immune response: CTLA-4 blocks early T cell activation in the 
lymphoid organs, whereas PD-1 inhibits effector T cell activity at later stage 
immune responses in peripheral tissues and in the tumor microenvironment. 
CTLA-4 deficient mice develop devastating autoimmune disease and massive 
lymphoproliferation, and die within five weeks of birth. In contrast, PD-1 deficient 
mice remain relatively healthy into later stages of life.248 
Adoptive T cell transfer (ACT) technology is another technique used in 
immunotherapy. It consists of the reinfusion of autologous anti-tumor T 
lymphocytes. ACT takes advantage on the reliance of immune cells in the tumor 
microenvironment, stimulating cells ex vivo, and manipulating the immune 
environment for the introduction of effector cells. Lymphodepletion by 
chemotherapy or radiation is used to enhance the antitumor effects of transferred 
lymphocytes. The therapy includes also co-administration of high doses of IL-2 as 
an immune stimulant for the expansion of the transferred lymphocytes. One form 
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of transferred lymphocytes is TILs, mononuclear lymphocytes that have propensity 
to surround and invade tumors. Autologous peripheral blood lymphocytes can also 
be genetically engineered to recognize specific tumor antigens.173, 242 
TILs are aimed to kill cancer cells directly, but engineered antibodies can be 
used to target known molecules within oncogenic pathways to reduce the cancer 
cell proliferation by activating the immune system. In addition, these 
biotherapeutics can opsonize tumor cells and trigger their death or removal by 
antibody-dependent cellular cytotoxicity or phagocytosis. For example, rituximab 
(anti-CD20 antibody) is the first monovalent antibody (mAb) approved by the FDA 
for treatment of hematologic cancers. Eight other monoclonal antibodies targeting 
six cancer-associated proteins (Her2/neu, EGFR, VEGF, CD20, CD52, and CD33) 
are approved for the treatment of solid and hematological malignancies. However, 
mAbs can stimulate redundant pathways and have limitations, such as promotion of 
cancer cell survival. Bispecific antibodies (bsAbs) have dual antigenic specificities 
and are capable to interact with multiple receptors/ligands. Bispecific T cell 
engagers (BiTEs) recruit T cell effectors and have become a valid therapeutic 
option in the treatment of a several cancers. To overcome the issues with 
rituximab, a tetravalent anti-CD20/CD3 bsAb was developed for treatment of B 
cell lymphoma. The anti-CD20 is specific for B cells, while the anti-CD3 reacts 
with T cells. This new antibody have 6 times higher cytotoxicity potential 
compared to standard rituximab and improved stability, solubility and production 
yield, but the clinical studies are ongoing.242, 243 
3.7 Bladder cancer-related inflammation 
Inflammation has an important role in bladder carcinogenesis. However, the role of 
acute and chronic inflammation and tumor immunity is still poorly understood in 
BC. Chronic infection is a risk factor for BC development.253, 254 Epidemical 
studies have shown a correlation between urinary tract infection and risk of BC, 
especially with three or more infection episodes. In addition, urinary tract 
infections associate with worse outcome in BC. On the contrary, antibiotics used to 
treat infrequent infections decrease the risk of BC via cytotoxicity against tumor 
cells. Higher exposure to nonsteroidal anti-inflammatory drugs (NSAIDs) may also 
decrease the risk of urothelial malignancy.253, 254 In addition to common urinary 
tract infection, a parasitic Schistosoma worm infection is strongly associated with 
BC, particularly with high-grade squamous cell carcinoma of the bladder.253, 255 S. 
Haematobium is endemic in Africa and the Middle East and it has been classified 
as group 1 carcinogen.256The initiation and progression of schistosomal BC is a 
complex and multistep process. It has been proposed that S. Haematobium eggs 
give rise to genotoxic factors causing a genomic instability in a host cell, which 
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leads to a proliferative response to repair tissue damage caused by inflammation. 
This activates oncogenes or inactivates tumor suppressor genes. S. Haematobium 
has also considered as oncogenic because of the induction of K-RAS mutations.254, 
257 It has been suggested, that chronic irritations of urinary tract (e.g. catheters) are 
also risk factors of BC via hyperplasia, metaplastic changes, and chronic 
inflammation in response to local injury of the urothelium.254, 258 
Despite chronic inflammation being a risk factor in BC, several studies have 
shown, that lymphocytes in the tumor tissue associate with better prognosis in BC. 
Inflammatory infiltrate associates with fewer recurrences, better survival, and is an 
independent prognostic factor in BC.259, 260 Acute inflammation is associated with 
anti-tumor response and impairment of acute inflammation at an early stage of 
tumorigenesis could promote cancer development.261 However, necrosis and 
invasive front inflammation have shown to be independent risk factors in high-
grade BC.262 The inflammation studies have several limitations. In meta-analysis 
2014 Masson-Lecomte et al. raised the problems in the heterogeneity of the 
populations and the term inflammatory infiltrate in inflammation studies in BC. 
They demanded precise characterization of the inflammatory infiltrate in the tumor 
and establishment of mechanistic hypotheses before drawing any further 
conclusions about the role of inflammation in BC.263  
Systemic inflammation markers have also been shown to affect BC survival. 
Systemic inflammatory marker C-reactive protein (CRP) is associated with 
survival in BC. CRP is a representative acute-phase reactant and a significant and 
sensitive inflammatory marker. High CRP (over 5mg/l) associates with higher risk 
of progression of the disease and has been shown to be an independent prognostic 
factor in BC.263-266 The neutrophil-to-lymphocyte ratio (N/L ratio) from peripheral 
blood samples is also considered to be a systemic inflammatory response marker.267 
Numerous studies have demonstrated, that the N/L ratio is a prognostic factor for 
survival in BC patients. Decreased lymphocyte count or N/L ratio rising over 2.5-
3.0 associates with poor prognosis and DSS, recurrence, and unfavorable treatment 
outcome.268-271 However, a clear definition of the cut-off value remains to be 
determined.272 Preoperatively N/L ratio predicts the lymph node metastases and 
survival after RC.272-274 The ratio predicts poor recurrence-free survival (RFS) in 
MIBC patients and is correlated with progression and recurrence in NMIBC 
patients.271, 275 In NAC treated BC patients high N/L ratio is associated with 
pathological response.276 
In addition to the peripheral ratio of neutrophils and lymphocytes, TILs have 
widely been studied in different cancer subtypes, as well as in BC. Generally, TILs 
are considered to be a positive prognostic factor in malignancies. They are fre-
quently found in the microenvironment of BC tissue and elicit both tumor-
suppressive and tumor-promoting effects.277 High prevalence of TILs is associated 
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with more favourable outcome in BC.277 Especially CD3+ and CD8+ tumor 
infiltrating lymphocytes have a positive prognostic role in BC.263, 278 CD4+FoxP3+ 
Treg cells correlate negatively with OS in the majority of solid tumors, but the 
prognostic role of these cells varies greatly depending on the cancer type.279 In BC, 
Tregs correlate positively with survival, while FoxP3 expression in BC cells 
associates with decreased survival in MIBC.278, 280 In cancer cells and macrophages, 
Tregs suppress MMP2 expression, which is a pro-metastatic molecule associated 
with poor prognosis in BC.280 However, FoxP3 positive T cells have also been 
shown to associate with higher risk for recurrence after TUR-BT.281 Stimulation of 
naive CD4+ cells by TGFβ and IL-6 initiates Th17 cell differentiation.282 In BC, 
Th17 cell levels are elevated in tumors relative to the peripheral blood levels, 
whereas Treg levels in the peripheral blood are higher than in the tumor tissue.258  
In addition to Th17 cell activation, IL-6 is also a major activator of the STAT3 
signaling pathway, which implicates in oncogenesis, tumor progression, and 
metastatic spread.283 IL-6 is produced under inflammatory conditions. It is the 
primary pro-inflammatory cytokine in humans and is produced by T cells and 
macrophages.258 In BC patients, IL-6 levels in urine and in serum are elevated 
compared to healthy controls. It has been shown to associate with higher stage and 
recurrence rate, increased risk for metastasis, and reduced survival in BC.284, 285 
However, tumor-suppressing effects of IL-6 has also been found in BC.254 In 
addition, high levels of IL-6 have been found in BC patients responsive to BCG 
instillations.283 
STAT3 and NF-κB are major inflammation-promoting transcription factors. 
They cause an perpetual oncogenic loop: NF-κB activation in immune cells in-
duces expression of cytokines that promote STAT3 activation in both malignant 
and immune cells, whereas persistently activated STAT3 has been shown to me-
diate NF-κB activity.286 NF-κB correlates with histological grade and T category in 
BC.254 IL-8 is another cytokine associating with invasiveness and growth of BC.283 
IL-8 has several properties: it is an angiogenic factor stimulating growth and 
survival of endothelial cells and an inflammatory factor secreted by leukocytes to 
promote chemotaxis of neutrophils and T cells. It can also avoid cell death. IL-8 
activity is mediated by CXCR1 and CXCR2. IL-8 attracts MDSCs, which are 
critical mediators of cell-associated immune suppression in BC.253, 287 The urinary 
concentration of IL-8 has been evaluated as a diagnostic biomarker of BC.288 IL-2 
has also been considered as a prognostic urinary biomarker of BC; low 
concentrations of IL-2 in the urine correlate with poor prognosis of the disease.283 
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3.7.1 Macrophages in bladder cancer 
Macrophages consist a majority of all CD45 positive cells in the mouse bladder.289 
They produce pro-inflammatory cytokines during infections and are the main 
control of the innate immune response.290 TAMs associate with the progression of 
BC.253 Although several studies have reported that CD68 positive macrophages 
associate with adverse outcome in BC there were no associations between CD68 
positive macrophages and survival in BC in a meta-analysis of 13 studies in 
2018.291-294 However, CD163 positive macrophages were shown to associate with 
poorer RFS after TUR-BT alone or in combination with BCG treatment.294 High 
levels of CD68 positive TAMs have been shown to associate with poorer response 
to BCG immunotherapy, as well.291 Furthermore, the polarization status of TAMs 
can limit the efficacy of BCG therapy; the presence of M2 type macrophages is 
considered to associate with poorer response for the treatment.292 TAM count is 
higher in MIBC tumors than in non-invasive tumors and the localization of TAMs 
have been shown to be different in NMIBC and MIBC tumors.293, 295 In NMIBC 
TAMs tend to localize in the stroma-tumor margin, whereas in MIBC TAMs are 
mostly infiltrated into the tumor tissue. TAMs have also shown to correlate with 
increased risk of recurrence in BC.292, 296  
In vitro co-culture studies have shown, that M1 macrophage levels decreases, 
while M2 macrophage levels increase during T24 BC cell line proliferation.297 
Mouse studies have shown, that BCG treatment efficiently induces cytotoxic 
activity in macrophages towards MBT-2 cells (mouse BC cell line).298 Soluble 
factors secreted by macrophages, such as IFNγ, TNFα, and IL-6, have been found 
to account up to 50% of the total killing of the MBT-2 cells. These cytokines are 
tumoricidal for both human and mouse BC. TNFα is primarily produced by 
activated macrophages.258 It stimulates the secretion of MMP-9, which contributes 
to tumor invasion and metastasis.254 In BC, TNFα associates with angiogenesis, 
which strongly associates with poorer prognosis of the disease.254, 299 The BCG-
induced cytotoxicity has been shown to be blocked by IL-10, and the blockade of 
IL-10 can potentially enhance the effect of BCG in the treatment of BC patients.300 
Th1 simulating cytokines, such as IL-2 and IL-18 enhance the effect of BCG 
treatment.298 
3.7.2 Immunotherapy in bladder cancer 
BC is one of the few cancer types for which there is long-standing evidence for the 
efficacy of immunotherapy. Intravesical BCG treatment utilizes the anti-tumor 
effects of local immune response. The instillation of BCG in NMIBC was firstly 
reported in 1930s and the first human study of intravesical BCG was conducted by 
Morales in 1976.301 In 1990, the FDA approved the use of intravesical BCG for 
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patients with NMIBC, and it is still recommended as the treatment of choice in 
NMIBC after TUR-BT.302 Despite the wide use of the treatment, the mechanism of 
the action of BCG therapy is still not fully understood. Induction of inflammation 
and activation of the immune system are the crucial features of the therapeutic 
response of BCG treatment.254 BCG is a live attenuated tuberculosis-related 
bacterium that attaches to the urothelium via extracellular protein fibronectin (FN). 
FN-BCG complexes induce proinflammatory cytokine release, immune cell 
recruitment, and direct cell-to-cell cytotoxicity.258 Neutrophils and macrophages 
arrive first to the region, followed by CD4+ cells. Multiple BCG instillations result 
the accumulation of NK cells, CD8+ cells, and macrophages in the suburothelial 
stroma. A wide range of cytokines are involved. Tumor destruction is considered to 
associate with cellular immunity by high proportion of T helper cells and in some 
degree with the direct tumoricidal action of BCG itself. Macrophages act as a first 
line defense of innate immunity against BCG infection. They have been considered 
to initiate BCG-induced anti-cancer responses and kill tumor cells.303 
Approximately 25% of the NMIBC patients do not respond to BCG.254 The reason 
for the unresponsiveness of the treatment is unclear. Patients responding to BCG 
commonly release large amounts of Th1 cytokines (e.g. IL-2 and IFNγ) whereas 
high amounts of Th2 cytokines (e.g. IL-4, IL-5, and IL-10) relate to BCG failure.304 
However, there is no biomarker in clinical use to predict the response to BCG. 
In addition to intravesical BCG treatment, new immunotherapy approaches have 
come through as the treatment options in BC. PD-L1 expression levels on BC cells 
have been shown to correlate with severity of the disease, as well as with the 
patient outcome.263, 305 Tumors with high levels of PD-L1 on cancer cells are more 
likely to be high-grade, more prone to recur, and the patient survival is poorer.136, 
137, 306 In addition, PD-L1 expression on tumor cells associates with increased 
resistance to BCG therapy, which requires a fully functioning immune system.306 
The presence of M2 macrophages in BC tumor has been shown to associate with 
poor response to immunotherapy.304   
A T-cell-based adoptive immunotherapy is another feaseble novel treatment 
modality for advanced BC.307, 308 It has already been shown to induce tumor 
regression in melanoma patients.309 In this method, autologous T lymphocytes from 
tumor-draining lymph nodes are utilized to result a robust response against tumor 
cells.310 The adoptive immunotherapy has potential to increase the OS for advanced 
BC and even result in a vaccination effect against cancer, but it still has technical 
problems to conquer to reach the benefits in the clinical world. 
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4 Markers 
4.1 CD68 
CD68 (also known as gp110 or macrosialin) is a 110 Kd transmembrane lysoso-
mal glycoprotein expressed on tissue macrophages and blood monocytes. It is 
considered to be a pan-macrophage marker that recognizes both M1 and M2 
phenotypes of macrophages.311 The function of CD68 is unknown, but it has been 
considered to play a role in phagocytic activities of tissue macrophages.312 In 
tissues, the infiltration of CD68 positive macrophages is observed most in papillary 
axes and stroma, and in lymphoid aggregates. CD68 expression can be also 
observed in some tumor cells.296 
CD68 positive macrophage counts have been shown to be higher in MIBC than 
in NMIBC.293 High levels of CD68 positive macrophages have also been shown to 
associate with higher stage, grade and tumor size, and with tumor recurrence and 
progression.291-293, 295, 304, 313 CD68+ macrophage infiltrates associate with 
unfavorable prognosis and are shown to be an independent prognostic factor in BC 
in certain studies.292, 293, 296, 314 However, in a meta-analysis in 2018 CD68 did not 
associate with BC survival.294 Increased number of CD68 positive macrophages 
associate with BCG failure and greater risk of recurrence after BCG therapy.291, 315 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure 4. CD68 staining in bladder cancer tissue. CD68 positivity is seen 
as brown color. Scale bar 50µm. 
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4.2 MAC387 
MAC387 is a monoclonal antibody recognizing the L1 protein, a 36 Kd 
myelomonocytic antigen, which is a member of the cytoplasmic calcium binding 
proteins known as calgranulins. It is expressed on tissue macrophages, monocytes, 
and granulocytes.316-318 The L1-light chain shows sequence homology with the 
cystic fibrosis antigen, and the two L1 chains are identical with myeloid-related 
proteins (MRP) 8 and 14 (S100A8 and S100A9, also known as calgranulin A and 
B, respectively).319 S100 proteins are involved in cell differentiation, cytoskeletal 
organization, and cell cycle regulation.320, 321 MAC387 has been also shown to 
recognize in a lesser extent the MRP8/MRP14 heterocomplex, also called 
calprotectin.322, 323 These intracellular MRPs have been used to define macrophage 
differentiation and different stages of inflammatory lesions in the central nervous 
system (early acute, late acute, chronic).324 Calprotectin is involved in innate 
immunity, leukocyte adhesion, and endothelial transmigration.325, 326 It is expressed 
by neutrophils, activated monocytes, and macrophages, and acts as a 
proinflammatory mediator in acute and chronic inflammation.321 MRP14 is 
expressed on recently infiltrated monocytes/macrophages during early acute 
inflammation, and thus, MAC387 is considered to be a marker of recently 
infiltrated monocytes/macrophages and might be the earliest macrophage marker 
expressed on such cells as they enter the tissu.324 Monocytes lose calprotectin 
gradually after migration from blood to tissues.327 High endothelial venules (HEVs) 
have been considered to be the entry site of MAC387 positive macrophages, 
because they are seen surrounding these venules.328 MAC387 is also expressed in 
some epithelial cells, and it has been used as a marker of squamous differentiation 
in BC (sensitivity of 99% and specificity of 70%).316, 329, 330 The presence of 
squamous cell differentiation is considered to be a predictor for local recurrence 
and worse survival in BC.331 MAC387 is expressed also on other cancer types, e.g. 
on breast cancer cells.332  
MPR8 and MPR14 are up-regulated in breast, lung, gastric, colorectal, 
pancreatic and prostate cancer.326 In breast cancer, MPR8 and MPR14 have been 
found to associate with poor tumor differentiation, vessel invasion, positive lymph 
nodes, and cancer progression.325, 332, 337 The association with poor differentiation 
has also been reported in lung and thyroid glad cancers, and high MAC387 positive 
macrophage count has been shown to associate with poor survival in 
cholangiocarcinoma.326, 334 In BC, MAC387 positive macrophages have not been 
studied. However, calgranulin A (S100A8) is overexpressed in BC tumor cells, 
especially in a metastatic disease.335, 336 Furthermore, higher urinary calprotectin 
concentrations have been detected in BC patients compared to healthy controls and 
S100A8 gene expression levels significantly predict the progression of MIBC.337, 
338 
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4.3 CLEVER-1 
CLEVER-1 (common lymphatic endothelial and vascular endothelial receptor-1) is 
a large 270-300kD type I transmembrane protein, a multifunctional scavenger 
receptor.339 It is also known as Stabilin-1 by Goerdt et al. and FEEL-1 (fasciclin, 
EGF-like, laminin-type EGF-like, and link domain-containing scavenger receptor-
1) by Adachi et al.340-342 CLEVER-1 is encoded by the Stab1 gene and it is 
expressed primarily in two cell types: tissue macrophages and endothelial cells.341  
It is present in HEVs in lymphoid organs and in lymphatic vessels in all lymphoid 
and non-lymphoid tissues except cerebellum, but absent from all blood vessel 
endothelium in normal non-lymphoid tissues.343 However, CLEVER-1 is 
upregulated on HEV-like vessels at sites of inflammation. It is expressed in a 
population of immunosuppressive tissue macrophages, but absent in blood 
leukocytes.339 CLEVER-1 has multiple ligands, such as modified low-density 
lipoprotein (LDL), phosphotidylserine expressed apoptotic cells, SPARC, placental 
lactogen, and bacteria.344 
CLEVER-1 is a class H scavenger receptor.345 Scavenger receptors are 
structurally very heterogeneous, but share functional properties as they identify and 
remove unwanted entities (modified self molecules, such as apoptotic cells or 
damaged proteins, or non-self molecules, such as microorganisms) by endocytosis, 
macropinocytosis, or phagocytosis. They also play role in cellular adhesion and 
antigen presentation, and are involved in the maintenance of homeostasis and in the 
pathogenesis of various diseases. Scavenger receptors are more prominently 
Figure 5. MAC387 staining in bladder cancer tissue. Little black arrow 
shows macrophage staining, big open arrow shows squamous 
differentiation. Scale bar 50µm. 
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expressed by M2 macrophages, but are not exclusive to this macrophage popu-
lation.346 
CLEVER-1 is used as a specific marker for alternatively activated M2 macro-
phages. In vivo CLEVER-1 expression requires stimulation e.g. by glucocorti-
coids; in in vitro human monocyte-derived macrophage cultures CLEVER-1 can be 
induced by stimulation of dexamethasone alone or with IL-4. IFNγ has a negative 
effect on CLEVER-1 expression. Expressed by M2 macrophages, CLEVER-1 
mediates the uptake and clearance of acetylated LDL and SPARC. SPARC is a 
universal regulator of tissue remodeling. It is involved in developmental processes, 
tissue remodeling, angiogenesis and wound healing by modulation of extracellular 
matrix organization, binding of growth factors, and induction of an anti-adhesive 
state.341, 347 In lymphoid organs, CLEVER-1 mediates lymphocyte binding and 
entrance to HEVs and to lymphatic endothelium. It also mediates the adhesion of 
lymphocytes, monocytes and granulocytes to HEV-like venules at sites of 
inflammation in non-lymphoid tissues.339, 348  
The prognostic significance of CLEVER-1 in bladder cancer is unknown. In 
other cancers, such as breast cancer, melanoma, and lymphoma, CLEVER-1 has 
been shown to contribute tumor progression.345, 349, 350 In colorectal cancer, high 
CLEVER-1 positive macrophage count associates with more favourable DSS and 
decreased risk of recurrence in stage II and III disease, but in contrast, with poorer 
DSS in higher stage disease.224 Karikoski et al. demonstrated with CLEVER-1 
deficient mice, that the absence of CLEVER-1 and, moreover, anti-CLEVER-1 
treatment inhibited melanoma progression.350 Furthermore, CLEVER-1 mediates 
binding of malignant cells to the lymphatic endothelium, and thus, has a role in 
tumor metastasis.351 In breast cancer, CLEVER-1 expression in lymph vessels has 
been shown to correlate with lymph node metastasis, and that high macrophage 
index correlate with a worse prognosis.352, 353 CLEVER-1/Stabilin-1 has been 
shown to mark a subpopulation of CD68 low/negative TAM in human breast 
cancer.349, 354 In addition, Riabov et al. showed in 2016 that breast cancer growth is 
suppressed in Stabilin-1 knockout mice. Stabilin-1 expression was most intensive 
in stage I and IV disease, which was speculated to result from its crucial role for 
early primary tumor growth and progression.349 The reduction in the expression of 
Stabilin-1 in the tumor microenvironment during the tumor progression has been 
shown also in hepatocellular carcinoma and glioblastoma mouse models.355, 356 
However, David et al. speculated TAMs to stop expressing Stabilin-1 as they 
switch phenotypes to one that promotes tissue remodeling and angiogenesis.356 The 
role of SPARC, the endocytic ligand of CLEVER-1, is debated and seems to vary 
in different cancer types. It has been shown to inhibit cancer growth in lung 
carcinoma, neuroblastoma and beast cancer, and the reduced expression of SPARC 
has been shown to correlate with poor prognosis in breast cancer patients.357, 361 
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However, it associates with increased tumor metastasis and proliferation in 
glioblastoma.356, 362 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
4.4 CD73 
CD73 is a plasma membrane-bound ecto-5’-nucleotidase (ecto-5’-NT), a 70 kD 
glycosyl-phosphatidylinositol (GPI)-linked molecule detected in several different 
tissues and cell types.363-365 It is also known as L-VAP-2.366 CD73 functions in the 
extracellular nucleotide turnover hydrolyzing extracellular 5’-mononucleotides 
(AMP) to the corresponding bioactive nucleosides (adenosine) (Figure 7).364 
Extracellular purines regulate cellular hemostasis and thrombosis via activation and 
aggregation of platelets and mediate several inflammatory responses, including the 
release of the cytokines, TNFα and IL-1β from monocytes/macrophages, and 
facilitate the leukocyte adhesion to the endothelium.367, 368 Intracellular adenosine 
triphosphate (ATP) is primarily utilized in energy-requiring processes (such as 
active transport and biosynthesis), whereas extracellular ATP is a powerful 
signaling molecule.  
Adenosine is a highly anti-inflammatory molecule that has a role in regulation 
of endothelial permeability and vasodilatation, neutrophil adhesion, and stimulation 
of chloride secretion.269-374 It binds to specific cell surface receptors that are 
expressed on a wide variety of cells (A1R, A2aR, A2bR, and A3R) and its effects 
are often opposite to inflammatory ATP.372, 375-377 Adenosine has a short half-life, 
only under 10 seconds and, thus, can be highly regulated.376 It accumulates in 
response to stress (such as hypoxia or tissue injury); increased adenosine levels are 
Figure 6. CLEVER-1 (antibody 2-7) staining in bladder cancer tissue. Little 
black arrow points positive macrophage staining as an example and big 
open arrow points vessel staining. Scale bar 50µm. 
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detected during inflammation and wound healing.372, 378 Extracellular adenosine 
signals tissue injury to surrounding tissues in an autocrine and paracrine manner. 
Increased levels of adenosine leads to decreased production of cytokines and 
decreased expression of adhesion molecules on endothelium and leukocytes, such 
as E-selectin, ICAM-1, and beta 2 integrins.379 As a negative regulator of immune 
cells, it protects normal tissue from inflammatory damage, but also cancer cells 
from the antitumoral T cells.380 
CD73 is expressed in a variable extent on different tissues. It is expressed on a 
subpopulation of peripheral blood lymphocytes: on the majority of B cells (70%) 
and CD8+ T cells (50%), but only on approximately 10% of CD4+ T cells.365, 381 
These cells form 15-25% of peripheral blood lymphocytes. Neutrophils, 
erythrocytes, platelets, and other blood cells express little or no CD73. CD73 is 
present on some epithelial cells of various origins and on vascular endothelial cells, 
predominantly on large vessels such as aorta, carotid and coronary artery.383, 383 It 
has been detected in colon, kidney, brain, liver, heart and lung.363 CD73 expression 
is upregulated by HIF-1α activation and exposure to type I interferons, and has 
been associated with Wnt signaling, which is deregulated in several cancers.384-387 
IL-1β, TNFα and prostaglandin E2 also enhances the activity of CD73, whereas 
IFNγ and IL-4 downregulate CD73.388, 389  
CD73 is a multifunctional molecule and its physiological role varies between 
cells and organs.382 Although the primary physiological role of CD73 is its 
regulatory function in the purinergic cascade (Figure 7), other non-enzymatic 
functions have also been proposed.390 It mediates lymphocyte binding and 
maintains the barrier function as a gatekeeper in epithelium and endothelium in 
various tissues, especially during hypoxia enhancing the generation of extracellular 
adenosine.366, 369, 371, 374, 386, 391-397 Leukocyte binding to CD73 on endothelium 
causes the inhibition of CD73 and, thus, decreased adenosine production.392 This 
increases the endothelial permeability and allows leukocytes to transmigrate 
through the vascular endothelium. Cd73-/- mice are viable, but have shown to have 
significant vascular leakage in multiple organs, enhanced leukocyte adhesion to 
vascular endothelium, and increased leukocyte migration to inflammatory    
sites.371, 385 It is a signal-transducing molecule in the immune system and it has a 
costimulatory role in T cell activation through the CD3/TCR signaling pathway.285 
It is also used as a lymphocyte maturation marker, as it is absent from the surface 
of immature B and T cells.365, 381, 398-400 
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Ecto-5’-NT:  Ecto-5’neucleotidase, CD73 
ADA:   Adenosine deaminase 
PNP:   Purine nucleoside phosphorylase 
E-NPP 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.4.1 CD73 in cancer 
CD73 has been considered as an important player of tumor progression, but its true 
role in cancer is still widely unknown. CD73 is expressed in several cancer types, 
such as ovarian, esophageal, gastric, colon, prostate and breast cancer.401-404 CD73 
associates with poor prognosis in certain cancer types, such as leukemia and breast 
cancer and the lack of CD73 leads to diminished tumor growth in colon cancer, 
lymphoma, breast cancer and melanoma mouse models.404-407 In breast cancer, 
CD73 supports tumor growth and enhances the migration, invasion and 
neovascularization of the tumor cells.408-410 It has also been suggested to act as a 
prognostic marker in breast cancer.409-410 Yegutkin et al. have shown with a CD73-
deficient mouse model, that CD73 activity favors tumor progression also in 
melanoma.370 Furthermore, they showed that it is amenable to therapeutic 
interventions, as it has also been shown in breast cancer.408 
Overexpression of CD73 has been shown to associate with resistance to anti-
tumor drugs, such as doxorubicin in breast cancer mouse models.404 High 
Figure 7. Purine in-activating pathway and ATP regenerating pathway. Green arrow depicts activating 
and red blunted line inhibitory regulatory mechanisms. Adapted from Yegutkin et al. 2002 and 
Yegutkin 2008.363, 390 
3
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concentrations of adenosine in tumors may lead to a failure of an effective anti-
tumor immune response. Thus, it has been suggested that CD73 could serve as a 
novel target for cancer treatment.411 Anti-CD73 treatment and knockdown of CD73 
on tumor cells by siRNA (small interfering RNA) increase the tumor free survival 
and reduce tumor growth and metastasis in mouse models.403, 408, 411, 412 has been 
proposed, that CD73 enhances tumor growth in a T cell-dependent manner, 
because the blockade of CD73 has no impact on tumor growth in T cell-deficient 
mice.403 The altered purinergic balance with the absence of CD73 causes a specific 
decrease in the numbers of intratumoral Tregs and M2 MR positive macrophages, 
and increase in IFNγ and NOS2 synthesis by TILs.370 Tregs and M2 macrophages 
are key players in diverting inflammatory reaction in the tumor microenvironment 
in a way that enhances the tumor growth.198, 413, 414 IFNγ, on the other hand, inhibits 
tumor formation and drives macrophage polarization into anti-tumoral M1 
macrophages.415 Inducible NOS is one of the best marker of M1 macrophages, and 
its synthesis is driven by IFNγ.190 Many of CD73 effects consequences the 
production of adenosine. Elevated levels of adenosine in the mouse tumor 
microenvironment have been described.416 Adenosine regulates macrophage 
activation; it inhibits the antitumoral M1 activation and enhances the activation 
towards protumoral M2 macrophages.417, 418 It accumulates in solid tumors and 
stimulates tumor growth and angiogenesis and inhibits cytokine synthesis, immune 
cell adhesion to the endothelium, and T cell and NK cell function, and thus, have 
tumor-promoting activities.402 CD73 expression on tumor cells has been shown to 
enhances resistance to new immunotherapeutic anti-PD-1 agents, as PD-1 blockade 
and the activation of T cells upregulate the expression of adenosine receptor A2aR 
making these cells more susceptible to adenosine-mediated suppression.419 Hence, 
the inhibition of CD73 in combination with anti-PD-1 drugs has been shown to 
increase the anti-tumor T cell responses. The blocking of CD73 also enhances 
chemotherapy responses e.g. in breast cancer.420  
BC cells express CD73 in vitro in grade 1 RT4 and in grade 3 T24 cell lines. 
However, RT4 cells seem to hydrolyze more efficiently tri- and diphosphonucle-
osides via CD39, while the less differentiated, more invasive T24 cells show higher 
levels of AMP hydrolysis via CD73.421 In a BC mouse model, an increased CD73 
expression in tumor cells has been detected.422 In human BC cells, CD73 status is 
comparable with non-cancerous urothelial cells.423 However, in contrary to many 
other cancers, Wettstein et al. have shown in 2015 that CD73 positive human BC 
cells associate with lower stage, lower grade, and with lower risk for 
progression.424 However, in this study CD73 failed to be an independent prognostic 
marker in multivariate analyses. Similar to BC, CD73 associates with more 
favourable prognosis also in ovarian and breast cancers.425-427 Hence, the anti-CD73 
treatment is not that simple in cancer therapy. Further investigations translating the 
64
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mouse model findings and preclinical studies into the clinic are needed. Extensive 
evidence of the CD73 expression in different cancer types and in different cell and 
tissue types need to be accomplished. 
 
 
Figure 8. CD73 staining in bladder cancer tissue:     
a. CD73 on urothelial cancer cells (magnification x20, 
scale bar 100µm), b. CD73 on stroma and vessels 
(magnification x10, scale bar 200µm), c. CD73 on 
lymphocytes (magnification x20, scale bar 100µm).  
 
a 
c 
b 
5
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Aims of the Study 
Bladder cancer is a heterogeneous disease. Non-invasive and especially well dif-
ferentiated tumors have often relatively indolent natural history but poorly differ-
entiated tumors are prone to invade, recur after treatment, and metastasize. There is 
a lack of biomarkers in clinical use to predict the outcome of the disease and to 
select the most effective treatment for the patient. 
Inflammation is a critical feature of carcinogenesis. Tumor-associated macro-
phages associate with poor prognosis in several cancers. However, there is evidence 
of macrophages associating with more favourable outcome, for example, in distinct 
groups of colorectal cancer. Current knowledge regarding the prognostic 
significance of TAMs in BC is limited. 
The aim of the study was to investigate immunological prognostic immunologi-
cal factors in human BC after TUR-BT and radical cystectomy, and the predictive 
functions of these factors in patients treated with neoadjuvant chemotherapy. 
 
The specific aims of the study were: 
 
1. To examine the prognostic value of TAMs in human bladder cancer with 
antibodies CD68, MAC387, and CLEVER-1.  
 
2. To examine the predictive value of TAMs (CD68, MAC387, and CLEVER-1) 
in bladder cancer patients treated with neoadjuvant chemotherapy. 
 
3. To examine the immunohistochemical expression and prognostic value of 
CD73 in human bladder cancer.  
  
66
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Materials and methods 
1 Patients 
The patient material and the immunostaining methods are summarized in Table 8. 
Non-urothelial BCs and cases with insufficient tissue material available for 
histological re-review and immunohistochemistry or unavailable clinical data were 
excluded from the studies. In studies I and III, patients with intravesical instillations 
(BCG or chemotherapy) or systemic chemotherapy prior the study inclusion were 
excluded. In the study II, inadequate NAC treatment (under 2 cycles) was included 
in the exclusion criteria. After exclusions, 184 BC patients were included in the 
study I, 68 patients in the study II, and 166 NMIBC and 104 MIBC patients were 
included in the study III. 
 
Table 8. Patient material and immunostaining methods in the studies. 
 Study I Study II Study III 
Number of     
patients 
184 68 270 
Hospital Turku University 
Hospital 
Turku and Helsinki 
University Hospitals 
Turku University 
Hospital 
Study             
period 
1985-2004 2007-2013 1985-2004 
Treatment     
modalities 
TUR-BT/RC NAC + RC TUR-BT/RC 
Tissue            
samples 
Whole sections TMA Whole sections   
(TUR-BT), TMA (RC) 
Antibodies CD68, MAC387, 
CLEVER-1 
CD68, MAC387, 
CLEVER-1 
CD73 
Immunostaining 
method 
Vectastain Elite ABC 
Kit (Vector 
Laboratories) 
Vectastain Elite ABC 
Kit (Vector 
Laboratories) 
Vectastain Elite ABC 
Kit (Vector 
Laboratories) 
Immunoscoring Manual Manual + digital Manual 
7
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TUR-BT was performed using standard techniques in all studies. In the study II, 
patients received 2-6 cycles (median 4 cycles) either cisplatin-gemcitabine (64/68 
patients) or carboplatin-gemcitabine (4/68 patients) prior to the RC. After RC, 
patients were followed every 3 months for the first year and semiannually thereafter 
A detailed clinicopathological database was assembled retrospectively. Histological 
samples were re-reviewed for histology, differentiation grade, and stage by expert 
uropathologists. The tumors were graded according to both WHO 1973 and the 
WHO/ISUP 2004 classifications and staged according to the 2010 TNM     
staging.47, 428 
2 Antibodies 
The antibodies used in the studies are shown in Table 9. 
 
 
 
 
Table 9. Antibodies used in the studies. 
 
Antibody Antigen Isotype Dilution Antigen retrieval Source 
 
Primary antibodies 
CD68 
(KP1) 
(ab845) 
Human CD68 Mouse 
IgG1 
1:5 none Abcam, U.K.  
MAC387 
(ab22506) 
S100A9 + 
Calprotectin 
(S100A8/A9) 
Mouse 
IgG1 
1:500 none Abcam, U.K.  
2-7 CLEVER-1 Rat  
IgG 
1:5 Proteinase K 
(Dako) 
Palani et al, 
2011329 
D7F9A NT5E/CD73 Rabbit 
IgG1 
1:500 Aptum 2000 
epitope recovery 
unit (Aptum 
biologics ltd) 
Cell Signaling 
Technology Inc. 
Negative controls 
3G6 Chicken T cells Mouse 
IgG1 
5µg/ml none Salmi &Jalkanen, 
1992 348 
MEL-14 Mouse L-selectin 
(CD62L) 
Rat 
IgG2a 
5µg/ml Proteinase K 
(Dako) 
Exbio, Czech 
Republic 
Rabbit 
IgG1 
isotype     
control 
Unknown Rabbit 
IgG1 
5µg/ml Aptum 2000 
epitope recovery 
unit (Aptum 
biologics ltd) 
BD Pharmingen 
68
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3 Scoring 
In study I, the whole tumor area was screened and three hotspot areas per block with 
most CD68+ macrophages, MAC387+ macrophages, and CLEVER-1+ mac-
rophages and vessels by eye were scored. A 0.0625 mm grid was used with 40x 
magnification with macrophages and 20x with vessels. The numbers of macro-
phages/vessels were calculated and scored semiquantitatively (from -/negative to 
+++/abundant) within one high-power field independently by two observers blinded 
to the clinical information. MAC387+ tumor cells were also detected and scored 
with semiquantitative scoring. The mean numbers of the hotspots were calculated to 
form the macrophage/vessel count for each patient. 
In study II the scoring was performed manually and digitally. The manual 
scoring was performed similarly as in study I. For digital scoring, the hotspots were 
scanned and analyzed with Fiji-ImageJ 2.0.0. The macrophage-positive areas were 
extracted by color deconvolution and the resulting image was thresholded. A 
minimal size limit was applied to exclude artefacts and macrophage-positive areas 
were calculated. For MAC387 analyses, the images were watershed and a size limit 
was applied to exclude larger positive tumor cells from macrophages. The mean 
percentages of hotspots were calculated and used in analyses. CLEVER-1+ vessels 
were calculated manually only. 
In study III, the CD73 immunoreactivity was assessed by two independent 
readers in a blinded fashion using a dichotomous scoring. CD73 expression was 
analyzed separately for the different cell types in the samples. Basal cell layer of the 
epithelium (BCL), suprabasal epithelial cells (SEC), tumor stroma fibroblasts, 
peritumoral endothelial cells (lymphatic and vascular endothelia), and lymphocyte 
infiltrates were scored as negative or positive.  
4 Statistical analyses 
Statistical analyses were performed with SPSS Statistics (versions 20, 21, and 24, 
IBM) and SAS System for Windows (version 9.3, SAS Institute Inc. Cary, NC, 
USA). The relevant statistical tests used in the studies are shown in Table 10. 
Outcome measures included disease-specific survival (DSS), overall survival (OS), 
recurrence-free survival (RFS), and progression-free survival (PFS). NAC response 
was categorized as follows: complete response (pT0N0), partial response 
(pT1/pTa/pTisN0), no response (pT2N0), and progression (pT3 and/or N+). In 
studies I and II, the macrophage and vessel counts were dichotomized according to 
the mean number (low vs. high). In study I combination variables from macrophage 
markers were generated: CD68/MAC387, CD68/CLEVER-1, and 
MAC387/CLEVER-1. Each of he combination variable included low-low, low-high, 
and high-high groups. In study II, MAC387+ tumor cells were divided into two 
9
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groups according to the density of positive cells (0-2 vs. 3). In study III, the 
variables were scored as dichotomized (negative vs. positive), disregarding CD73+ 
lymphocytes, which were dichotomized as <1% vs. ≥1%. All statistical tests were 
two-sided, and P values of <0.05 were considered as statistically significant. 
Table 10. Statistical tests used in the studies 
The association studied  Statistical test used 
The markers vs.  
clinicopathological variables 
Pearson’s Chi-Square test 
Fisher’s exact test 
Spearman rank-order correlation coefficient test 
Mann-Whitney U test 
Kruskal-Wallis test 
The markers vs. 
 outcome 
The Kaplan-Meier method 
Cox proportional hazards regression models 
The NAC response vs.  
clinicopathological characteristics 
Pearson Chi-square test 
Fisher’s exact test 
The markers vs.  
the NAC response 
Regression analyses 
Mann-Whitney U test 
Pearson’s Chi-Square test 
Fisher’s exact test 
 
5 Ethics 
The study protocols were approved by the Research Ethics board of the Hospital 
District of Southwest Finland (1.8.2006/301). Written consents were obtained from 
the patients participating the studies. The studies did not affect the patients or their 
further treatment of follow-up in any way. All the sample collections were done on 
already existing tissue specimens received during the diagnosis and treatment of the 
patients. All studies were performed in accordance with the Declaration of Helsinki. 
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Results 
1 The study populations 
Table 11. Clinicopathological characteristics of the study populations. 
Study I Study II Study III 
 TUR-BT 
n=92 (%) 
RC 
n=92 (%) 
 
n=68 
(%) 
NMIBC 
n=166 (%) 
MIBC 
n=104 (%) 
 
Gender Male 69 (75) 74 (80) 58 (85) 137 (83) 78 (75) 
Age (y) Median  
(range) 
71  
(34-92) 
65  
(38-78) 
65  
(47-76) 
67  
(34-92) 
66  
(35-84) 
Smoking No 
Yes 
34 (37) 
35 (38) 
43 (47) 
54 (59) 
9 (13) 
52 (76) 
96 (58) 
70 (42) 
46 (44) 
58 (56) 
Grade,  
WHO  
1973 
G1 37 (40) 2 (2) 0 45 (27) 0 
G2 17 (19) 26 (28) 1 (1) 58 (35) 23 (22) 
G3 30 (33) 64 (70) 67 (99) 56 (34) 81 (78) 
Grade, 
WHO/ISUP 
2004 
PUNLMP 0 0 0 33 (20) 0 
Low 60 (55) 19 (21) 17 (25) 50 (30) 6 (6) 
High 32 (35) 73 (79) 51 (75) 83 (50) 98 (94) 
pT 
category 
pTa 
81 (88) 33 (36) 
0 83 (50) 0 
pTcis 0 66 (40) 0 
pT1 0 17 (10 0 
pT2 11(12) 24 (26) 48 (71) 0 46 (44) 
pT3 0 23 (25) 18 (27) 0 44 (42) 
pT4 0 12 (13) 2 (3) 0 14 (14) 
CIS Yes NA NA 15 (22) 40 (24) 24 (23) 
LVI Yes NA NA 17 (25) 6 (4) 60 (58) 
pN  
category 
Positive NA NA 7 (11) 0 13 (13) 
Negative NA NA 58 (89) 166 (100) 101 (87) 
Outcome Alive 33 (36) 26 (28) 53 (78) 65 (39) 15 (14) 
Dead, BC 22 (24) 39 (42) 13 (19) 27 (16) 62 (40) 
Dead, other 37 (40) 17 (19) 2 (3) 63 (38) 22 (21) 
Recurrence Yes 47 (51) NA 13 (19) 61 (37) 58 (56) 
Progression Yes 34 (37) NA NA 24 (15) 9 (9) 
Follow-up  
time (mo) 
Median 
(range) 
6.9 
(0-14.3) 
4.2  
(0-17.8) 
3.6  
(0.3-7.7) 
6.8  
(0-22.0) 
1.5  
(0-20.5) 
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2 TAMs in bladder cancer (Study I and II) 
To study TAMs in BC, the prognostic and predictive role of three macrophage 
markers were evaluated by immunohistochemistry in TUR-BT and RC samples. 
CD68 was analyzed as a pan-macrophage marker, MAC387+ macrophages repre-
sented a subgroup of recently infiltrated macrophages, and CLEVER-1 was ex-
pressed on M2 macrophages, as well as on endothelial cells. MAC387 expression on 
cancer cells was studied, as well. 
2.1 CD68, MAC387 and CLEVER-1 expression in BC 
CD68, MAC387, and CLEVER-1 expressions were analyzed in TUR-BT and RC 
samples in study I. In study II markers were analyzed in TUR-BT samples from 
patients treated with neoadjuvant chemotherapy and RC after sample taking. 
Macrophage and vessel counts were dichotomized according to the mean value into 
low/high groups and the results are represented in Table 12. 
Table 12. Markers analyzed in study I and II. The macrophage and vessel counts 
were dichotomized according to the mean value. 
Marker Score 
Study I Study II 
TUR-BT 
n=92 (%) 
RC     
n=92 (%) 
NAC    
n=68 (%) 
CD68+  
macrophages 
Mean number (range) 18 (0-81) 30 (0-102) 59 (0-175) 
Low 61 (66) 34 (60) 30 (44) 
High 31 (34) 31 (34) 38 (56) 
MAC387+  
macrophages 
Mean number (range) 19 (0-135) 34 (0-197) 78 (8-240) 
Low 62 (67) 41 (65) 37 (54) 
High 30 (32) 22 (35) 31 (46) 
MAC387+  
tumor cells 
0 NA NA 9 (14) 
1 NA NA 29 (44) 
2 NA NA 15 (23) 
3 NA NA 12 (18) 
CLEVER-1+  
macrophages 
Mean number (range) 26 (0-73) 11 (0-41) 53 (0-209) 
Low 56 (61) 43 (60) 34 (50) 
High 36 (39) 29 (40) 34 (50) 
CLEVER-1+ 
vessels 
Mean number (range) 8 (0-22) 0 (0-6) 4 (0-27) 
Low 56 (61) 42 (65) 39 (57) 
High 36 (39) 23 (35) 29 (43) 
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In study II, different immunohistochemical methods analyzing macrophages im-
munohistochemically in tissues were tested. Macrophages were counted from whole 
sections and TMAs to study if TMA could be utilized when investigating 
macrophages. TMAs correlated with whole sections in CD68 and MAC387 stain-
ings (p=0.002 and p<0.001, respectively), but not in CLEVER-1 stainings (p=0.41). 
Macrophages were also counted digitally and it was shown, that the digital and 
manual countings correlated with each other in all markers studied (p-values in 
CD68 0.008, MAC387 <0.001, and CLEVER-1 <0.001, respectively). All further 
correlation and survival analyses were tested with the manually counted 
macrophages from whole sections. 
2.2 The prognostic role of CD68, MAC387 and CLEVER-1 
The associations between immunohistological markers and clinicopathological 
variables of the BC patients were analyzed in the studies. In study I high numbers of 
CD68+ macrophages and MAC387+ macrophages associated with higher pT 
category and tumor grade. In contrast, lower CLEVER-1+ macrophage and vessel 
counts associated with more adverse T-category and grade of the tumor. In study II, 
only an association between high CD68+ macrophage count and the presence of LVI 
was noted. The markers did not associate with any other clinicopathological 
variables in study II. 
An overview of survival analyses in studies I and II is shown in Table 13. The 
Kaplan-Meier analyses and the Cox proportional hazards regression analyses 
affecting OS in detail in studies I and II are presented in Figure 9 and Table 14. High 
counts of CD68+ and MAC387+ macrophages associated significantly with higher 
risk of progression, as well as with poorer DSS and OS after TUR-BT. CLEVER-1+ 
macrophages did not associate with survival, but in contrast, high CLEVER-1+ 
vessel count associated with lower risk of progression and favourable DSS in the 
univariate analyses. However, any of these associations did not remain significant in 
multivariate analyses. After RC, only MAC387+ macrophages associated with 
greater risk of death due to the BC in univariate, but not in multivariate analyses.  
In study II high counts of CD68+ macrophages associated with shorter OS after 
NAC and RC in multivariate analysis with 3.97 risk of death in the high vs. low 
macrophage group (95% confidence interval, CI, 1.11-14.12).  High counts of 
CLEVER-1+ macrophages associated with poorer OS in univariate analysis, as well, 
but failed to stay significant in multivariate tests. MAC387+ macrophages/tumor 
cells or CLEVER-1+ vessels did not affect the survival in study II.  
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Table 13. Overview of the survival analyses (univariate and multivariate Cox proportional 
hazards regression model) in studies I and II. P-values and hazard ratios of the Cox 
models are shown (HR; p).  
Test 
(HR; p) 
Study I 
TUR-BT 
Study I 
RC 
Study II 
NAC 
OS DSS PFS RFS OS DSS OS 
CD68+ macrophages 
Univariate 1.031; 
<0.001* 
1.043; 
<0.001* 
1.031; 
<0.001* 
1.005; 
0.68 
1.004; 
0.51 
1.004; 
0.57 
3.5; 
0.053 
Multivariate  1.012; 
0.19 
1.019; 
0.075 
1.005; 
0.64 
0.996; 
0.77 
0.997; 
0.72 
0.994; 
0.51 
3.97; 
0.033* 
MAC387+ macrophages 
Univariate 1.016; 
0.002* 
1.029; 
<0.001* 
1.022; 
<0.001* 
0.998; 
0.85 
1.006; 
0.070 
1.008; 
0.032* 
1.48; 
0.45 
Multivariate  1.003; 
0.65 
1.011; 
0.16 
1.005; 
0.55 
0.978; 
0.046* 
1.002; 
0.56 
1.003; 
0.59 
1.57; 
0.39 
CLEVER-1+ macrophages 
Univariate 1.011; 
0.30 
1.008; 
0.62 
1.010; 
0.48 
1.007; 
0.61 
1.017; 
0.28 
1.020; 
0.29 
3.17; 
0.048* 
Multivariate  1.005; 
0.62 
0.955; 
0.73 
0.999; 
0.93 
1.002; 
0.87 
1.017; 
0.27 
1.017; 
0.33 
2.94; 
0.066 
CLEVER-1+ vessels 
Univariate 0.958; 
0.17 
0.898; 
0.046* 
0.910; 
0.030* 
0.997; 
0.94 
1.052; 
0.75 
1.105; 
0.60 
0.64; 
0.42 
Multivariate  1.015; 
0.65 
0.989; 
0.83 
0.971; 
0.53 
0.998; 
0.95 
1.149; 
0.39 
1.222; 
0.27 
0.65; 
0.43 
* Significant p-value 
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Figure 9. Kaplan-Meier estimates of the markers for OS in study cohorts: a-d. study I, TUR-BT cohort; 
d-g. study I, RC cohort; and h-k study II, NAC cohort. 
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Table 14. Univariate and multivariate Cox proportional hazards regression analyses of 
CD68+ macrophages, MAC387+ macrophages, CLEVER-1+ macrophages, and CLEVER-
1+ vessels affecting OS. In study I the markers were analyzed as continuous variables in 
Cox analyses and in study II the markers were analyzed as continuous and dichotomized 
variables. 
 Univariate Multivariate 
Marker HR 95% CI p-value HR 95% CI p-value 
Study I TUR-BT 
CD68+      
macrophages 
1.031 1.016-1.046 <0.001* 1.012a 0.994-1.013 0.19 
MAC387+ 
macrophages 
1.016 1.006-1.027 0.002* 1.003a 0.989-1.018 0.65 
CLEVER-1+ 
macrophages 
1.011 0.990-1.032 0.30 1.005a 0.985-1.026 0.62 
CLEVER-1+ 
vessels 
0.958 0.901-1.019 0.17 1.015a 0.950-1.086 0.65 
Study I RC 
CD68+      
macrophages 
1.004 0.993-1.015 0.51 0.997b 0.983-1.012 0.72 
MAC387+ 
macrophages 
1.006 0.999-1.013 0.070 1.002b 0.994-1.010 0.56 
CLEVER-1+ 
macrophages 
1.017 0.986-1.049 0.28 1.017b 0.987-1.049 0.27 
CLEVER-1+ 
vessels 
1.052 0.768-1.442 0.75 1.149b 0.839-1.573 0.39 
Study II NAC 
CD68+      
macrophages 
1.009/ 
3.50 
0.994-1.023/ 
0.99-12.44 
0.024*/ 
0.053 
1.008/ 
3.97c 
0.995-1.021/ 
1.11-14.12 
0.23/ 
0.033* 
MAC387+ 
macrophages 
1.002/ 
1.48 
0.990-1.014/ 
0.54-4.08 
0.80/ 
0.45 
1.002/ 
1.57c 
0.991-1.013/ 
0.57-4.32 
0.73/  
0.39 
CLEVER-1+ 
macrophages 
0.999/ 
3.17 
0.981-1.018/ 
1.01-9.97 
0.95/ 
0.048* 
0.998/ 
2.94c 
0.982-1.015/ 
0.93-0.27 
0.82/ 
0.066 
CLEVER-1+ 
vessels 
0.873/ 
0.64 
0.718-1.062/ 
0.22-1.87 
0.17/ 
0.42 
0.901/ 
0.65c 
0.748-1.086/ 
0.22-1.90 
0.28/ 
0.43 
a Analyses adjusted with grade, T-category, age, and tumor number. 
b Analyses adjusted with grade, T-category, and age. 
c Analyses adjusted with T-category. 
* Significant p-value 
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In study I, the prognostic roles of combination variables generated from macro-
phage markers (CD68/MAC387, CD68/CLEVER-1, and MAC387/CLEVER-1) 
were analyzed. The results according to the OS are presented in Figure 10 and Table 
15. All groups with “double-high” macrophage counts (CD68high/MAC387high, 
CD68high/CLEVER-1high, and MAC387high/CLEVER-1high) associated with 
shorter PFS and worse survival compared to other groups in TUR-BT samples. 
When CD68/MAC387 groups were tested, the “double-low” group had the longest 
PFS. In CD68/CLEVER-1 or in MAC387/CLEVER-1 groups there were no 
differences between the “double-low” group and CD68high/CLEVER-1low or 
MAC387high/CLEVER-1low groups. Moreover, CD68/MAC387 “double-high” 
and CD68/CLEVER-1 “double-high” groups were independent prognostic factors 
for OS with HR 3.5 (95% CI 1.1-11) and 3.8 (95% CI 1.4-10), respectively. When 
the combination data was analyzed from RC samples, the “double-high” groups 
from CD68/MAC387 and CD68/CLEVER-1 associated with worse OS in Kaplan-
Meier and univariate analyses, but did not remain as independent prognostic factors 
in multivariate Cox proportional hazards regression model. 
 
Table 15. Univariate and multivariate Cox proportional hazards regression analyses of 
macrophage combination groups affecting OS. 
 
Univariate Multivariate 
Marker HR 95% CI p-value HR 95% CI p-value 
Study I TUR-BT 
CD68/MAC387-/- REF REF 
CD68/MAC387-/+ 1.8 0.99-3.3 0.054 1.6a 0.72-3.4 0.26 
CD68/MAC387+/+ 6.9 3.4-14 <0.001* 3.5a 1.1-11 0.036* 
CD68/CLEVER-1-/- REF REF 
CD68/CLEVER-1-/+ 0.89 0.47-1.7 0.71 1.1a 0.55-2.3 0.77 
CD68/CLEVER-1+/+ 3.1 3.4-14 <0.001* 3.8a 1.4-10 0.008* 
MAC387/CLEVER-1-/- REF REF 
MAC387/CLEVER-1-/+ 0.94 0.50-1.8 0.85 1.4a 0.71-2.8 0.34 
MAC387/CLEVER-1+/+ 2.9 1.4-5.9 0.004* 1.6a 0.66-3.7 0.32 
Study I RC 
CD68/MAC387-/- REF REF 
CD68/MAC387-/+ 1.2 0.48-3.0 0.70 1.1b 0.34-3.5 0.88 
CD68/MAC387+/+ 2.9 1.2-7.2 0.020* 2.1b 0.79-5.7 0.13 
CD68/CLEVER-1-/- REF REF 
CD68/CLEVER-1-/+ 2.0 0.89-4.5 0.095 1.3b 0.53-3.0 0.60 
CD68/CLEVER-1+/+ 3.4 1.2-10 0.027* 2.2b 0.69-6.8 0.18 
MAC387/CLEVER-1-/- REF REF 
MAC387/CLEVER-1-/+ 1.8 0.84-3.8 0.14 1.0b 0.44-2.4 0.95 
MAC387/CLEVER-1+/+ 2.0 0.63-6.4 0.24 2.6b 0.72-9.1 0.15 
a Analyses adjusted with grade, T-category, age, and tumor number. 
b Analyses adjusted with grade, T-category, and age. 
* Significant p-value 
7
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2.3 The predictive role of CD68, MAC387 and CLEVER-1 
In study II the predictive roles of CD68, MAC387, and CLEVER-1 were 
investigated in NAC treated BC patients. No associations between known clinico-
pathological characteristics (gender, smoking, type of chemotherapy, tumor grade, 
or presence of CIS, or LVI) and response to NAC were noticed. Associations 
between chemotherapy response and studied markers are shown in Table 16. The 
overall response rate for complete response in the study was 41%. 21% of the 
Figure 10. Kaplan-Meier estimates of the combination groups for OS 
in TUR-BT cohort (a.-c.) and RC cohort (d.-f.) in study I. 
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patients received a partial response and 25% of the tumors progressed during NAC. 
CD68+ or MAC387+ macrophages did not associate with the chemotherapy 
response. However, a high MAC387+ tumor cell density associated with progression 
following NAC with risk of 3.76 (95% CI 1.10-12.82). Of the patients with high 
MAC387+ tumor cell density, 47% progressed during the follow-up, while 20% 
received a complete response (pT0N0). In contrast, 19% of the patients with low 
amounts of MAC387+ tumor cells progressed during the treatment, while 47% of 
these patients had no tumors at the time of RC (Table 17.). High CLEVER-1+ 
macrophage count associated with poorer response to NAC (HR 2.78, 95% CI 1.00-
7.67) (Figure 11). 
Table 16.  Associations between markers and chemotherapy response. Regression analyses were used 
to evaluate the associations between the chemotherapy response and marker groups dichotomized 
according to the mean value. Mann-Whitney U test was used to evaluate the association between the 
continuous variables and chemotherapy response, a figure is provided for the significant findings (Figure 
11). Pearson Chi-square/Fisher’s exact test was used to evaluate the association between MAC387+ 
tumor cells and chemotherapy response (low/high 0-2 vs. 3; all groups 0-3). 
Variable 
Complete vs. other Complete/Partial vs. other Other vs. progression 
HR 95% CI p-value HR 95% CI p-value HR 95% CI p-value 
CD68+          
macroph. 
Low/high  0.72 0.27-1.91 0.50 1.13 0.42-3.023 0.81 1.63 0.52-5.078 0.40 
Continuous 
  
0.33 
  
0.58 
  
0.97 
MAC387+    
macroph. 
Low/high  0.94 0.36-2.49 0.91 1.038 0.39-2.77 0.94 1.48 0.49-4.46 0.48 
Continuous 
  
0.42 
  
0.40 
  
0.53 
MAC387+    
tumor cells 
Low/high  3.57 0.90-14.13 0.070 3.18 0.97-10.37 0.056 3.76 1.10-12.82 0.034* 
All groups  
  
0.41 
  
0.36 
  
0.40 
CLEVER-1+         
macroph. 
Low/high  1.63 0.62-4.32 0.33 2.78 1.006-7.67 0.049* 1.61 0.53-4.88 0.40 
Continuous 
  
0.49 
  
0.21 
  
0.88 
CLEVER-1+         
vessels 
Low/high  0.99 0.37-2.62 0.98 0.76 0.28-2.050 0.58 0.47 0.14-1.52 0.21 
Continuous 
  
0.26 
  
0.10 
  
0.012* 
* Significant p-value 
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Table 17. Dichotomized marker counts, n (%), in different chemotherapy 
response groups. 
Variable n (%) Complete       response 
Partial          
response 
No      
response Progression 
CD68+             
macrophages 
Low, n=75 11 (37) 8 (27) 5 (17) 6 (20) 
High, n=38 17 (45) 6 (16) 4 (11) 11 (29) 
MAC387+     
macrophages  
Low, n=37 15 (41) 8 (22) 6 (16) 8 (22) 
High, n=31 13 (42) 6 (19) 3 (10) 9 (29) 
MAC387+    
tumor cells 
Low, n=62 25 (47) 11 (21) 7 (13) 10 (19) 
High, n=15 3 (20) 3 (30) 2 (13) 7 (47) 
CLEVER-1+         
macrophages 
Low, n=34 16 (47) 9 (27) 2 (6) 7 (21) 
High, n=34 12 (35) 5 (15) 7 (21) 10 (29) 
CLEVER-1+         
vessels 
Low, n=39 16 (41) 7 (18) 4 (10) 12 (31) 
High, n=29 12 (41) 7 (24) 5 (17) 5 (17) 
 
 
 
 
 
Figure 11. Association between neoadjuvant chemotherapy 
response (progression vs. Other) and CLEVER-1+ vessels. 
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3 CD73 in bladder cancer (Study III) 
3.1 CD73 expression in BC 
The expression patterns of CD73 were analyzed in different cellular types in BC 
tumors: epithelium, endothelium, stromal fibroblasts, and lymphocytes. The dis-
tribution of CD73 expression in the different cellular compartments is represented in 
Table 18. The expression of CD73 between different cell types in BC tumors varied 
highly. CD73 stained differently BCL and SEC in BC tumors. When identified, 
BCL was positive approximately in 2/3 tumors in NMIBC and MIBC cohorts, 
whereas SEC remained negative in approximately 70% of the tumors. However, 
BCL could be identified only in 12% of poorly differentiated MIBC tumors, while in 
NMIBC samples BCL was seen in 62% of the samples. In the NMIBC cohort, only 
22% of the patients had CD73 positive stromal fibroblasts, whereas in the MIBC 
cohort almost half of the patients had CD73 positive fibroblasts. The majority of the 
tumors in both cohorts had CD73 positive vessels. Approximately half of he patients 
had only <1% of CD73 positive tumor-infiltrating lymphocytes. 
Table 18. Cell type specific expression of CD73 in BC. 
Cell type Score 
NMIBC 
n=166 (%) 
MIBC 
n=104 (%) 
Basal cell layer of 
epithelium (BCL) 
Negative 30 (18) 4 (4) 
Positive 67 (40) 8 (8) 
Not applicable 63 (38) 91 (88) 
Suprabasal epithelial 
cells (SEC) 
Negative 117 (71) 78 (75) 
Positive 42 (25) 25 (24) 
Epithelium (total) 
Negative 79 (48) 74 (71) 
Positive 80 (48) 29 (28) 
Stromal fibroblasts 
Negative 129 (78) 53 (51) 
Positive 37 (22) 46 (48) 
Endothelial cells 
Negative 49 (30) 23 (22) 
Positive 117 (70) 78 (75) 
Lymphocytes 
<1% positive 74 (45) 51 (49) 
≥1% positive 88 (53) 52 (50) 
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3.2 The prognostic role of CD73 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The correlations between CD73 positivity in BC and the clinicopathological charac-
teristics were evaluated in Study III. In the NMIBC cohort, CD73 positive epi-
thelium correlated significantly with grade of the tumor and T category. The ma-
jority of grade 3 tumors had lost CD73 from the epithelium, while tumors with 
lower grade had more CD73 positive epithelial cells. Most of the Ta tumors had 
positive total epithelium in contrast to Tcis and T1 tumors. CD73 positive BCL 
correlated also with grade of the tumor but not with T category. However, SEC did 
Figure 12. Correlations between the grade of the tumor 
and T category to CD73 positivity on different cellular 
components in NMIBC cohort in study III.  
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not have any significant correlations with any parameters studied. Tumor grade and 
T category correlated also with CD73 positive endothelial cells and lymphocytes. 
However, the frequency of CD73 positive endothelial cells was increased in more 
advanced tumors compared to more indolent ones. There were also more CD73 
positive lymphocytes in Tcis and T1 tumors as in Ta tumors. CD73 positivity among 
stromal fibroblasts did not correlate with any of the clinicopathological parameters 
in the NMIBC cohort. The significant correlations between grade and T category 
and the CD73 positive cell types are shown in Figure 12. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. Significant correlations between the 
clinicopathological variables and CD73 positivity on different 
cellular components in MIBC cohort in study III: a. N category 
vs. SEC, b. T category vs. Endothelial cells, and c. Grade vs. 
Stromal fibroblasts.  
3
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In MIBC cohort, CD73 positive epithelium correlated significantly with N 
category, but not with tumor grade or T category. All MIBC patients with lymph 
node metastases had CD73 negative epithelial cells. CD73 positive endothelial cells 
correlated with T category in MIBC cohort. In contrast to NMIBC cohort, there were 
more CD73 positive vessels in tumors with lower T category. Stromal fibroblasts, in 
contrast, were more frequently CD73 positive in grade 3 tumors than in grade 2. The 
significant correlations in the MIBC cohort are shown in Figure 11. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. A. Association of CD73 positivity in total epithelium and PFS in NMIBC cohort. B. Association 
of CD73 positivity in stromal fibroblasts and PFS in NMIBC cohort. C. Association of CD73 positivity in 
total epithelium and OSS in MIBC cohort. D. Association of CD73 positivity in total epithelium and OSS 
in MIBC cohort. 
84
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The prognostic value of CD73 positivity in different cellular components in 
NMIBC according to RFS and PFS and in MIBC to DSS and OS was analyzed with 
Kaplan-Meier method and Cox proportional hazards regression model. In the 
NMIBC cohort, CD73 positive total epithelium associated with more favourable 
PFS, whereas CD73 positive stromal fibroblasts associated with poorer PFS in 
Kaplan-Meier analyses (Figure 12a-b.). In MIBC cohort, CD73 positive epithelium 
(total and SEC) associated with better DSS and OS (Figure 12c-d.). The results on 
total epithelium and SEC were similar to each other, because BCL could not be 
identified in most of the MIBC tumors. 
 
Table 19. Univariate and multivariate Cox proportional hazards regression analyses of cell-
type-specific CD73 expression affecting RFS, PFS, DSS, and OS in NMIBC cohort. 
Variable 
NMIBC 
Univariate Multivariate 
HR 95% CI p-value HR 95% CI p-value 
BCL 
Neg. vs. Pos. 
RFS 0.68 0.34-1.35 0.27 0.46 0.11-1.92 0.28 
PFS 0.43 0.13-1.43 0.17 0.45 0.12-1.64 0.23 
DSS 0.65 0.36-1.18 0.16 1.54 0.45-5.35 0.49 
OS 0.29 0.092-0.92 0.035* 0.082 0.007-0.96 0.047* 
SEC 
Neg. vs. Pos. 
RFS 0.80 0.45-1.40 0.43 0.37 0.10-1.39 0.14 
PFS 0.72 0.27-1.90 0.51 0.92 0.33-2.54 0.87 
DSS 0.76 0.47-1.22 0.28 0.52 0.21-1.31 0.17 
 OS 0.54 0.21-1.43 0.22 0.41 0.087-1.94 0.26 
Epithelium 
(total) 
Neg. vs. Pos. 
RFS 0.74 0.44-1.23 0.25 0.36 0.12-1.11 0.076 
PFS 0.27 0.11-0.67 0.005* 0.36 0.13-1.00 0.049* 
DSS 0.56 0.37-0.87 0.01* 0.62 0.29-1.32 0.21 
OS 0.26 0.11-0.63 0.002* 0.18 0.035-0.93 0.041* 
Endothelial 
cells 
Neg. vs. Pos. 
RFS 0.78 0.46-1.31 0.35 0.55 0.19-1.57 0.26 
PFS 1.75 0.72-4.23 0.21 1.18 0.45-3.14 0.74 
DSS 0.82 0.53-1.27 0.37 0.76 0.33-1.76 0.52 
OS 0.85 0.38-1.89 0.69 0.26 0.057-1.17 0.079 
Stromal    
fibroblasts 
Neg. vs. Pos. 
RFS 1.69 0.93-3.10 0.086 1.04 0.29-3.78 0.95 
PFS 2.46 0.98-6.17 0.055 2.54 1.00-6.55 0.053 
DSS 1.73 1.07-2.79 0.025* 1.28 0.56-2.95 0.57 
OS 1.81 0.79-4.14 0.16 1.03 0.29-3.65 0.96 
Lymphocytes 
Neg. vs. Pos. 
RFS 0.8 0.48-1.34 0.40 0.53 0.18-1.57 0.25 
PFS 2.19 0.90-5.31 0.083 2.19 0.90-5.32 0.084 
DSS 0.89 0.58-1.37 0.60 1.23 0.55-2.75 0.61 
OS 0.75 0.34-1.63 0.46 0.24 0.053-1.06 0.06 
*Significant p-value 
 
In Cox proportional hazards regression model CD73 positivity in total epithelium 
associated significantly with longer PFS and better DSS and OS in the NMIBC 
cohort. Moreover, in multivariate analyses, CD73 positive epithelium associated 
independently with longer PFS and better OS. BCL associated also with better OS 
both in univariate and multivariate analyses, but SEC did not affect the survival in 
5
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NMIBC cohort. In contrast to the CD73 positive epithelium, CD73 positive stromal 
fibroblasts associated with poorer DSS in NMIBC cohort. However, this result did 
not remain significant in multivariate analysis. CD73 positive endothelial cells or 
lymphocytes did not associate with outcome in the NMIBC cohort. The Cox 
proportional hazards regression analyses in the NMIBC cohort are shown in Table 
19. 
In MIBC cohort, CD73 positivity on SEC associated significantly with better 
RFS, DSS, and OS. CD73 positive SEC predicted also independently longer DSS in 
multivariate analysis. In addition, CD73 positivity on total epithelium associated 
with better PFS and DSS, and predicted DSS independently in multivariate analysis. 
Because of the lack of BCL in the samples, CD73 positivity on BCL could not be 
analyzed in multivariate analyses. CD73 expression on endothelial cells, stromal 
fibroblasts, or lymphocytes did not associate with outcome in univariate models. 
However, CD73 positive endothelial cells associated independently with more 
favourable PFS, DSS, and OS. The Cox proportional hazards regression analyses in 
the MIBC cohort are shown in Table 20. 
 
Table 20. Univariate and multivariate Cox proportional hazards regression analyses of 
cell-type-specific CD73 expression affecting PFS, DSS, and OS in MIBC cohort. 
Variable 
MIBC 
Univariate Multivariate 
HR 95% CI p-value HR 95% CI p-value 
BCL 
Neg. vs. Pos. 
RFS 1.78 0.20-15.97 0.61 - - - 
DSS 0.82 0.20-3.30 0.78 - - - 
OS 0.88 0.16-4.82 0.88 - - - 
SEC 
Neg. vs. Pos. 
RFS 0.39 0.19-0.83 0.014* 0.24 0.049-1.14 0.072 
DSS 0.48 0.27-0.85 0.012* 0.16 0.033-0.74 0.019* 
 OS 0.48 0.24-0.94 0.032* 0.23 0.047-1.10 0.065 
Epithelium 
(total) 
Neg. vs. Pos. 
RFS 0.47 0.25-0.92 0.026* 0.24 0.049-1.14 0.072 
DSS 0.55 0.32-0.93 0.025* 0.16 0.033-0.76 0.019* 
OS 0.54 0.29-1.00 0.051 0.30 0.047-1.10 0.065 
Endothelial 
cells 
Neg. vs. Pos. 
RFS 0.67 0.38-1.20 0.18 0.14 0.04-0.48 0.002* 
DSS 0.89 0.52-1.51 0.66 0.17 0.054-0.56 0.004* 
OS 0.69 0.39-1.21 0.19 0.14 0.041-0.50 0.002* 
Stromal    
fibroblasts 
Neg. vs. Pos. 
RFS 0.84 0.50-1.43 0.53 1.22 0.47-3.16 0.68 
DSS 0.95 0.62-1.47 0.83 0.92 0.37-2.29 0.86 
OS 0.97 0.58-1.60 0.89 1.20 0.46-3.10 0.71 
Lymphocytes 
Neg. vs. Pos. 
RFS 0.75 0.44-1.27 0.28 0.67 0.29-1.53 0.34 
DSS 0.97 0.63-1.50 0.91 0.81 0.33-1.73 0.59 
OS 0.87 0.52-1.43 0.58 0.68 0.30-1.56 0.36 
*Significant p-value 
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Discussion 
1 CD68, MAC387, and CLEVER-1 in bladder cancer 
BC is a heterogenous disease with a broad diversity in survival between superficial 
non-invasive disease and invasive, metastatic disease. Despite the good prognosis of 
many NMIBC patients, over half of the patients receive recurrence and the 
progression to MIBC is not uncommon. Because BC tumors are often nearly 
symptomless, frequent follow-up is needed. This causes inconvenience to the patient 
and major social costs. There is a critical need for biomarkers to assess accurately 
the outcome of BC and help guide the decision-making between treatment 
alternatives and follow-up protocols. In this study, CD68, MAC387, and CLEVER-1 
were investigated as prognostic biomarkers in BC. The results demonstrate that 
intratumoral macrophage density is significantly associated with conventional high-
risk features including high grade and advanced T category in BC. Furthermore, 
high macrophage count associates with poorer survival and higher risk for 
progression after TUR-BT. CD68 positive macrophage count is an independent 
prognostic factor for overall death in BC patients treated with NAC and RC. 
As in many cancers, several studies have shown that CD68 positive macrophages 
associate with more advanced disease, greater risk for recurrence and progression, 
and poorer survival in BC.291-293, 295, 296, 304, 313, 314 However, in a meta-analysis in 
2018 consisting of 13 studies, Wu and colleagues did not find any prognostic value 
in CD68 positive TAMs with regard to OS in BC patients.294 Our study from Plos 
One in 2015 was included in this meta-analysis with the most patients and the 
highest Newcastle-Ottawa scale score (NOS score 9). The meta-analysis was in line 
with our study, as we did not find any association between CD68 positive 
macrophages and BC survival in TUR-BT and RC treated patients. However, we 
found an independent association between CD68 positive macrophages and survival 
in NAC treated BC. CD68 is classically considered as a pan-macrophage marker, 
which does not distinguish the polarization of the macrophages. Therefore, we 
investigated two different macrophage populations in addition to CD68 positive 
macrophages: MAC387 and CLEVER-1 positive macrophages. MAC387 positive 
macrophages are a largely unknown subgroup of macrophages, which are considered 
as recently infiltrated, possibly the earliest macrophage group in the tissue during 
7
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early acute inflammation.324 MAC387 positive macrophages have not been studied 
in BC earlier and our work is the first to detect a relationship between MAC387 
positive macrophage density and poor outcome in BC in univariate analyses. In line 
with our results, S100A8 protein, one of the ligands of MAC387, is overexpressed in 
advanced BC and predicts the progression of the disease.335-338 MAC387 positive 
macrophages associate with poor survival with several other cancers, too, e.g. with 
breast cancer and cholangiocarcinoma.332, 334, 430 Soulas and co-workers speculate in 
their encephalitis study, that MAC387 positive macrophages would be M1-
polarized, because of the proinflammatory activities of MRP14 and the absence of 
CD163 and CCR expression on MAC387 positive cells.324 However, in our study 
MAC387 positive macrophages did not show antitumoral functions typical to M1 
macrophages, but associated with more aggressive disease similar to CD68 positive 
macrophages. There is still a lack of a definitive surface molecule as a biomarker for 
proinflammatory M1 macrophages. 
In our study, M2-polarized macrophages were investigated with CLEVER-1 an-
tibody, a macrophage marker not investigated in BC earlier. CLEVER-1 is a large 
scavenger receptor expressed on afferent and efferent lymphatic and sinusoidal 
endothelial cells, as well as on a subset of immunosuppressive and pro-tumoral M2 
macrophages with multiple functions.342, 435 Another M2 macrophage marker, 
CD163, has been shown to act as a prognostic biomarker in BC in the meta-analysis 
in 2018.294 However, our study showed incoherent results when studied CLEVER-1 
positive M2 macrophages in BC patients treated with TUR-BT, RC alone, or NAC 
before RC: CLEVER-1 positive macrophages did not associate with survival after 
TUR-BT or RC alone, but had an association with poorer survival in univariate 
analyses in patients treated with NAC and RC. CLEVER-1 positive macrophages 
have also shown opposite prognostic results in different stages of cancer, e.g. in 
colorectal cancer.224 It has been speculated, that macrophages loose the expression 
of CLEVER-1 when switching to phenotypes promoting tissue remodeling and 
angiogenesis.356 Surprisingly, however, CLEVER-1 positive vessels seem to 
associate with lower risk of progression and more favourable DSS in BC. This result 
was disparate to earlier findings e.g. in colorectal and breast cancers.224, 352 Thus, the 
prognostic role of CLEVER-1 in cancer cannot be oversimplified. The reason for 
CLEVER-1 positive vessels acting as protective factors in BC is unclear and need 
further investigations. However, a trend towards this result was seen in both of our 
studies about CLEVER-1 in BC. CLEVER-1 is expressed in HEVs in lymphoid 
organs and in afferent lymphatic vessels in non-lymphoid tissues.343 It is also 
upregulated on HEV-like vessels at sites of inflammation.339 In our study, the vessels 
studied were not distinguished as vascular or lymphatic vessels. BC is a highly 
immunogenic cancer, and one can speculate, that CLEVER-1 positive vessels could 
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act as a gate for antitumoral inflammatory cells to the tumor tissue. However, as 
stated, further studies to define this finding are warranted. 
Although single macrophage markers were not significant prognostic factors in 
TUR-BT or RC treated BC in multivariate analyses, combinations of two markers 
provided independent prognostic information in multivariate models in the TUR-BT 
cohort. Combination groups with CD68 and MAC387, CD68 and CLEVER-1, and 
MAC387 and CLEVER-1 were generated. The relationship between CD68, 
MAC387, and CLEVER-1 positive macrophages is not known. It is unclear, whether 
these macrophage groups are subgroups of each other, different phenotype variations 
from same macrophages, or different macrophage groups activated and recruited by 
different factors. As these markers detect different populations of TAMs, the 
combination groups may better identify tumors that are skewed either towards M1 
phenotype (CD68high/MAC387high and MAC387high/CLEVER-1low) or M2 type 
(CD68high/CLEVER-1high and MAC387low/CLEVER-1high). However, these 
groups were generated statistically, and thus, these groups do no represent 
macrophages with distinct marker expressions, but tumors with distinct ratios of 
different macrophage subtypes. It would be interesting to investigate BC tumors 
with double-stainings to find more distinctive macrophage subgroups. The results 
from our study showed, that despite the studied macrophage subtypes, higher 
macrophage count in general associated with poorer prognosis in BC. The 
combinations of the macrophage groups provided an auxiliary tool for prognostic 
factors in BC. CD68/MAC387 and CD68/CLEVER-1 groups could represent 
opposite macrophage polarizations, but the results were nearly similar. In 
CD68/CLEVER-1 combinations CD68 positive macrophages seemed to be critical 
for the survival as CD68high/CLEVER-1low/high groups associated with poorer 
survival than CD68low/CLEVER-1low/high groups and there were no differences 
whether the macrophages were M2 polarized CLEVER-1 positive cells or not. This 
phenomenon was also seen in MAC387/CLEVER-1 groups, where 
MAC387high/CLEVER-1low/high patients associated with poorer survival than 
MAC387low/CLEVER-1low/high patients. 
This study has the known limitations of retrospective studies. Some clinical prac-
tices, e.g. performing the lymphadenectomy, might have changed during the long 
follow-up. In addition, the grading system was changed and the 2004 WHO/ISUP 
classification was defined after the 1973 WHO classification. However, the 2004 
WHO/ISUP classification was utilized in the entire cohort after re-review of all 
cases by an expert genitourinary pathologist. In addition, there are several challenges 
when macrophages are investigated immunohistochemically. First of all, the 
heterogeneity of macrophages complicates the research: CD68 positive macrophages 
are a wide group of diffuse polarization orientations and do not explain the different 
roles between antitumoral/proinflammatory and pro-tumoral/anti-inflammatory 
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macrophages in the tumor. Macrophages may switch their phenotype during the 
process or tumorigenesis and thus, the stage of the disease is crucial in macrophage 
research.201, 215 Even more, macrophage phenotype can vary according to their 
location in tumors, such as sites of initial tumor cell invasion, perivascular area, 
stromal region, and hypoxic or necrotic areas.187, 203, 204 Hence, it would be important 
to investigate the role of different macrophages at different sites of the tumor. 
Macrophages tend to locate in clusters, which make the scoring of the TAMs in the 
tumor tissue more challenging and diverse especially in small samples, such as in 
TMA. In this study, macrophages were analyzed from whole histological 
immunosections and from TMA. The results demonstrated, that these analyzes may 
vary and it needs to be considered when studying TAMs. 
Previous intravesical treatments were considered as the exclusion criteria in this 
study, because these treatments change the inflammatory microenvironment in the 
tumor. However, this complicates the interpretation of the results with a common 
BC patient receiving, for example, BCG treatments. Thus, it would be important to 
investigate the biomarkers in BCG treated BC, too. BCG is an important treatment 
modality in NMIBC, which utilizes the antitumor effect of local immune response. 
Macrophages act as a first line defense of innate immunity against BCG infection 
and have been considered to initiate BCG-induced anti-cancer responses.303 Cells of 
the urothelium respond to the treatment with an inflammatory cascade and release 
cytokines, such as IL-8 and TNF, and recruit neutrophils to destroy malignant 
cells.431 However, tumors with high TAM counts have also been shown to have 
worse outcome and to be less responsive to BCG treatment.291, 292, 432 CD68 positive 
and CD163 positive macrophages associate with BCG failure.315 It would be 
interesting to investigate further the role of different macrophage subtypes in the 
response to BCG treatment and even the possibility to enhance the effect of BCG 
treatment by manipulating the macrophage polarization in the bladder. 
BCG is one of the oldest cancer immunotherapies. However, the treatment of BC 
is transforming due to new checkpoint inhibitor immunotherapies. The expectations 
for these drugs are high. Clinicians are, however, challenged to select the patients 
who will benefit from these treatments. Some patients receive poor responses to the 
new PD-1/PD-L1 therapies, but the reason for this is still unknown. No correlation 
between the PD-L1 positivity and the response rate for the inhibitors has been 
observed.117 TAMs express high levels of PD-1 and its ligands.229 Because the PD-
L1 inhibitor treatment has shown antitumor activity even with non-PD-L1-
expressing tumors, macrophages have been suggested to be the key element in the 
response to PD-L1 inhibitors.233 TAMs remain inactive and do not exert antigen-
presenting activity in CPI resistant tumors.230 In some tumors, macrophages 
neutralize efforts to reactivate CD8+ T cells. (216) Manipulation of TAM phenotype 
could improve the efficacy of the immunotherapy. On the other hand, PD-L1 
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treatment has shown to reverse the immunosuppressive macrophage phenotype and 
trigger the macrophage-mediated antitumoral activity.231 Thus, it would be 
extremely interesting to be able to expand our studies about CD68, MAC387, and 
CLEVER-1 into CPI treated patients. 
The clinicians are challenged not only with selecting patients benefiting from 
CPI treatment but also from chemotherapy, and especially from neoadjuvant 
chemotherapy. Approximately 30-40% of the patients receiving NAC respond with 
no tumor (pT0N0) in cystectomy. The non-responders suffer from the toxicity of the 
chemotherapy agents and delay of the surgery. On the other hand, patients without 
micrometastatic disease are overtreated with toxic therapy. Among multiple 
different molecules, markers indicating DNA damage have been investigated as 
predictive factors for chemotherapy response. However, to date, there are no 
biomarkers in clinical use to indicate which patients will benefit from NAC in the 
treatment of BC. This is the first study investigating CD68, MAC387, and 
CLEVER-1 in BC patients treated with NAC. We reported, that high CD68 positive 
macrophage count is an independent prognostic factor for overall death in patients 
treated with NAC. When the markers were studied as predictive factors in NAC 
treated patients, neither CD68 nor MAC387 positive macrophages did affect the 
response to NAC. Instead, high MAC387 positive tumor cell count associated with 
progression following NAC while most of the patients with low MAC387 positive 
tumor cell count received a complete response for NAC and had no tumors at the 
time of RC. In addition, high CLEVER-1 positive macrophage count associated with 
poorer response to NAC, whereas low count of CLEVER-1 positive vessels 
associated with progression after NAC. 
MAC387 expression on tumor cells has been used as a marker of squamous dif-
ferentiation in BC, which is considered as a risk factor for local recurrence and 
poorer survival.316, 329-331 Squamous cell carcinoma is the most commonly found 
non-urothelial histological subtype. Squamous cell differentiation has been observed 
also when dividing BC into molecular subtypes. However, BC is often a molecularly 
heterogenous disease and different molecular subtypes may emerge in the same 
tumor. Basal squamous tumors are aggressive tumors with frequent invasive and 
metastatic features.60, 64, 433 However, in contrast to luminal tumors, they tend to 
respond to NAC and they have been reported as the best candidates for NAC.67, 68 
MAC387 positive tumor cells indicate the squamous metaplasia within the bladder 
tumor, and thus, act as predictive markers for tumors most suitable for NAC. In my 
knowledge, TAM expression in different molecular subtypes in BC has not been 
studied. The subtypes display prognostic significance and associate with different 
benefit from systemic therapies. It would be interesting to investigate what kind of 
differences there are in the TAM appearance in different BC subtypes with different 
kind of characteristics and survival prognosis. 
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Macrophages play an important role in the chemotherapy response and re-
sistance. They can synergize with therapy or induce protumoral functions through 
the activation of tissue repair mechanisms.212 They increase tumor progression by 
promotion of angiogenesis, maintenance of stem cells and inhibition of immune 
responses.434 On the other had, chemotherapy agents can inhibit or activate 
macrophage mediated antitumor responses and the modulation of tumor responses to 
chemotherapy can vary between different cytotoxic factors and tumors.435, 356 
CLEVER-1 is expressed on M2 type macrophages considered as protumoral and 
anti-inflammatory. This subtype of TAMs seems to associate with poorer NAC 
response and progression on the tumor in BC patients. However, low counts of 
CLEVER-1 positive vessels associated also with progression of the disease after 
NAC. This is in line with our results from TUR-BT and RC treated BC patients, 
where CLEVER-1 positive vessels seemed to act as protective factors. These results 
demonstrate, that CLEVER-1 treatment for enhancing NAC in BC patients or for 
BC in the first place, either, would not be appropriate. 
In addition to affecting other cancer therapies, TAMs are considered and 
investigated as treatment targets themselves in several diseases, such as asthma, 
atherosclerosis, and cancer, as well.226 There are currently several drugs being tested 
in clinical trials targeting TAM recruitment, survival, and reprogramming as 
monotherapies or in combination with chemotherapy or immunotherapy.212 Our 
study demonstrates, that CD68 and MAC387 positive TAMs associate with more 
advanced BC and poorer survival of the disease. Further investigations of these 
molecules as therapeutic targets in BC are in place. Anti-CLEVER-1 treatment has 
been shown to inhibit disease progression in malignant melanoma model.350 
However, our study shows, that CLEVER-1 is not only a protumoral factor in BC, 
but CLEVER-1 vessels also act as a protective fashion in these tumors, which 
naturally weakens CLEVER-1 as a therapeutic target in BC. Blocking the 
protumoral role of TAMs and reprogramming TAMs into antitumoral M1-like 
macrophages is a fascinating therapeutic approach in cancer. However, because of 
the heterogeneity of the macrophages, further studies are needed to distinguish the 
functions of the polarization subtypes in tumors. 
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2 CD73 in bladder cancer 
CD73 is a multifunctional ecto-5’nucleotidase, which functions in the extracellular 
nucleotide turnover hydrolyzing extracellular AMP to its bioactive nucleoside, 
adenosine.363, 364 Adenosine is a highly anti-inflammatory molecule with role e.g. in 
regulation of endothelial permeability and neutrophil adhesion.369-374 The 
physiological function of CD73 varies between different cells.382 In cancer, CD73 
has been considered as an important player of tumor progression, but its true role in 
cancer is still widely unknown. CD73 has been shown to associate with poor 
prognosis in several cancers, such as leukemia and breast cancer.404, 406  Furthermore, 
CD73 have been considered as possible prognostic biomarker and therapy target e.g. 
in melanoma and breast cancer.401, 409, 410 
In contrast to many other cancer types, CD73 expression on BC cells has been 
shown to associate with lower stage and grade and lower risk for progression.424 
However, there are only few studies about CD73 in BC and further investigations 
are needed. In our study, CD73 was studied in different cell components in BC. The 
expression pattern of CD73 was analyzed in epithelial cells, endothelial cells, 
stromal fibroblasts, and lymphocytes in BC tumors. The expression of CD73 on 
these cell types varied highly.  
CD73 positive epithelium correlated significantly with lower grade and T catego-
ry in NMIBC and lower lymph node metastasis risk in MIBC tumors. In addition, 
CD73 positivity on epithelial cells associated with lower risk for progression in 
NMIBC patients and lower recurrence rate and better survival in MIBC. Moreover, 
CD73 positive epithelium was an independent prognostic factor both in NMIBC and 
MIBC. The CD73 expression varied substantially between the basal cell layer of the 
epithelium (BCL) and the rest of the epithelial/cancer cells (suprabasal epithelial 
cells, SEC): BCL was CD73 positive in the majority of the samples, whereas the 
majority of SEC remained CD73 negative. However, BCL was noticed only in 
better-differentiated tumors (12% in MIBC vs. 62% in NMIBC). 
In contrast, the results showed CD73 positivity on stromal fibroblasts associating 
with poorer PFS and DSS in NMIBC tumors. However, this result could not been 
seen in MIBC. On the other hand, the frequency of CD73 positive endothelial cells 
was increased in more advanced NMIBC tumors, whereas MIBC patients with lower 
T category had more CD73 positive vessels than patients with higher T category.  In 
addition, CD73 positive endothelial cells predicted more favourable survival in 
multivariate analyses in the MIBC cohort. CD73 was expressed at very low 
frequencies on TILs in most BC patients. Higher CD73 expression on lymphocytes 
correlated with more aggressive disease in NMIBC. However, CD73 positive 
lymphocytes did not predict disease survival. 
Our results are in line with a previous study by Wettstein and colleagues.424 They 
showed an association between CD73 positive BC cells and lower stage, grade and 
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risk for progression. However, in their study CD73 positivity on cancer cells was not 
an independent prognostic biomarker in BC. Our results of the favourable effect of 
CD73 positivity on epithelium is also in line with earlier studies suggesting that the 
CD73 negativity is associated with the malignant transformation of the 
urothelium.421, 422 Our study is the first to investigate CD73 in different cell types in 
BC. The results point out, that the identity of the cell type expressing CD73 is 
important when interpreting the association of CD73 expression and survival. 
Moreover, our data imply that CD73 is unlikely to be a successful therapeutic target 
in BC. The systemic approaches would simultaneously target multiple different cell 
types, in which biological functions of CD73 varies. Interestingly, CD73 negativity 
on endothelial cells predicted poor outcome in the MIBC cohort in multivariate 
models. However, CD73 positivity on endothelial cells correlated with more 
advanced disease in the NMIBC cohort. Endothelial CD73 is involved in controlling 
the permeability of the blood vessels as well as in the regulation of the leukocyte 
extravasation.437 CD73 is also expressed on lymphatic endothelium, in which its 
functions remain unknown.363, 438 The blood and lymphatic vessels were not 
distinguished in our study. It is possible, that endothelial CD73 regulates the 
permeability and antitumor immunity in BC in a manner, which remains 
independent of the tumor grade and stage. Cancer-associated fibroblasts are known 
to express CD73.439 CD73 is also present on mesenchymal stem cells, which may be 
recruited to the stroma during the tumor progression.440 EMT may contribute also in 
generating CD73 positive fibroblast-like stromal cells. Different pathogenesis, such 
as cell-type origin, epigenetic regulators, driver mutations, and overall mutational 
load, and invasive potential of NMIBC and MIBC may affect the biological role of 
endothelial CD73 in cancer progression. It would be also interesting to investigate 
CD73 expression not only in different cell types in BC, but also in different 
molecular subtypes of BC. Because the expression of CD73 varies highly between 
different cellular types in tumors, the expression pattern may be different in different 
subtypes of same cancer type, too. 
The present study is a retrospective, single institutional study with a limited 
number of patients and thus, limited number of disease specific deaths. Further-
more, we only studied CD73 protein expression and not the enzymatic activity of 
CD73, which is crucial for the production of immunosuppressing adenosine. 
However, the enzymatic activity of CD73 usually usually well with the protein 
expression.  
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Conclusions and the future 
 
The recurrence rate of NMIBC is high, and frequent procedures and intense follow-
up results in BC being one of the most expensive cancers to treat. Treatment options 
for advanced BC are limited and novel therapies are needed. There is a lack of new 
biomarkers to help diagnose aggressive cases that require more intensive treatment. 
In this study CD68, MAC387, CLEVER-1, and CD73 were studied as prognostic 
and predictive factors in BC. The specific conclusions of the studies are summarized 
in Table 21. Further questions and new possible study objectives arise from these 
studies (Table 22).  
In this study, we found that high TAM counts associate with more advanced dis-
ease and poorer survival in BC patients. CD68 positive macrophage count is an 
independent prognostic biomarker in NAC treated BC. The role of CLEVER-1 
positive macrophages in BC remains unknown, but surprisingly, CLEVER-1 pos-
itive vessels seem to be a protective factor in BC. When used in combinations, 
“double-high” macrophage groups have also independent prognostic value in BC 
and could potentially be used to identify aggressive cases among BC patients.  
TAMs were studied in NAC treated BC patients as predictive biomarkers. We 
found, that MAC387 positive tumor cells and CLEVER-1 positive macrophages and 
vessels associate with the response for NAC in BC patients. High MAC387 tumor 
cell density associates with disease progression after NAC, whereas majority the 
patients with lower amount of MAC387 positive tumor cells receive a complete 
response for the treatment. Patients with higher amounts of CLEVER-1 positive 
vessels associate with more favourable response after NAC, whereas CLEVER-1 
positive macrophages associated with poorer response to NAC. Our results 
demonstrate, that MAC387 and CLEVER-1 are possible predictive biomarkers to 
predict which BC patients are more prone to benefit from NAC. However, these 
results need validation with larger patient cohorts from multicenter studies.  
Our study is the first to show, that CD73 expression varies highly between dif-
ferent cell types even in the same tumor samples. CD73 positive epithelium in-
dependently predicts better survival and lower risk for progression and recurrence in 
BC. In contrast, CD73 positivity on stromal fibroblasts associates with poorer 
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survival in NMIBC. The frequency of CD73 positive endothelial cells associate with 
more advanced NMIBC tumors, whereas in muscle-invasive disease CD73 positive 
vessels associate with lower T category. In addition, CD73 positive endothelial cells 
predicted more favourable survival in multivariate analyses in MIBC patients. CD73 
was expressed at very low frequencies on TILs in most BC patients. Higher CD73 
expression on lymphocytes correlates with more aggressive disease in NMIBC. Our 
results show, that the identity of the cell type expressing CD73 is important when 
interpreting the association of CD73 expression and survival. Moreover, our data 
imply that CD73 is unlikely to be a successful therapeutic target in BC due to the 
differences in the expression pattern and functions in different cell types. 
Table 21. Specific conclusions of the studies. 
CD68, MAC387, and CLEVER-1 as prognostic biomarkers in BC 
I Intratumoral TAM density (CD68 and MAC387 positive macrophages) associate with 
conventional high-risk features, including high grade and advanced T category, and poorer 
survival in univariate analyses in BC. 
II CD68 positive macrophage count is an independent prognostic factor for overall death in BC 
patients treated with NAC and RC. 
III In contrast to earlier findings in other cancer types, CLEVER-1 positive vessels associate with 
lower risk of progression and more favourable DSS in BC. Thus, CLEVER-1 treatment would not 
be reasonable in BC. 
IV The combinations of the macrophage groups provide an auxiliary tool to predict the prognosis of 
BC: “double-high” macrophage groups have an independent prognostic value in BC and could 
potentially be used to identify aggressive cases among BC patients. 
CD68, MAC387, and CLEVER-1 as predictive biomarkers in NAC treated BC  
I MAC387 positivity on BC cells is a potential predictive marker for NAC treatment in BC. 
II High CLEVER-1 positive macrophage count and low CLEVER-1 vessel count associate with 
poorer response to NAC. 
CD73 as prognostic biomarker in BC 
I The expression of CD73 on different cell types in BC tumors varies highly and the identity of the 
cell type expressing CD73 is important when interpreting the association of CD73 expression and 
survival. 
- CD73 positive epithelium is an independent positive prognostic factor both in NMIBC and MIBC. 
- CD73 positivity on stromal fibroblasts associates with poorer PFS and DSS in NMIBC. 
- The frequency of CD73 positive endothelial cells is increased in more advanced NMIBC tumors, 
whereas in MIBC it predicts more favourable survival in multivariate analyses. 
- Higher CD73 positive lymphocyte count correlates with more aggressive disease in NMIBC. 
II CD73 is unlikely to be a successful therapeutic target in BC. 
96
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Table 22. The future study objectives. 
 
I Investigation of more detailed macrophage groups in BC with double-stainings and other 
macrophage markers (a) in different stages of BC,  (b) in different sites in BC tumors, such 
as initial tumor cell invasion areas, perivascular area, stromal region, and hypoxic or necrotic 
areas, as well as in the metastatic foci, and (c) in different molecular subtypes of BC. 
 II Detailed investigation of the characteristics and function of MAC387 macrophages. 
 III The validation of the protective role of CLEVER-1 vessels in BC and further studies about 
the mechanism behind this. 
 
IV Investigation of the relationship between CD68, MAC387, and CLEVER-1 positive 
macrophages: Are they subgroups of each other, different phenotype variations from same 
macrophages, or different macrophage groups activated and recruited by different factors? 
V The validation of the predictive role of MAC387 and CLEVER-1 in NAC treated BC patients. 
VI CD68, MAC387, and CLEVER-1 reaction in the BCG treatment. 
 VII Investigation of CD68, MAC387, and CLEVER-1 as predictive factors in checkpoint inhibitor 
treatments. 
 VII
I 
Investigation of TAMs (CD68 and MAC387) as treatment targets in BC. 
 IX Investigation of CD73 expression on different cell types in other cancers. 
 
X Investigation of the role of CD73 subtypes in different molecular subtypes of BC. 
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Abbreviations 
ACT Adoptive T cell transfer  
ADCC Antibody-dependent cell cytotoxicity 
ADCP Antibody-dependent cell phagocytosis 
ADP Adenosine diphosphate 
AKT Protein kinase B  
APC Antigen presenting cell 
ATM Ataxia telangiectasia mutated gene  
ATP Adenosine triphosphate 
AMP Adenosine monophosphate 
AUA American Urological Association  
BC Bladder cancer 
BCA-1 B cell attracting chemokine  
BCG Bacillus Calmette-Guérin  
BCL Basal cell layer of the epithelium 
BiTE Bispecific T cell engager  
bsAb Bispecific antibody  
BTA Bladder tumor antigen  
BTLA B and T lymphocyte attenuator 
CI Confidence interval 
CIS Carcinoma in situ  
CLEVER-1 Common lymphatic endothelial and vascular endothelial 
receptor-1 
COX2 Cyclooxygenase 2 
CPI Immune checkpoint inhibitor  
CTL Cytotoxic T cell 
CTLA-4 Cytotoxic T-lymphocyte-associated protein 4 
CT Computed tomography 
cT Clinical T category 
CRP C-reactive protein  
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CXC/CC C-X-C/C-C motif chemokine 
DC Dendritic cell 
DNA Deoxyribonucleic acid 
DPX Distyrene plasticized xylene  
DSS Disease-specific survival  
EAU European Association of Urology  
ECM Extracellular matrix  
ecto-5’-NT Ecto-5’-nucleotidase  
EGFR Epidermal growth factor receptor 
EMT Epithelial-to-mesenchymal transition  
ERCC1/2 Excision repair cross complementing 1 and 2  
FANCC Fanconi anemia complementation group C gene  
FDA The United States Food and Drug Administration 
FEEL-1 Fasciclin, EGF-like, laminin-type EGF-like, and link domain-
containing scavenger receptor-1 
FGFR3 Fibroblast growth factor receptor-3 
FISH Fluorescence in situ hybridization 
FN Fibronectin 
FoxP3 Forkhead box P3 
GPI Glycosyl-phosphatidylinositol  
gp130 Glycoprotein 130 
gro-α Growth-regulated oncogene α 
GSTM1 Gluthathione S-transferase-μ1  
HER-2 Human epidermal growth factor receptor-2 
HEV High endothelial venule 
HIF Hypoxia-inducible transcription factor 
HR Hazard ratio 
HSC Hematopoietic stem cell 
ICAM-1 Intercellular adhesion molecule-1 
IDO Indoleamine dioxigenase 
IFNγ Interferon γ 
IL Interleukin 
iNOS Inducible nitric oxide synthase  
IP-10 IFNγ-induced protein-10  
ISUP International Society of Urological Pathology 
JAK Janus kinase 
LAG-3 Lymphocyte activation gene-3 
LDL Low-density lipoprotein 
102
31187368_Vaitoskirja_Minna_Tervahartiala_Laaketiet_tdk_sisus_B5_1308.indd   102 13.8.2019   10.47
Abbreviations 
 100 
LPS Lipopolysaccharide 
LVI Lymphovascular invasion  
mAb Monovalent antibody  
MCP-1 Monocyte chemotactic protein-1  
M-CSF Macrophage colony-stimulating factor  
MDC Macrophage derived chemokine 
MDSC Myeloid-derived suppressor cell 
MHC Major histocompatibility complex 
MIBC Muscle invasive bladder cancer 
MIF Migration inhibitory factor  
MIG Monokine induced by gamma interferon 
MMP-9 Matrix metalloproteinase 9 
MR Mannose receptor 
MRI Magnetic resonance imaging 
mRNA Messenger ribonucleic acid 
MRP Myeloid-related protein  
MTC Macrophage-mediated tumor cytotoxicity 
mTOR The mammalian target of rapamycin  
NAC Neoadjuvant chemotherapy 
NAT2 N-acetyltransferase 2 
NCCN National Comprehensive Cancer Network  
NER The nucleoside excision repair  
NF-κB Nuclear factor kappa light chain enhancer of activated B cells 
NK cells Natural killer cells 
N/L ratio Neutrophil-to-lymphocyte ratio  
NMIBC Non-muscle invasive bladder cancer 
NMP22 Nuclear matrix protein 22  
NOS Newcastle-Ottawa scale 
NSAID Nonsteroidal anti-inflammatory drug 
OS Overall survival  
PDD Photodynamic diagnosis 
PD-1/PD-L1 Programmed death 1/programmed death-ligand 1  
PFS Progression-free survival  
PI3K Phosphoinositide 3 kinase  
pT Pathological T category 
PTEN Phosphatase and tensin homologue  
PUNMLP Papillary urothelial neoplasm of low malignant potential 
p53 Tumor protein 53 
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RANTES Regulated upon activation normal T cell expressed and secreted  
RB1 Retinoblastoma gene  
RC Radical cystectomy  
RFS Recurrence-free survival  
RNI Reactive nitrogen intermediate 
ROI Reactive oxygen intermediate 
ROS Reactive oxygen species  
SDF-1 Stromal derived factor-1  
SEC Suprabasal epithelial cells  
SIG1RR Single immunoglobulin interleukin 1 receptor-related protein 
siRNA Small interfering ribonucleic acid 
SPARC Secreted protein, acidic rich in cysteine 
SR Scavenging receptor 
STAT3 Signal transducer and activator of transcription 
TAM Tumor-associated macrophage 
TAN Tumor-associated neutrophil 
TARC Thymus and activation regulated chemokine 
TCR T cell receptor  
TGFβ Transforming growth factor β  
Th cell T helper cell 
TIL Tumor-infiltrating leukocytes 
TIM-3 T cell immunoglobulin and immunoreceptor tyrosine-based 
inhibitory motif domain-3 
TIR8 Toll-interleukin receptor-8  
Tis, CIS Carcinoma in situ  
TLR Toll-like receptor 
TMA Tissue microarray  
TNF Tumor necrosis factor  
TNM Tumor, Node, Metastasis classification system 
Treg cell T regulatory cell 
TUR-BT Transurethral resection of bladder tumor  
UICC 
uPa 
Union for International Cancer Control 
Urokinase plasminogen activator 
VCAM-1 Vascular cell adhesion molecule-1 
VEGF Vascular endothelial growth factor  
VHL/HIF Von Hippel Lindau/Hypoxia-inducible factor 
WHO World Health Organization 
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